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Environmental exposures during sensitive windows of development can reprogram
normal physiological responses and alter disease susceptibility later in life in a process
known as developmental reprogramming. We have shown that neonatal exposure to
the xenoestrogen diethylstilbestrol (DES) can developmentally reprogram the
reproductive tract in genetically susceptible Eker rats giving rise to complete
penetrance of uterine leiomyoma. Based on this, we hypothesized that xenoestrogens,
including genistein (GEN) and bisphenol A (BPA), reprogram estrogen-responsive
gene expression in the myometrium and promote the development of uterine
leiomyoma. We proposed the mechanism that is responsible for the developmental
reprogramming of gene expression was through estrogen (E2)/ xenoestrogen inducedrapid ER signaling, which modifies the histone methyltransferase Enhancer of Zeste
homolog 2 (EZH2) via activation of the PI3K/AKT pathway. We further hypothesized
that there is a xenostrogen-specific effect on this pathway altering patterns of histone
modification, DNA methylation and gene expression. In addition to our novel finding
that E2/DES-induced phosphorylation of EZH2 by AKT reduces the levels of
H3K27me3 in vitro and in vivo, this work demonstrates in vivo that a brief neonatal
exposure to GEN, in contrast to BPA, activates the PI3K/AKT pathway to regulate
EZH2 and decreases H3K27me3 levels in the neonatal uterus. Given that H3K27me3
is a repressive mark that has been shown to result in DNA methylation and gene
silencing we investigated the methylation of developmentally reprogrammed genes. In
support of this evidence, we show that neonatal DES exposure in comparison to VEH,
leads to hypomethylation of the promoter of a developmentally reprogrammed gene,
Gria2, that become hyper-responsive to estrogen in the adult myometrium indicating
v

that DES exposure alter gene expression via chromatin remodeling and loss of DNA
methylation. In the adult uterus, GEN and BPA exposure developmentally
reprogrammed expression of estrogen-responsive genes in a manner opposite of one
another, correlating with our previous data. Furthermore, the ability of GEN and BPA
to developmental reprogram gene expression correlated with tumor incidence and
multiplicity. These data show that xenoestrogens have unique effects on the activation
of non-genomic signaling in the developing uterus that promotes epigenetic and
genetic alterations, which are predictive of developmental reprogramming and
correlate with their ability to modulate hormone-dependent tumor development.
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CHAPTER 1: INTRODUCTION AND BACKGROUND
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1.1 INTRODUCTION
Developing organisms take cues from the surrounding environment in order
to prepare for the impending stimuli and to maintain homeostasis based on sensing of
available energy. An important part of this sensory mechanism is the endocrine
system. At critical times during its development, important feedback systems are
established. As such, any aberrant stimuli or endocrine disruption can impede the
normal feedback mechanism leading to improper signaling and alterations in
morphology of endocrine organs, such as the reproductive tract. Endocrine disruption
during development can subsequently increase the risk of neoplastic transformation of
the reproductive tract and development of hormone-dependent tumors. Furthermore,
endocrine disruption during developmental in individuals that are already genetically
susceptible to hormone-dependent tumors are put at significantly higher risk for tumor
development. However, the etiology of hormone-dependent tumors and the
mechanisms by which environmental endocrine disrupters reprogram susceptibility to
tumor development are still be defined. It is the purpose of this section, therefore, to
address the issues surrounding developmental reprogramming of tumor risk.

1.2 DEVELOPMENTAL REPROGRAMMING
The theory of developmental reprogramming was originally postulated by
Barker in 1989 to explain a phenomenon he and his colleagues observed in adults
born in the lowest birth-weight quartile. Subsequent to their low birth-weight and low
weight at 1 year these individuals had significantly higher mortality rates from
cardiovascular disease and significantly higher rates of diabetes (1). Barker
determined from these data that low birth weight, secondary to in utero growth
restriction

(IUGR),

developmentally

reprogrammed

the

normal

response

to

endogenous and environmental stimuli. As a result, adult disease arose in these
individuals, a concept Barker termed developmental reprogramming.
Developmental reprogramming that causes adult disease, also known as fetal
origins of adult disease (FOAD), is a theory that potentiated our study of the origins of
neoplasias arising in the reproductive tract. The theory that early life exposure to
anthropogenic or natural chemicals could increase the risk for reproductive tract
2

disease was supported by a classic example in humans of developmental
reprogramming by an environmental stimuli, diethylstilbestrol (DES) (2). In utero
exposure to DES, a synthetic estrogen, led to female reproductive tract malformation
and severely compromised reproductive tract function, and ultimately in some women
caused the development of a rare form of vaginal adenocarcinoma (3). Several followup studies in DES-exposed individuals have shown the extent of reprogramming
affects of DES. These reprogramming effects include an increased risk for breast
cancer (4) and increased infertility in women (5), in addition to an increased incidence
in testicular cancer in men (6). Importantly, recent reports have demonstrated that in
utero exposure to DES has transgenerational effects. Daughters of women exposed to
DES, called DES granddaughters, also have an increased risk of menstrual
dysfunction (7) through a mechanism that is thought to be primarily epigenetic (8).
These transgenerational effects have also been demonstrated in animal models. For
example, female offspring (F2-F3) of F1 females neonatally exposed to DES have an
increased incidence of uterine adenocarcinomas than offspring control females (9).
DES is an example of an endocrine disrupting chemical (EDC). The mechanism by
which DES and other EDCs function to induce developmental reprogramming is still
unknown.
1.2.1 Endocrine Disruptors
1.2.1.1 SUMMARY OF THE ENDOCRINE SYSTEM
In order to maintain metabolic homeostasis, endocrine organs send and receive
signals in the form of feedback loops. The endocrine organs include the gonads,
adrenals, pituitary, hypothalamus and thyroid, which function to secrete hormone(s)
that act upon target tissues to produce a response through hormone binding to specific
cell surface receptors. The effect produced can include both positive feedback, which
is secretion of a hormone that signals the original organ to continue to release the
hormone, and negative feedback, which is secretion of a hormone that signals the
original organ to cease hormone release. Deregulation of these feedback loops can
cause a hormone imbalance leading to metabolic disruption.
One major network of the endocrine system is the hypothalamic-pituitary-gonadal
(HPG) axis.

The cascade of signals from the HPG axis originates from the
3

hypothalamic neurons with the pulsatile release of gonadotropin-releasing hormone
(GnRH). GnRH released into the blood binds GnRH receptors in the anterior pituitary,
which triggers the release of luteinizing- and follicle-stimulating hormone (LH and FSH)
from gonadotrope cells. LH and FSH then bind to receptors in the gonads located in
granulose and theca cells (ovary) or Leydig and Sertoli cells (testis), which culminates
in their production of steroid hormones (i.e. estrogen and testosterone). In addition,
other regulatory proteins such as inhibin are also produced, and these ultimately affect
the response of target tissues. The cells in the gonads then send feedback signals, for
example progesterone release from theca cells, which instructs the pituitary and
hypothalamus to stop the release of LH, FSH and GnRH (Figure 1.1).
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FIGURE 1.1 – ILLUSTRATIVE
PITUTARY-GONADAL

(HPG)

REPRESENTATION OF THE MAMMALIAN HYPOTHALAMIC-

AXIS.

In the hypothalamus gonadotropin releasing hormone

(GnRH) is secreted from GnRH neurons into the portal blood system. GnRH receptors
in the pituitary bind GnRH, which induces the production and secretion of the
gonadotropins leutinizing hormone (LH) and follicle stimulating hormone (FSH). LH
and FSH then travel systemically to the ovary (females) or testis (males) to induce
production of steroid hormones. In the ovary, LH binds LH receptors in the theca cells
to produce progesterone and androsteindione. Androsteindione is secreted in a
paracrine manner to the granulosa cells while progesterone feeds back negatively to
the pituitary and hypothalamus to reduce secretion of GnRH, LH and prolactin.
Prolactin secreted from the pituitary also feeds back negatively to the hypothalamus to
reduce corticotrophin releasing hormone. FSH binds FSH receptors in granulosa cells
to produce estradiol, which feeds back positively to the hypothalamus to increase
GnRH secretion and negatively to the hypothalamus and pituitary to reduce FSH
secretion. In the testis, LH binds receptors on the Leydig cells, which secrete
testosterone

in

a

paracrine

manner

to

the

Sertoli

cells.

Testosterone,

dihydrotestosterone (DHT) and/or estradiol negatively feed back from the testis to the
hypothalamus and pituitary to reduce secretion of GnRH and LH. FSH binds to
receptors on the Sertoli cells stimulating them to produce inhibin B, which is also
secreted from the granulosa cells, and feeds back negatively to the pituitary to reduce
secretion of FSH. This illustration is representative of the HPG axis, and it should be
noted that testosterone and estradiol also have other target tissues within the body for
example bone and muscle.
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Estrogen (e.g. 17β-estradiol) is a key hormone that induces the transduction of
signals from the female reproductive system to the pituitary and hypothalamus. In
females, 17β-estradiol (E2) is necessary for normal reproductive tract development
and is produced in the human fetus at about 17 weeks of gestation (10) or around
postnatal day 9 (11) in rodents. This hormone is responsible for a number of critical
functions in the reproductive tract, including control of proliferation and differentiation
of estrogen-responsive tissues. E2 is paramount in maintaining normal function of the
ovaries, uterus and vagina, to maintain ovulation, pregnancy and menses. E2 is also a
critical hormone outside of the reproductive tract, where it controls metabolic
homeostasis in the bone, brain and cardiovascular system. E2 production begins when
LH binds to its receptor on the theca cells in the ovary, which stimulates them to
produce androstenedione. Androstenedione then traverses the basement membrane
and enters the granulosa cells where, upon binding of FSH to its receptor on the
granulosa cells, it is converted to 17β-estradiol. At this time 17β-estradiol enters the
blood (12), where it targets the estrogen receptor (ER) in specific tissues to elicit its
effects. The ability of estrogen to induce a response in estrogen-responsive tissues is
mainly via the ER. ER is a nuclear hormone receptor that dimerizes upon its ligand
binding (normally E2) and induces the expression of genes that contain an estrogen
response element (ERE). Prior to binding of E2 to ER, the ER is confined to the
cytosol in its inactive state, which is accomplished through the binding of ER to large
protein complexes (e.g. heat shock protein 90). After E2 binds to ER, ER monomers
dissociate from the inactivating protein complexes, dimerize, and translocate to the
nucleus, where they bind to specific regions of DNA within genes that contain EREs in
their regulatory regions (e.g. promoters and enhancers) (Figure 1.2). An additional
mechanism that controls expression of estrogen-responsive genes is the recruitment
of co-activators and co-repressors that function as initiators or repressors of
transcription, which will be discussed in more detail in section 1.3.

7

FIGURE 1.2 – DIAGRAM

OF GENOMIC NUCLEAR HORMONE RECEPTOR SIGNALING AND

TRANSCRIPTIONAL ACTIVATION.

Hormone (H) and certain EDCs can enter the cell where

nuclear hormone receptors (NHR) are kept inactive by chaperone proteins including
heat shock protein 90 (HSP90) until liganded by hormones (or EDCs). Liganded NHRs
form dimers and translocate to the nucleus where they interact with co-activators (e.g.
p160, p300 or CBP) and bind to a hormone responsive elements (HRE) in the DNA.
After gene transactivation, NHRs are degraded by the proteosome or recycled back to
the cytoplasm.
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1.2.1.2 XENOESTROGEN-INDUCED DEVELOPMENTAL REPROGRAMMING
Chemicals that disrupt the normal signaling and homeostasis of the endocrine
system are termed endocrine disrupting chemicals (EDCs). EDCs are found
ubiquitously in the environment and can occur naturally or as anthropogenic
substances. EDCs can disrupt the endocrine system via several mechanisms, one of
which is by acting as hormone mimetics. EDCs affect hormone receptor signaling by
acting as agonists or as antagonists, which activate or inhibit receptor signaling,
respectively. Often EDCs interfere with hormone receptor binding to endogenous
hormone, and this has numerous effects, including disturbing gene expression,
metabolism and hormone synthesis. One specific class of EDCs is xenoestrogens,
which are chemicals that behave like or have estrogenic properties and are known to
bind the ER. Given that the ER is a promiscuous nuclear hormone receptor that binds
to a variety of chemical compounds, the potential for aberrant ER activation leading to
perturbation of normal development, hormone homeostasis and fertility is substantial
(13). The majority of xenoestrogens (including DES) act as ER agonists, mimicking the
effects of endogenous E2. Alternatively, xenoestrogens can antagonize ER-DNA
binding [e.g. Bisphenol A (BPA) (14)], alter co-activator/co-repressor recruitment [e.g.
4-tert-Octylphenol and BPA (15)], or increase the expression of ER co-repressors [e.g.
NCOR1/SMRT (16, 17)].
The dose and route of administration of an EDC is an important factor that
affects the ability of EDCs to induce developmental reprogramming effects. Several
controversial issues have arisen due to the lack of continuity of dose and
administration between studies assessing the effects of xenoestrogen exposure during
development. The issue of dose is of importance because several xenoestrogens
demonstrate a non-monotonic “U shape” dose response, including the xenoestrogens
evaluated in this work (18). Because of the non-linear dose response seen between
high and low doses of xenoestrogens, the extrapolation of low or physiologically
relevant doses from high or pharmacological doses is not generally prudent. In
addition, the ability of neonatal animals to metabolize xenoestrogens has also been a
confounding

factor

due

to

the

neonate’s

immature

Phase

II

metabolism

(glucuronodation) as compared to adult rodents (19-21). This disparity has created
9

another variable that introduces variation between studies, making comparisons and
extrapolations difficult.
For example, the isoflavone, genistin (GIN), which is the primary component of
soy-formula, is present in the lumen of the intestinal tract as a glycoside/glucoside.
This glycoside undergoes hydrolysis in the small intestine via beta-glycosidase, which
is an enzyme that is associated with lower bowel microflora and is requisite for
absorption of glycosylated chemicals. After absorption, the deglycosylated (aglycone),
now the EDC genistein (GEN), is metabolized by the Phase II enzymes uridine-5’diphosphate glucuronosyl-transferases, and sulfotransferases, and is excreted in the
bile or urine. Conjugates in the bile are hydrolyzed by intestinal bacteria and excreted
in the feces, or they undergo further metabolism through re-absorption into
enterohepatic circulation, or they are degraded. The major products resulting from
metabolism found in the hepatic portal vein are glucuronides (22).
Since the aglycone form, GEN, is the “estrogenic” or active form, it is important
to know the amount of genistein aglycone that is present in plasma, because this is a
measure or the body’s ability to metabolize aglycone via glucuronodation (i.e. its ability
to inactivate and excrete GEN). Perinatal rodents have reduced glucuronidation, and
this is exemplified in the half-life of genistein aglycone, which is higher in neonatal
animals as compared to adults (12-19 hours vs. 2-4 hours, respectively) (23, 24). The
EDC BPA is processed in a similar fashion, and fetal and neonatal rats do not
efficiently metabolize BPA because their enzyme systems are not fully matured. For
example, an oral dose of 10 mg/kg in post-natal day (PND) 4 rats results in 100-1000
times higher concentrations of BPA than the same dose in adult rats. However, at
doses of <1mg/kg neonatal rats are able to efficiently metabolize BPA to the
glucuronidated form. Importantly, oral vs. subcutanous (s.c.) routes at low doses (35 or
395 ug/kg) in neonates does not result in significant differences in plasma
concentrations (25). Therefore, the factors of dose, route of administration, and age of
the animal were all taken into consideration when designing the following experiments.
In addition, extrapolations from the data presented herein were carefully analyzed in
the context of the parameters discussed above. The doses, routes and plasma
concentrations of the xenoestrogens used in this work are listed in Table 1.1 and are
shown in relationship to the physiologically relevant exposure level in the ageappropriate human population.
10

TABLE 1.1
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1.2.1.2.1 DES AND DEVELOPMENTAL REPROGRAMMING
The potent synthetic estrogen DES is a classical example of a xenoestrogen
that acts as an EDC. DES, which was used from 1940-1970 as a pharmaceutical
agent, was prescribed to pregnant women to prevent miscarriages and premature
delivery. Approximately 2-8 million Americans were exposed in utero to DES before
the FDA banned its use in 1971 (26). The ban of DES was predicated upon multiple
studies and case reports documenting exposure-related development of a rare vaginal
cancer, vaginal clear cell carcinoma in early adult post-pubertal girls, in addition to
reproductive tract malformations, infertility, preeclampsia and the benign uterine
neoplasias, uterine leiomyomas (27-31). Similarly, males exposed in utero to DES did
not escape the developmental reprogramming effects, as evidenced by reports
documenting testicular hyperplasia and hypospodias, epididymal cysts and impaired
spermatogenesis (32, 33).

In subsequent follow-up studies of women exposed in

utero to DES, a significant correlation was found between exposure and an increased
risk of breast cancer (34). These studies indicate that DES is a transplacental
carcinogen that may act via developmental reprogramming of the reproductive tract,
demonstrating the sensitivity of differentiating tissues to endocrine disruptors.
The developmental reprogramming effects of DES exposure have also been
well-documented in numerous animal studies (33). Specifically, studies in CD-1 mice
demonstrate that postnatal exposure to DES (PND 1-5) induces the formation of
uterine adenocarcinomas, and to a lesser extent, uterine leiomyomas (35, 36).
Characterization of the developmental reprogramming effects of postnatal DES
exposure in the reproductive tract revealed malformations in the ovary and oviduct (37,
38). In addition, alterations in the epithelium of the uterus and vagina, increased
vaginal epithelial cornification (35, 39) and alterations in uterine gland formation (40)
have also been identified. However, in utero exposure of mice to DES, in contrast to
the postnatal exposure data presented above, does not result in significant
development of vaginal adenosis. This is in comparison to mice exposed to DES on
PND 1-5, which gave rise to a 75% incidence of vaginal adenosis in adulthood (41).
Similarly, exposure to DES postnatally and postweaning induced significant
12

developmental effects as compared to in utero exposure (42). These data further
substantiate the postnatal period as the most susceptible window for DES-induced
developmental reprogramming of the reproductive tract in rodents. The main reason
postulated for the differences in the window of susceptibility to DES exposure between
humans and rodents can be attributed to the periods of differentiation and
development of the uterus. While the majority of human uterine development is
completed between 19-38 weeks of gestation, rodent uterine development is
completed between PNDs 3-19 (43).
1.2.1.2.2 GENISTEIN AND DEVELOPMENTAL REPROGRAMMING
While the lingering effects of DES remain as evidence of the millions of
individuals exposed to DES in utero, the lessons learned from DES exposure have led
to the investigation of the effects of other natural and anthropogenic xenoestrogens.
The phytoestrogen, GEN, is one such xenoestrogen that has been studied extensively,
because it is found in soy infant formulas and multiple other food products that are
consumed by infants. The concern regarding infants consuming soy-based formula is
the high amounts of soy isolates, such as GIN, that infants are exposed to during
critical developmental windows. In comparison to adults who consume soy-based
foods, infants consuming soy formula are exposed to approximately 10 times the
amount of genistein (6-9 mg/kg/d vs. 1 mg/kg/d) (44). To date, 3 epidemiological
studies of human infants consuming soy-formula have demonstrated adverse affects
of exposure. These reports have correlated consumption of soy-formula, as compared
to breast- or cow-milk, with increased breast tissue at 2 years of age (45), with a
higher maturation index of cells from the vaginal wall (46), as well as with increased
incidence of uterine leiomyoma (47). Importantly, GEN has also been demonstrated at
environmentally relevant doses (1.4-5.4 µM in plasma) (23, 48, 49) to induce
developmental reprogramming of the female reproductive tract and mammary glands
in numerous animals studies (20). While animal studies show that genistein does
cross the placental barrier (50), the more relevant neonatal exposure to GEN in
rodents leads to both carcinogenic effects, including uterine adenocarcinomas (51,
52), as well as non-carcinogenic effects. These effects include infertility, altered
estrous cyclicity, accelerated vaginal opening, early reproductive senescence,
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multioocyte follicles and multiple histopathological alterations of the reproductive tract
and mammary glands (52-58).
As with DES exposure, the timing of GEN exposure in animals alters the
differentiation and susceptibility of exposed tissues, such as the mammary glands.
Unlike the uterus, however, the differentiation of the mammary gland is similar
between humans and rodents with the majority of development taking place before
birth. In utero versus neonatal GEN exposure, however, differentially alters the
susceptibility to carcinogen-induced mammary carcinogenesis in rodent studies. If
GEN exposure occurs in utero, carcinogen-induced mammary cancer is increased,
whereas there is a chemopreventative effect on mammary cancer if exposure occurs
neonatally (59-61). These studies demonstrate that changes in GEN-induced
differentiation of the mammary gland correlate with the induction or prevention of
mammary tumors. The ability of GEN to alter tissue differentiation, is a component this
xenoestrogen utilizes to induce developmental reprogramming. These studies illustrate
the different developmental windows of susceptibility to carcinogenesis from
xenoestrogen exposure.
1.2.1.2.3 BPA AND DEVELOPMENTAL REPROGRAMMING
Another endocrine disruptor, bisphenol A (BPA), was originally synthesized at
the same time as DES and was to be used as a synthetic estrogen (62, 63). However,
it later became used prolifically as a cross-linking chemical in production of epoxy
resins and polycarbonate plastics. Due to its chemical instability, BPA easily leaches
from plastics after heating and contaminates food and beverages. BPA is also used in
can liners and dental sealants, which confers another avenue of human exposure.
Recently, correlation of urinary BPA concentration in human studies has been
positively associated with heart disease and diabetes (64, 65). Furthermore, several
studies, including a study from the CDC, demonstrated that BPA can be found in
nanomolar concentrations in urine, serum and breast milk (66-68). Importantly, human
studies of fluids from the maternal-fetal-placental unit have also identified
concentrations of BPA (0.2 – 104 ng/mL (6 nM in cord blood)) that are within the range
of those that have shown toxic effects in offspring from animal studies. This indicates
that BPA can cross the placental barrier (69).
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In several animal studies, in utero and neonatal BPA exposure results in
reproductive tract alterations in both males and females. In utero exposure alters
oogenesis (70), advances puberty, (69) and changes endometrial gland proliferation,
uterine epithelium and vaginal morphology (71-73). Similar to in utero exposure,
neonatal exposure to BPA alters oogenesis (74), however, neonatal BPA exposure
also induces alterations in estrous cyclicity (75) and steroid hormone-response in the
uterine stroma (16) and persistent vaginal cornification (76). Importantly, neonatal BPA
exposure

promotes

neoplastic

transformations,

including

cystic

endometrial

hyperplasia (64, 77) and age-related prostatic intraepithelial neoplasia (78). With the
results of these rodent studies showing the deleterious effects of both in utero and
neonatal exposure, in combination with the wide range of concentrations of BPA found
in humans, the potential for developmental reprogramming of the human reproductive
tract and promotion of neoplastic transformation from BPA exposure is apparent.

1.3 MECHANISMS OF DEVELOPMENTAL REPROGRAMMING
While the exact mechanism by which xenoestrogens induce developmental
reprogramming remains elusive, several theories have been explored. The main
mechanism of action through which xenoestrogens have been shown to affect cellular
function is via activation or repression of nuclear hormone receptors (NHR). While
hydrophilic xenoestrogens initiate rapid signaling via membrane-bound NHRs, other
lipophillic xenoestrogens passively enter the cell to activate NHRs and regulate
expression of estrogen-responsive genes (79). NHRs are activated by steroid
hormone ligands, or by chemicals that behave like steroid hormones (e.g.
xenoestrogens). Hormone ligands induce a conformational change in the protein
structure of the NHRs that allows dimerization and translocation to the nucleus, where
they act as transcription factors that result in expression or repression of genes.
Accessory proteins such as co-activators and co-repressors also often manipulate the
function of NHRs by recruiting other proteins or by tethering the complex to the DNA.
While xenoestrogens predominately act on Type I NHRs (e.g. androgen receptor (AR),
progesterone receptor (PR) and estrogen receptor (ER)), other EDCs bind to Type II
or Type III NHRs, which are normally liganded by non-steroid hormones or act as
orphan receptors, respectively.
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1.3.1 Xenoestrogen-Induced Genomic Mechanisms of Endocrine Disruption
Xenoestrogens transactivate estrogen-responsive genes through binding to ER
to elicit a genomic response. ER is a Type 1 NHR that is expressed as either ERα or
ERβ, which form either homo- or heterodimers with one another (80). Both isoforms
contain similar conserved domains, which include an N-terminal transactivation
domain, a zinc finger DNA binding site and a C-terminal ligand-binding domain.
However, the ER isoforms can act antagonistically towards each other. For example,
ERβ can promote apoptosis and inhibit the proliferation induced by ERα (81). Once
ER is liganded, dimers are formed that translocate to the nucleus where they bind
specific regions in the DNA, classically termed estrogen response elements (ERE). In
order to activate transcription of ERE-containing genes, other coregulatory proteins
are required, such as steroid receptor coactivator 1 (SRC-1) (82).
Xenoestrogens can act as both agonists and antagonists of ER activity. DES,
for example, can bind ERα and induce transcriptional activation of HOX genes, such
as Hoxa9 and Hoxa10, which contain EREs in their promoters (83). However, with
other xenoestrogens, such as GEN, both agonism and antagonism of ER can occur. In
vitro, for GEN to act as an ER agonist, low-doses (<9 µM) are required, and they
induce cell growth. At high-doses (9-100 µM) GEN inhibits activation of downstream
signaling via receptor tyrosine kinases (RTKs) (84, 85) and subsequently cell growth.
BPA can also act as an ER antagonist by inhibiting ER binding to DNA (14), in addition
to preferentially recruiting ER co-repressors to estrogen-responsive genes. Another
mechanism by which xenoestrogens can alter genomic responses is via differential
binding to ERα versus ERβ. As indicated previously, ERα activity can be inhibited by
liganded-ERβ. As shown in Table 1.2, xenoestrogens have variable affinity for the
different isoforms of ER. Specifically, in vitro studies indicate that GEN has a stronger
binding affinity for ERβ versus ERα (15, 86). Due to the tissue-specific expression
differences in ERα versus ERβ (e.g. uterus expresses mainly ERα and the prostate
expresses mainly ERβ), the binding affinity may account for the differential effects of
GEN, BPA and DES in vivo. Animal studies have also demonstrated xenoestrogenspecific effects on the reproductive tract, lending further support to this theory (87).
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TABLE 1.2
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1.3.2 Xenoestrogen-Induced Non-Genomic Mechanisms of Endocrine Disruption
In addition to genomic activation, xenoestrogens can also activate NHRs via
non-genomic signaling, which takes place in the cytoplasm and is independent of
NHR-DNA binding. As compared to genomic signaling, which occurs slowly (hours 
days), non-genomic signaling is rapid (seconds  minutes). The ability of hormones to
induce non-genomic activation was demonstrated originally by Losel and Wehling (88)
utilizing spermatozoa, which do not contain a ‘normal’ nucleus and thus lack genomic
signaling. Evidence of xenoestrogen-induced non-genomic signaling came from the
demonstration that xenoestrogens still have an effect on nucleated cells treated with
inhibitors of protein synthesis, which blocks the downstream effectors of genomic
signaling. Furthermore, xenoestrogens that cannot enter the cell still elicit signaling
events, mimicked by BSA bound E2, and this must also be a genomic signalingindependent mechanism. Thus, the ability of xenoestrogens to interfere with normal
hormone signaling via non-genomic signaling could also give rise to developmental
reprogramming.
Multiple non-genomic signaling pathways can be induced by estrogen (Figure
1.3). Normally, E2 induces Ca++ mobilization (89), elevates Ca++ concentrations, (90)
activates growth factor receptors and G-protein coupled receptors (GPCR) (Thomas
2005) (91) as well as protein kinases (92, 93) via ligand bound ER and non-classical
ERs. However, xenoestrogens, including DES, GEN and BPA, can also give rise to
non-genomic signaling events. In the reproductive tract, E2, as well as xenoestrogens,
induce fluctuations in Ca++-dependent signaling, leading to changes in apoptosis,
neuronal transmission, muscle contraction and gene expression. Downstream
signaling events of Ca++ mobilization subsequently activate kinases in an ERdependent manner, such as mitogen-activated protein kinases (MAPK) and protein
kinase C (PKC) (89, 93), which are responsible for regulating mitogenic, stress and
inflammatory signals. However, both E2 and xenoestrogens can activate multiple
kinases (e.g. Ras-Raf-MEK-ERK/MAPK) in vitro in an ER-dependent manner that is
independent of Ca++ signaling (94-96). Additionally, E2 and xenoestrogens have been
shown to activate certain GPCRs (97), though this is separate from the membranebound ER (mERα). However, the ability of GPCRs to mediate estrogen signaling is
controversial (98, 99). Thomas et al. (100, 101) demonstrated in ER-null breast cancer
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cells (SKBr3) that GPR30 could bind not only E2, but also the xenoestrogens,
ortho,para-dichlorodiphenyldichloroethylene (o,p'-DDE), GEN and BPA,

which

induced the activation of adenylate cyclase. The second messenger produced by
adenylate cyclase and ATP, adenosine 3’, 5’-monophosphate (cAMP), binds protein
kinase A (PKA), which allows PKA (R subunit) to phosphorylate cAMP responseelement-binding protein (CREB) (102, 103). As a transcription factor, CREB can aid in
transcription of estrogen-responsive genes including aromatase and c-fos/c-jun (104).
Recently, Bouskine et al. (105) reported that in human seminoma cells, BPA, but not
E2 or DES, was able to induce proliferation by activation of PKA and PKG through
binding to a GPC non-classical ER. However, non-genomic activation was
independent of classical ER, since the ER antagonist, ICI 182780, could not abrogate
the signaling. E2 bound to BSA (which cannot enter the cell), however, was able to
produce the same effect as BPA, i.e. phosphorylation of CREB, indicating the
xenoestrogen-specific effects on non-genomic signaling.
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Figure 1.3 – Mechanisms of Estrogen and Xenoestrogen-Induced NonGenomic Signaling. 1) Calcium mobilization, as the result of non-genomic signaling
through protein kinase C (PKC) via activation of GCPRs by liganded ER, is one of the
consequences of estrogen or xenoestrogen exposure. 2) Activation of GCPRs by
estrogen or xenoestrogens also induces non-genomic signaling and expression of
estrogen-responsive (canonical and non-canonical) genes via protein kinase A (PKA)
activation of ER. Estrogen-induced GCPR activation also signals via CREB to induce
aromatase expression. 3) In addition to GFs, estrogens and xenoestrogens can
promote cell survival, proliferation and estrogen-responsive gene expression via
activation of the PI3K/Akt and MAPK pathways. Activation of GFRs can also induce
PI3K and MAPK signaling, which can both phosphorylate the ER. Alternatively,
liganded-ER can bind directly to the p85 subunit of PI3K to activate Akt or bind Shc to
activate the ERK1/2, which can also phosphorylate ER. 4) Chromatin modifying
proteins can also be posttranslationally modified by estrogen-activated AKT, which
alters histone marks on chromatin giving rise to changes in expression of estrogenresponsive genes.

20

While both isoforms of ER have been shown to reside in the cytosol, nucleus
and mitochondrial membranes (102, 106, 107), putative non-classical membranebound ERs are still debated because ER does not contain a transmembrane domain.
Razandi et al. (102), however, was able to demonstrate that ER-negative Chinese
hamster ovary (CHO) cells transfected with ER produced ER in both the cell
membrane and nucleus. ER was also found to associate with several membrane
signaling proteins including Src, Shc and caveolin-1. Overexpression of caveolin-1
was demonstrated to induce translocation of nuclear ER to the cytoplasm, resulting in
ER-dependent kinase activation (108, 109). Despite the research being done on
membrane-bound ER, the exact mechanism, be it via association with other
membrane-bound proteins or posttranslational modification, by which ER associates
with the membrane remains enigmatic.
Importantly, growth factors, E2 or xenoestrogen-induced kinase activation
results in ERα phosphorylation at Ser118 (by, for example, MAPK and PKC) and
Ser167 (e.g. by Akt) (110), which can recruit co-activators of ER, leading to changes in
estrogen-responsive gene expression (111-115). Growth factors such as EGF and
IGF-1, however, can also lead to ERα phosphorylation via kinase activation by
enzymes such as MAPK, independently of E2 binding (116). In addition, ER can bind
directly to p85 (117), a subunit of phosphoinositol-3-kinase (PI3K), as well as to
Erb2/Her2 receptor tyrosine kinase (114), in an E2-dependent manner, which leads to
both activation and phosphorylation of Akt. The phosphorylation of Akt has multiple
downstream effects, which ultimately results in cell survival. Xenoestrogens, including
DES (118), GEN (at low doses; < 50µM) (119) and BPA (93) can also activate the
PI3K pathway in vitro. An important recent finding of the E2/xenoestrogen-mediated
activation of Akt is the downstream regulation of a histone modification enzyme,
enhancer of zeste homolog 2 (EZH2), which is a histone methyltransferase (HMT).
The phosphorylation of EZH2 by Akt was identified in vitro as a downstream signaling
event by insulin-like growth factor (IGF), which decreased the HMTase activity and
association of EZH2 with chromatin (120). The resulting event was the decreased trimethylation of histone H3 at lysine 27 and increased gene expression. Subsequently,
it was found both in vitro and in vivo that DES can also result in increased pEZH2 in an
ER-dependent mechanism. Furthermore, this increase in pEZH2 was abrogated in
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mice lacking ERα (ERKO mice). These data demonstrate another mechanism of
xenoestrogen-induced developmental reprogramming via non-genomic signaling as
well as histone modification.
1.3.3 Epigenetic Developmental Reprogramming
Early developmental biologists and geneticists recognized that DNA sequence
is insufficient to give rise to the tremendous variation in phenotype found in higher
organisms (121) (8). Conrad Waddington was the first to use the term “epigenetics” to
describe the means by which differentiation makes traits reproducible due to the
establishment and maintenance of gene expression profiles through a process called
“canalization” (122) (123).

The word epigenetics is now used to describe the

molecular mechanisms that make gene expression patterns and subsequent traits
heritable in a manner independent of DNA sequence variations. Fetal development is
a powerful illustration of the importance of epigenetic regulation in which the DNA
sequence from a single cell generates all cell types and tissues of the body (121).
While epigenetic structures found in various cell types must be stable and
heritable to produce distinctive traits found in tissues of the body, the epigenome is
also dynamic, which allows gene expression profiles to change in response to
environmental stimuli. Importantly, such responses are appropriate and normal to
enable organisms to protect themselves from environmental stressors or to adapt to
new environments.

However, inappropriate stimulation of these same pathways

during development, when the fetus is particularly sensitive to environmental factors,
could result in aberrant changes in epigenome (124). Monozygotic twins are a classic
example of the influence of the environment on the epigenome. Despite having
identical DNA sequences, disease incidence is variable among identical twins,
suggesting that environmental factors are promoting the observed differences (125).
Because environmental stimuli clearly affect epigenetic structures and
subsequent disease susceptibility, it is critical to further investigate the mechanisms by
which epigenetic structures are perturbed by environmental factors. Unfortunately,
little is known about how environmental chemicals, such as endocrine disruptors
(ECDs), alter the epigenome and contribute to the etiology of diseases such as
obesity, diabetes, infertility, and cancer. The purpose of this section is to review the
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mechanisms of epigenetic gene regulation, specifically histone modification and DNA
methylation, as well as, to summarize what is known about the effect of EDCs on the
epigenome.

1.3.3.1 DNA METHYLATION
DNA methylation was the first epigenetic modification to be identified and is the
best characterized epigenetic structure (126) (127). Methylation occurs by transfer of
a methyl group to the cytosine found in a cytosine guanine dinucleotide (CpG) by
enzymes termed DNA methyltransferases (DNMTs). The majority of CpGs are found
within regions of the genome called CpG islands (CGIs). CGIs are unique regions of
DNA that have an high (>50%) GC content (128) (129). CGIs are generally found in
the 5’ promoter region of genes and often contain structures critical to the regulation of
the associated gene. In fact, 50-70% of all genes possess a CGI, which is generally
unmethylated (130) (131) (132) (133).
As mentioned, DNMTs are responsible for the transfer of a methyl group to
cytosine. There are four isoforms of this enzyme found in mammals, DNMT1, DNMT2,
DNMT3a, and DNMT3b. With the exception of DNMT2, which only weakly methylates
DNA (129) and is thought to methylate other cellular targets (134), DNMTs are critical
for normal development as demonstrated in DNMT knockout mouse models, which
have significant genetic defects and die during development (135) (136) (137) (138)
(139) (140). The isoforms of DNMTs each have unique functions. DNMT3a and 3b,
also called de novo DNMTs, are responsible for the establishment of DNA methylation
patterns during fetal development (141).

Unlike de novo DNMTs, DNMT1 is

responsible for the propagation of DNA methylation patterns during cell division (133).
The effect of DNA methylation on gene expression was discovered using an
inhibitor of DNMTs called 5-deoxy-azacytidine (5azaC), which is not only a DNMT
antagonist but also cannot be methylated when incorporated into DNA. Using this
antagonist, genes formerly silenced during development, such as those found on the X
chromosome, could subsequently be expressed (142) (143) (144).

These

groundbreaking studies revealed that DNA methylation participates in silencing of
gene expression. It is now appreciated that DNA methylation is not only a critical part
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of fetal development, but also a critical mechanism in multiple disease states. For
example, aberrant tumor suppressor gene silencing via DNA methylation allows for
unrestricted division in cancer cells (145) (146) (133).
DNA methylation silences gene expression by creating docking sites for
proteins called methyl-CpG-binding proteins (MDBs) (147). MDBs bind to methylated
DNA and recruit histone modifying enzymes, including histone methyltransferases
(HMTs) and histone deacetylases (HDACs), that promote the formation of a closed
chromatin conformation, or heterochromatin.

The closed chromatin conformation

prevents binding of transcription factors and other coactivator complexes to gene
promoters and as such prevents gene expression (148) (149) (150) (151).
1.3.3.2 HISTONE MODIFICATION
DNA is bound to scaffold proteins called histones, forming a higher order
structure referred to as chromatin.

Chromatin is made up of an octamer of four

histone proteins, H2A, H2B, H3, and H4. In addition, Histone H1 is a linker protein
found between nucleosomes.

Chromatin structure is dictated by posttranslational

modifications (PTMs) that occur on DNA and histone proteins. The N-terminal region
of histone proteins, or histone “tails”, are subject to a number of PTMs, including
phosphorylation, ubiquitination, sumolyation, acetylation, and methylation.

These

PTMs correspond to either promotion or inhibition of gene expression, in general.
The combination of PTMs found on histones in a given region of the genome generate
binding sites for domains of other regulatory proteins, such as chromo- and
bromodomain containing proteins, that bind to these chromatin “reading” domains and
promote binding of “effectors”. The effect that binding of the “effectors” to PTMs on
histones has on chromatin ultimately governs gene expression (152) (153) (154).
HMT enzymes catalyze histone methylation.

Unlike DNA methylation, site-

specific histone methylation can cause induction or repression of transcription (152).
Two types of HMT enzymes known to exist, which are classified by the amino acid that
they methylate on histone proteins, are histone lysine methyltransferases (HKMTs)
and protein arginine methyltransferaseas (PRMTs). In contrast to DNA methylation,
histone methylation is reversible and is known to fluctuate in response to cellular
stimuli (155).

For example, histone lysine methylation is removed by histone
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demethyases, including lysine-specific demethylase 1 (LSD1) and Jumonji domaincontaining hydroxylases (JMJDs) (156) (157) (158). Another mechanism that allows
for rapid fluctuation in histone methylation, as mentioned previously, is the ability of
HMTs to be post-translationally modified by upstream signal transduction pathways. In
addition to the ability of AKT to induce phosphorylation of EZH2, other kinases have
also been demonstrated to phosphorylate HMTs. Specifically, coactivator-associated
arginine methyltransferase 1 (CARM1) phosphorylation (by an unknown kinase)
results in a reduction of its substrate affinity and enzymatic activity as demonstrated by
Higashimoto et al. (159) and Feng et al. (160). While several groups have postulated
that phosphorylation of HMTs alters protein conformation leading to reduced enzyme
activity or its interaction with its different co-factors (i.e. SETDB1 phosphorylation is
required for CHD7 recruitment (161)), Feng and colleagues have illustrated the precise
effect phosphoryation has on CARM1 structure and enzyme activity. Solving the
crystal structure of CARM1 allowed them to show that phosphorylation at Ser 217
disrupted the hydrogen bond of the hydroxyl group with the carbonyl oxygen atom of
Tyr 154. Normally, this hydrogen bond locks in S-adenosylmethionine (SAM) and
provides enzyme activity for CARM1, however disruption of this bond by
phosphorylation inhibits SAM binding. Furthermore, Ser 217 phosphorylation also
increased cytoplasmic localization. Besides phosphorylation, other PTMs such as
GlcNAcylation, which is catalyzed by an O-GlcNAc transferase sensitive to serum
glucose, can also alter activity of HMTs. For example the GlcNAcylation of HKMT
myeloid/lymphoid or mixed-lineage leukemia 5 (MLL5), allows for its HMT activity to
catalyze the mon- and dimethylation of H3K4 (162). Despite being reversible, histone
methylation patterns are heritable and also appear to be, at least in some cases,
precursors for other epigenetic modifications such as DNA methylation (163) (164)
(165).
1.3.4 Xenoestrogen-Mediated Epigenetic Reprogramming
The mechanism(s) by which early life exposure to endocrine disrupting
chemicals such as xenoestrogens developmentally reprograms reproductive tract
tissue are largely unknown.

However, it is now appreciated that modulation of

epigenetic structures to permanently alter gene expression is a major mechanism of
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EDC-induced developmental programming. This is thought to be due to the fact that
the fetus has a very dynamic epigenome during development and continuously subject
to change prior to reaching phases of terminal differentiation. The epigenome is very
sensitive to environmental stimuli, including exposure to heavy metals EDCs, which
can disrupt epigenetic structures by interrupting the normal sequence of structural
changes occurring during development. The timing of exposure is also critical to the
outcome of these exposures.

Known windows of development sensitive to

reprogramming include gamete maturation (oogenesis and spermatoenesis), prior to
zygote implantation when de novo methylation occurs, and during lineage-specific
differentiation (166) (141) (167).

Developmental reprogramming to gametes may

cause abnormal epigenetic modifications and subsequent changes in gene expression
and disease incidence to become inherited to offspring. This phenomenon is called
transgenerational epigenetic effects.
Early life exposure to EDCs has been linked to changes in DNA methylation
patterns in adult tissues, which corresponds to altered gene expression patterns. For
example, neonatal exposure to DES reprogrammed the expression of tumorassociated genes such as cyclin D1, lactoferrin, and transforming growth factor beta in
the uterus CD-1 mice (36) (168) (169).

Li et al. (170) (171) demonstrated that

neonatal DES exposure induces hypomethylation and persistent expression of the cfos and lactoferrin genes.

Similarly, neonatal exposure to BPA and DES caused

hypermethylation in the Hoxa10 gene, correlating with reduced expression in adult
uterine tissue (172) (16) (173). Tang and colleagues (REF) also showed that reduced
methylation of the nucleosomal binding protein 1 (Nsbp1) promoter following neonatal
DES or genistein exposure was associated with elevated gene expression and
increased tumor incidence. Remarkably, changes in DNA methylation imparted by
DES-exposure are insufficient to induce uterine tumors, as ovariecomized CD-1 mice
neonatally exposed to DES fail to develop uterine tumors. These data bring to light
the critical role of endogenous hormone to the increased uterine tumor formation,
suggesting that it is the interaction between the imprint caused by DES and the natural
hormonal milieu that modulates tumor risk (35) (169) (174).
Like the female reproductive tract, the male reproductive tract is also
susceptible to EDC-induced developmental reprogramming. Ho and colleagues (175)
revealed that BPA exposure promoted hypomethylation of the phospohodiesterase
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type 4 variant 4 (PDE4D4) gene. Importantly, increased expression and activity of the
PDE4D4 of this gene produced elevated levels of camp, which was associated with
increased formation of intraepithelial neoplasia (PIN) leisions in adult animals.
Interestingly, the reproductive tract is not the only organ system reprogrammed by
exposure to EDC’s during development.

Various hormone-responsive tissues are

subject to EDC-induced developmental reprogramming. One of the most fascinating
and poorly understood targets of these chemicals is the brain. Recent studies have
demonstrated that fetal or neonatal exposure to EDCs affects morphology in specific
regions of the brain such as the hypothalamus, distribution of brain hormone
receptors, and alters adult behaviors (176), (177). Waalkes and colleagues observed
that inorganic arsenic gave rise to hypomethylation and elevated expression of ER in
liver of mice exposed in utero. These data reveal that early life exposure to EDCs may
affect several organ systems to give rise to numerous physiological changes.

1.3.5 Xenoestroen-Induced Transgenerational Inheritance
Alterations in gene expression and subsequent phenotype can be induced by a
variety of environmental exposures. It is thought that changes in the epigenome of
oocytes or spermatocytes gives rise to these transgernational effects (178, 179). A
number of recent studies have demonstrated that many EDCs, including DES,
methoxychlor, vincolzolin, and PCBs, can modify rodent phenotype, and that these
modifications are heritable though many generations (180, 181). For example, Anway
and collegues (182) demonstrated that in utero exposure to methoxycholor or
vinclozolin reduced fertility through altering DNA methylation patterns in rats. The
authors found this phenotype to be inherited through F4 generation rodents. Similarly,
vinclozolin appears to affect reproductive function and tumor incidence in female rats
exposed to this EDC during gestation (183). While it appears that EDCs not only
affects the generation of organisms immediately exposed to these chemicals, but
subsequent generations of exposed organisms, this data remains very controversial
(184).
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1.4 XENOESTROGENS AND DEVELOPMENTAL ORIGINS OF HORMONEDEPENDENT TUMORS
Endocrine tissues developing during the perinatal period are vulnerable to
endogenous and exogenous stimuli due to the ongoing programming of the endocrine
axis and development of the reproductive tract and accessory endocrine organs.
However, the methods by which perturbation of hormone signaling during
development increases hormone-dependent tumor risk is not well understood. A key to
these early programming events is the endocrine signaling of hormones in the
reproductive tract and feedback of hormones from the gonads or accessory glands to
the hypothalamus and pituitary. Paracrine and autocrine signaling, such as discussed
above, also play important roles in programming of endocrine tissue. During puberty in
the mammary epithelium, for example, mammary differentiation is prevented via
autocrine signaling from growth hormone (GH) (185). Importantly, tumors can supplant
the requirement for exogenous mitogenic signals in order to transform normal
paracrine-responsive prostate and breast tissue into neoplastic tissue (186, 187) .
During development, disruption of endocrine signaling by EDCs can have several
effects: 1) they can generate premature, faulty or alternative endocrine signaling; 2)
they can change the epigenetic landscape of the genome, which can increase the
susceptibility of tissues to neoplastic transformation, especially after puberty when
endogenous hormones stimulate proliferation and differentiation of reproductive tract
tissues; and/or 3) they can change the normal hormonal milieu such that differentiation
in disrupted or altered (169, 188).
Disruption of estrogen homeostasis or ER can negatively impact female
reproductive tract development and result in development of adult reproductive tract
neoplasias, as evidenced by results from in utero exposure to the xenoestrogen DES.
E2 also plays important roles in metabolism and in coordinating the morphological
alterations that occur during the menstrual cycle and pregnancy. Likewise, the
exposure of an adult to abnormal levels of E2 or xenoestrogens can result in infertility
and cancer. This problem, however, is amplified during development when the
reproductive tract is still differentiating, because of the plasticity of the undifferentiated
cells. It is known from the Barker studies of nutrient deprivation during development
(discussed in section 1.1) that signals during development can alter susceptibility to
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cardiovascular disease and diabetes. Similarly, signals of nutrient availability result in
changes in glucocorticoid levels in the fetus, leaving an epigenetic hormonal “imprint”
that determines the ability of the offspring to adapt to the future environment via DNA
methylation of the glucocorticoid receptor (189). When there is a constrast or
“mismatch” between the maternal environment and the environment of the offspring, it
has been postulated that the plasticity of the epigenome may constrain the offspring to
a phenotype that increases risk for adult disease (190, 191).
A key factor in controlling E2 exposure during development is the estrogen
scavenger alpha-feto protein (AFP). AFP is produced by the liver until ~PND 16 in
rodents and decreases precipitously after gestation week 14 in humans (192), which
allows the reproductive tract to initially develop in an estrogen-independent manner.
However, AFP does not usually recognize xenoestrogens, and so exposure to
xenoestrogens during this critical time has been shown to developmentally reprogram
the reproductive tract, or create a “mismatch” in future ER signaling of the offspring.
This “mismatch” can result in permanent alteration of the adult response to
endogenous estrogen (193), and subsequently increase the risk of reproductive tract
neoplasias. Interestingly, in animal models where AFP has been deleted, the
phenotypic result is similar to that of neonatal DES exposure, such that the mice are
infertile and anovulatory (194). This evidence indicates that the reproductive tract
environment during development is dependent upon estrogen concentrations.
In utero exposure to DES in humans is associated with an increased occurrence of
multiple functional disorders, deformations and neoplasias of the female reproductive
tract. These disorders include malformed uteri, infertility, vaginal clear cell carcinomas,
endometriosis and potentially uterine fibroids. Exposure to DES, however, is just one
of many EDCs that have been shown to be associated with disorders of the female
reproductive tract. Epidemiological studies of adult exposure to organochlorines, such
as TCDD, DDT, methoxychlor and PCBs, have shown a correlation between adult
exposure and endometriosis in 4/10 studies (195). DES exposure in utero has also
been correlated with an increased risk of endometriosis (80%; 1.8 relative risk) in
“DES daughters” according to a report from the Nurses’ Health Study II (196).
Additionally, animal studies of in utero or neonatal exposure to xenoestrogens have
demonstrated a developmental reprogramming effect leading to multi-oocyte follicles
and aneuploidy (upon exposure to DES, GEN or BPA). These reprogramming effects,
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which negatively impact fertility and offspring, also result in endometrial neoplasia
(from TCDD or DES) and uterine neoplasias (exposure to DES or GEN) such as
uterine adenocarcinomas (35, 51) and leiomyomas (197). The evidence from all of
these studies indicates that a “mismatch” can be created by inappropriate estrogen
exposure that leads to an abnormal hormonal milieu and increased uterine neoplasias.
1.4.1 Etiology of Uterine Leiomyoma
Developmental reprogramming of uterine neoplasias has been demonstrated by
exposure to xenoestrogens in humans and in animal studies. Specifically, DES
exposure in utero in humans is correlated with an increased risk for uterine
leiomyomas or fibroids (76% in exposed group vs. 52% in unexposed group with
leiomyomas; odds ratio [OR] 2.4, CI 1.1-5.4) (29). Additionally, in women older than 35
years of age who reported “probable” or “definite” exposure to DES in utero, there was
a significant correlation with increased incidence of uterine leiomyoma (47). However,
this association remains controversial (198). Importantly, uterine leiomyomata are one
of the most common gynecological tumors in women (77%) and the leading cause of
hysterectomy among women of childbearing age (199). Uterine leiomyoma are
monoclonal (200) hormone-dependent benign neoplasms that arise from the smooth
muscle layer of the myometrium, and they are characterized by an excess secretion of
extracellular matrix (ECM) proteins. Genetic abnormalities have been observed in
about 40% of uterine leiomyoma, and they include translocations and deletions of
chromosomes 6 and 7 that are associated with mutations in the genes high mobility
group A2 (HMGA2), transforming growth factor beta (TGFβ), fumarate hydratase (FH)
and high mobility group A1 (HMGA1) (201). However, no one common gene mutation
has been linked in all uterine leiomyomas.
Hormone-dependency of uterine leiomyomas has been demonstrated by
several studies, and have shown increased expression of both ER (202) and PR (203)
as well as leiomyoma-specific increases in 17β-estradiol (204) and progesterone
concentrations (205). Together with hormone dependency, several growth factors can
mediate the mitogentic signals of estrogen and progesterone in uterine leiomyomas,
including TGFβ, PDGF (206, 207), bFGF, EGF, IGF-1/IGF-1 receptor and IGF-II (208).
Beyond the role TGFβ has in regulating differentiation and development, it also has
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downstream effects. These effects include the modulation of expression of genes that
result in ECM production and regulation, such as collagens, matrix metalloproteases
(MMP) and tissue inhibitors of MMPs (TIMP) (209). Recently, it was found in vitro that
TGFβ could activate Akt and repress PTEN through miRNA expression/activation,
resulting in increased expression of the ECM protein Col1A2 (210).

For fibrotic

disorders like leiomyomas, tissue remodeling through ECM proteins is a key event in
their progression. Since it has been shown that xenoestrogens modulate miRNA
expression in breast progenitor cells (211), it is possible that they could also
reprogram expression of miRNAs that control the expression of ECM proteins. This
reprogramming of ECM proteins during development could, therefore, increase the risk
of uterine leiomyoma.
Several factors that increase risk for uterine leiomyoma development have
been identified, and they include nulliparity, early menarchy, age (women late in their
reproductive years), ethnicity (e.g. African-American) and obesity (212, 213). Multiple
epidemiological studies of risk factors associated with development of uterine
leiomyomas clearly indicate a relationship between unopposed estrogen and tumor
development. This relationship is supported by the increased risk with nulliparity and
the decreased risk with multiple pregnancies, which has been demonstrated in both
human and animal studies. Furthermore, the risk factor associated with early
menarche, which increases time of exposure to unopposed estrogen, also supports
this relationship. Another theory of uterine leiomyoma development proposes that
progesterone may be more influential than estrogens (205), given that mitotic rates in
leiomyomas are highest when progesterone peaks in the secretory phase of menses
(214). In addition, the progesterone antagonist mifepristone (RU486) has also proven
to be clinically effective at treating uterine leiomyomas.
The question of the initiating event for leiomyoma tumorigenesis, however, still
remains outstanding. Given the widespread prevalence of this disease (i.e. the number
of hysterectomies due to uterine leiomyoma) is 33% in the US (215), 68% in Nigeria
(216), 47.6% in Malaysia (217), and 66.7% in France (218)), it seems the initiator
event(s) would necessarily be shared by many women. As dictated by the principle of
Occams razor, that is, the simplest answer is usually the correct explanation, the
relationship between unopposed estrogen exposure and development of uterine
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leiomyomas seems most likely to be the initiating circumstance. Compared to our
evolutionary lifespan, in the last hundred years we live longer, have children later,
have fewer children, have earlier menarche and have increased obesity incidence
(associated with increased circulating estrogen), which makes the common
denominator very likely to be unopposed exposure to estrogen (212). However, the
predominance of progesterone in uterine leiomyoma development cannot be excluded.
Extending from these theories, we may hypothesize that an early life exposure to
xenoestrogens could create a hormonal milieu via developmental reprogramming of
the reproductive tract that mimics the promotional effects of unopposed estrogen
exposure.
1.4.2 Rodent Uterus Development and the Eker Rat Model of Uterine Leiomyoma
Given that estrogens drive the majority of female reproductive tract neoplasias,
it logically follows that it would be important to determine if developmental exposure to
estrogenic EDCs predispose the reproductive tract to neoplastic transformation. To
understand the etiology of reproductive tract neoplasias, it is necessary to be familiar
with the ontogeny of uterine development, which is species-specific and, as such, has
different windows of susceptibility to EDC exposure. Unlike humans, who complete the
majority of uterine development before birth, rodent uterine development and
maturation is primarily completed after birth (219). Specifically, while Wolffian ducts
regress, Müllarian ducts differentiate into the components of the female reproductive
tract (vagina, oviduct, cervix and uterus) around gestational day 17. In the neonatal
rat, the uterus differentiates from rudimentary mesenchyme and luminal epithelium into
a more differentiated myometrium, with endometrial glands and circular myometrium
present by PND 10. Between PND 10-15, both the longitudinal and circular layers of
the myometrium, as well as the glandular endometrial stroma differentiation, are
completed (220, 221). An important protein that regulates the amount of available
estrogen in the fetus or neonate is alpha-feto protein (AFP), which, as discussed in
section 1.5, binds endogenous estrogen and allows the uterus to develop in an
estrogen-independent manner until ~PND 16 in rodents. This estrogen-independent
uterine development correlates with hormone-independent development of the
endometrial gland. This window when the fetus should be developing in a hormone32

free environment indicates that exposure to DES (which is not bound by AFP) before
PND 16 may cause precocious and permanent gene expression alterations in the
uterus, especially of estrogen-responsive genes. This response to xenoestrogens has
been demonstrated in studies showing that neonatal exposure to DES in CD-1 mice
during critical windows of uterine development (i.e. PND 1-5) permanently alters
normal gene expression of lactoferrin and c-fos, and this persists in tumors (i.e. uterine
adenocarcinomas) (170, 222, 223). Our lab has also shown the existence of a critical
window of susceptibility, PND 3-12, for the development of uterine leiomyoma upon
exposure to DES in the genetically susceptible Eker rat model.
While inheritance of gene defects is the strongest risk factor for cancer,
environmental factors, including obesity, smoking, diet and exercise also contribute to
cancer risk. Early development of malignant vaginal clear cell carcinomas only
occurred in 1% of the DES exposed population, indicating the contributions of other
risk factors, including the inheritance of gene defects. Differential penetrance or
expressivity of disease phenotypes has been canonically attributed to factors such as
modifier genes, environmental factors, allelic variation and gene-environment
interactions (224). The contribution of both gene defects and environmental factors
have been demonstrated to increase cancer risk in epidemiological studies.
Inheritance of mutations in the tumor suppressor genes BRCA1 or BRCA2 are
associated with development of breast and ovarian cancer. However, inheritance of
these mutations demonstrates incomplete penetrance. King and colleagues (225)
examined this issue using data from the New York Breast Cancer Study, which
showed that there was a significant increase in risk for breast cancer in women born
after 1940 as compared to those born before 1940. This study found a significant
positive effect of exercise and body mass index (BMI) in adolescence with decreased
breast cancer incidence in women carrying a BRCA1/2 mutation. Interestingly, in a
study comparing former non-athletes with former athletes, it was found that in former
non-athletes, the relative risk (RR) of developing uterine leiomyoma was 2.53
(RR=1.86 for breast cancer) (226). This may be attributable to the protective benefits
of college athletics, which includes lean body composition as well as dietary factors
(227). A confounding factor in this study is the late age of onset of menarche as well
as the prevalence of ammenorea in female athletes, both of which would decrease the
amount of exposure to unopposed estrogen. This information supports the importance
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of the hormonal milieu in the risk of development of reproductive tract diseases, such
as uterine leiomyomas, and its impact on penetrance of tumor suppressor gene
defects.
One of the best-characterized models of uterine leiomyoma is the Long-Evans
Eker rat model. The Eker rat, which carries a genetic defect, was the first animal
model of renal cell carcinoma, and the gene defect was shown to be inherited in an
autosomal-dominant fashion (228). The Eker rat model also was shown by our group
to develop spontaneous uterine leiomyomas, in addition to the rare leiomyosarcomas
and splenic hemangiosarcomas (229-231). The genetic alteration found to be
associated with these tumors was a germline mutation identified as a retroviral
insertion of DNA (5Kb) between exon 30 and 31 in the tumor suppressor gene
tuberous sclerosis 2 (Tsc-2). This mutation results in the expression of a 3’ deletion of
the GTPase-activating protein (GAP) domain of the TSC2 transcript (232, 233). The Cterminal GAP domain of TSC2 interacts with Rheb, a guanosine triphosphatase
(GTPase), causing a conformational change to its GDP-bound “off” state. In this
conformation, Rheb cannot mediate downstream activation of mammalian target of
rapamycin (mTOR). In a recent study, examination of disease-associated TSC2
mutants revealed that nearly all had a deleterious effect on the GTP hydrolysis activity
of Rheb (234). Furthermore, Eker rats that inherit two mutant copies of Tsc-2 die
between E11 and E13 (235), whereas inheritance of two wild type Tsc-2 alleles
produces no tumors in these animals (236, 237).
Using the Eker rat, we have been able to study the etiology of hormonallydriven uterine leiomyomas and the effects of neonatal xenoestrogen exposure. Eker
rat uterine leiomyomas arise at a spontaneous rate of 65% by 16 months of age,
although they are detectable as early as 10 months. This is similar to the incidence
found in humans. In the Eker rat, as in humans, the majority of uterine leiomyomas
arise from the smooth muscle of the myometrium, and are classified as either typical
(fusiform), epithelioid or mixed. The leiomyomas are typically found at the uterocervical
junction, although several have been found in the uterine horns, and rarely in the
vagina. Additionally, the rare uterine leiomyosarcoma arises in the Eker rat (3/100),
one of which was shown to metastasize to the lung, which is also the typical point of
leiomyosarcoma metastasis in humans. Histologically, the Eker rat uterine leiomyomas
are similar to human uterine leiomyomas. They are characterized by well-differentiated
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smooth muscle cells that are fusiform and elongated in appearance (230). Like human
uterine leiomyomas, Eker rat uterine leiomyomas also have a low mitotic index.
Another characteristic of Eker rat uterine leiomyomas is the loss of tuberin expression
in the majority of tumors, which is the protein expressed from the gene Tsc-2. Loss of
tuberin expression has also been demonstrated in ~50% of human uterine leiomyomas
(N=60 samples) (238). Additionally, in a microarray profiling analysis of human uterine
leiomyomas, tuberin expression was decreased significantly (239). However, only
~50% of the uterine leiomyomas from Eker rats have shown loss of heterozygosity of
the second wild-type allele of Tsc-2, indicating the wild-type allele may undergo missegregation, mitotic recombination, silencing or point mutagenesis (240-243).
Additionally, it is possible that aberrant expression of miRNAs could lead to the loss of
tuberin expression under altered hormonal milieu.
In addition to Eker rat uterine leiomyomas being histologically similar to human
uterine leiomyomas, they are also similar in gene expression profiles. Using data from
five studies (244-247) of gene expression profiles comparing human uterine
leiomyoma to normal myometrium, we compared the gene expression profiles of
genes differentially expressed in human and Eker rat uterine leiomyoma. Of these
differentially expressed genes, 37/566 genes were found to be commonly altered in
both species (Table 1.3) Similarly, Crabtree et al. (248), performed a microarray
analysis using normal myometrium or uterine leiomyoma from human samples and
from Eker rats. They also found that multiple genes (578/1543) were commonly
differentially expressed in tumors from both human and rats, further supporting the
importance of the Eker rat as a model of human uterine leiomyoma.
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TABLE 1.3
36

While we know that inheritance of a tumor suppressor gene defect, such as
BRCA1/2 or Tsc-2, increases the risk for cancer, less is known about the impact of
environmental influences in individuals with genetic mutations on disease penetrance.
Additionally, from multiple human and animal studies it has been shown that
environmental estrogens can alter disease susceptibility in several different genetic
backgrounds. We, as well as others, have demonstrated that one of the most
susceptible windows for increased risk of reproductive tract disease from
xenoestrogen exposure is during reproductive tract development. Given that DES can
developmentally reprogram the reproductive tract in both humans and in genetically
susceptible animal models of reproductive tract disease, we hypothesized that
neonatal exposure to GEN and BPA developmentally reprograms the reproductive
tract through changes in estrogen-responsive gene expression, which increases the
incidence of uterine leiomyoma in Eker rats. The purpose of these studies herein were
to determine: 1) which genes, specific to uterine leiomyoma, are candidates for
developmental reprogramming by xenoestrogen exposure (Specific Aim 1); 2) can
other environmentally relevant xenoestrogens, GEN and BPA, modulate tumorigenesis
in the Eker rat model (Specific Aim 2); and 3) by what mechanism do xenoestrogens
induce developmental reprogramming of the reproductive tract to confer an increased
risk for uterine leiomyoma (Specific Aim 3).
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CHAPTER 2: IDENTIFICATION OF GENES ASSOCIATED WITH
UTERINE LEIOMYOMA REPROGRAMMED BY NEONATAL
EXPOSURE TO DIETHYLSTILBESTROL
(Published Manuscript, Reproductive Sciences, 2008; Appendix A)
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2.1 PURPOSE OF STUDY
The ability of developing tissues to take cues from the environment, while
important for normal patterning, leave it susceptible to aberrant programming leading
to abnormal physiological responses in adulthood. Developmental reprogramming of
disease, or the fetal origins of adult disease, as coined originally by Barker et al., has
been a demonstrated phenomenon for multiple diseases that have origins in utero,
including diabetes and cardiovascular disease (1, 249). Several environmental factors,
such as maternal diet, hypoxia and anthropogenic chemicals, can lead to
developmental reprogramming of the reproductive tract (250, 251). In addition, the
effect of aberrant environmental stimuli can alter the normal morphological program
and hormonal milieu, leading to neoplastic transformation and reduced fertility (5, 252),
which is best exemplified by development of vaginal clear cell carcinoma after in utero
exposure to DES (27).
The etiology of uterine leiomyoma is not well understood. However, the
increased risk of uterine leiomyoma in some cohorts of women exposed to DES
supports the theory that xenoestrogens affect developmental reprogramming, which
leads to diseases of the reproductive tract. Using the genetically susceptible Eker rat,
our previous studies also support the relationship between early life exposure to DES
and increased incidence of uterine leiomyoma (197). In order to elucidate the
mechanism by which DES elicits its developmental reprogramming effects that results
in increased tumor incidence, we conducted gene expression profiling. The purpose of
this study was to identify estrogen-responsive gene targets of developmental
reprogramming by xenoestrogens, which are associated with uterine leiomyoma
development. Identification of genes that are susceptible to aberrant estrogen
exposure is key to understanding the mechanism of developmental reprogramming
and the etiology of uterine leiomyoma.

2.2 METHODOLOGY
2.2.1 Animals and Treatments
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Eker rats from a closed colony at MD Anderson Cancer Center, Science ParkResearch Division were cared for in accordance with the study protocol approved by
MD Anderson Animal Care and Use Committee. Eker rats were given water and
standard rat chow (Harlan Teklad 22/5 (7022) Rodent Diet, Houston, TX) ad libitum
and were maintained on a 14:10 light-dark cycle, which is historically associated with a
65% tumor incidence in this animal model. The reprogramming effects of
xenoestrogen exposure was examined after treating neonatal Eker rats on three
consecutive days, PND 10-12, with 1µg/g body weight of DES [(Sigma Chemical Co.,
St. Louis, MO) in sesame oil] using a total of 50 µl of sesame oil vehicle per s.c.
injection. A separate group of animals were given 50 µl of sesame oil injections as
vehicle controls (VEH). For microarray analysis, 16-month-old Eker rats were
sacrificed via CO2 asphyxiation for tumor and myometrium collection. For
developmental reprogramming analysis, 5-month-old animals were sacrificed for
myometrium collection to determine reproductive tract morphology and isolate RNA for
gene expression analysis. Analysis of estrogen response in neonatal uteri was
evaluated by sacrificing (cervical dislocation) PND 12 animals 6 hours after the last of
3 DES or VEH injections given consecutively on PND 10-12.
2.2.2 Tissue Collection and Histology
From rats sacrificed at 5 and 16 months, vagina, ovaries and uterus were
removed and a section of the uterus (upper right horn) was taken for histology. The
remaining tissue (tumors and whole neonatal uteri or adult myometrium) were snap
frozen in liquid N2 or fixed in 10% neutral buffered formalin (NBF) for 24-48 hours and
then transferred into 70% ethanol before paraffin embedding, sectioning (6 µm) and
staining. Sectioned ovaries, uteri and vagina were stained with hematoxylin and eosin
for analysis of estrus or stage of reproductive senscence in 5 month old and 16 month
old animals, respectively, prior to gene expression analysis. For gene expression
analysis, uteri from adult animals were scraped with a sterile scalpel in cold PBS to
obtain myometrium free of endometrium, and along with tumor tissue, snap frozen in
liquid N2 and stored at -80°. In order to obtain adequate amounts of tissue for RNA
extraction from neonatal animals, 3 uteri were pooled together per sample. Also,
cardiac blood was taken from 5 and 16 month old animals and allowed to clot at 4°C
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overnight, and then the serum was separated by centrifugation at 4°C (1500 X g) for
10 minutes and stored at -20°C until analyzed for hormone (E2 and P4) levels.
2.2.3 Histological Staging of Estrous
Staging was performed in accordance with the procedure described by Cook et
al. (197). Briefly, the stage of estrus or reproductive senescence was determined by
histological examination of ovary, vagina and uterine tissues of 16 and 5-month-old
rats. For 16-month-old rats, they were classified by stage of reproductive senescence
[Pseudo Pregnant (PP), Persistent Estrus (PE) or Anestrus (AN)], as determined by
histological examination of ovaries, vagina and uteri. The stage of reproductive
senescence classified as PP is defined as have a mucified vaginal epithelium and
enlarged ovarian corpora lutea. The PE stage is defined as having a cornified vaginal
epithelium and multiple ovarian follicles; whereas animals in the AN stage have
atrophic ovaries and senescent vaginal epithelium. For 5-month-old VEH rats, stage of
estrus was categorized into proliferative [proestrus (Pro) and estrus (E)] or secretory
[metestrus (Met) and diestrus (Di)] phases as determined by histological examination
of ovaries, vagina and uteri. Animals in proestrus have a keratinized vaginal
epithelium, which begins to slough off during estrus. During metestrus the vagina
becomes muscified and inflammatory cells are present in the uterus; whereas in
diestrus the lumen of the uterus (sagittal section) appears collapsed. For DES-treated
rats that do not cycle normally due to disrupted ovarian function (197), estrogen and
progesterone levels were determined via radioimmunoassay (RIA), obtained using the
Ultra-sensitive Estradiol and Active Progesterone kits from Diagnostic Systems
Laboratories (Webster, TX) according to the manufacturer’s protocol, and as described
by Cook et al. (197). Following the RIA assay all tubes were inverted and allowed to
dry for 2 hours. All tubes were then counted on the gamma radiation counter for 1
minute. After RIA analysis, DES-treated rats were grouped into either high estrogen
and progesterone levels (High E/P) and compared to proliferative phase animals, or
low estrogen and progesterone (Low E/P) for comparison to secretory phase animals.
2.2.4 Microarray Analysis
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RNA from tumors and normal myometrium of 16-month-old Eker rats was
isolated as described previously (197) and analyzed using an Affymetrix Chip Rat 230
2.0 array. Analysis of the array was conducted using the Gene dChip program with
confidence interval set at 95% and differences in fold change in gene expression were
significant at p < 0.05.
2.2.5 Microarray and Statistical Analysis
For analysis of the gene expression changes from the Gene Chip Rat Genome
230 2.0 array, raw signal intensities for each probe set as they are contained in the
CEL

files

were

analyzed

(http://biosun1.harvard.edu/complab/dchip/)

using
model-based

Chen's
expression

dChip
analysis

to

obtain significant genes with fold changes of >1.5 or <-1.5, and a false discovery rate
<0.4% of 50 permutations. After obtaining model-based expression values, both
biased and unbiased hierarchical clustering high-level analysis was performed using
dChip. For statistical analysis of real-time PCR data, a linear model analysis was
applied to estimate the interaction effects of gene and treatment.
2.2.6 Microarray Validation and Real-Time PCR (qPCR)
Validation of microarray data was conducted by real-time PCR of cDNA from
identical samples (if available) or comparable age and stage matched myometrium
and tumors. Frozen tissue (tumors or myometrium) from 16 month old animals were
crushed under liquid nitrogen with mortar and pestle and RNA was isolated after DNA
removal, according to protocol for Ambion’s RiboPureTM Kit (Austin, TX). Following
RNA extraction, cDNA was made by reverse-transcribing 1 µg of RNA using the
Invitrogen SuperscriptTM First-Strand Synthesis System for RT-PCR (Invitrogen,
Carlsbad, CA). Aliquots of cDNA were made for each sample and stored in a 1:10
dilution of tRNA water at -20°C until analyzed. Real-time PCR was performed using
the 7900T Fast Real-Time detection system from Applied Biosystems (ABI, Foster
City, CA). Fast Real-Time Taq-Man assays from ABI were used to analyze gene
expression of Gdf10, Cspg2, Car8, Calbindin D9k, Vcam1, Kcnf1, Rasd2, Sfrp2,
Tacstd1, Krt19, Rps6kb1, Nr2f2, Gria2, Igfbp5, Spp1, Dio2, Aqp3, Ramp3 and Mmp3.
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All real-time PCR reactions were performed by first mixing Universal Fast Real-Time
Master Mix from ABI with the gene assay mix, and then adding 2 µl of cDNA from each
sample to make up a 25 µl volume. For an endogenous control, glyceraldehyde-3phosphate (GAPDH) was used, which included probe and forward and reverse primer
in a 25 µl reaction volume. The following set of conditions were used for each real-time
reaction: 95°C for 10 minutes followed by 40 cycles at 95°C for 1 second and 60°C for
20 seconds. The real-time PCR reactions were all performed in triplicate and were
quantified using the -ΔΔCT

method, which uses the average CT of the GAPDH

subtracted from the target gene CT to obtain the average ΔCT. A calibrator from each
set of samples was chosen from which to subtract individual VEH and DES sample
ΔCT values to obtain the -ΔΔCT. The fold change for each sample was calculated in
comparison to the calibrator by taking 2

-ΔΔCT

. The calibrator for both 16 month and

PND 12 rats was VEH treated myometrium or uteri. For samples from 5-month-old
rats, estrous VEH treated myometrium was used as the calibrator.

2.3 RESULTS
2.3.1 Discovery of Candidate Genes Associated With Uterine Leiomyoma and
Developmental Reprograming in Eker Rats
In

order

to

obtain

candidate

genes

for

DES-induced

developmental

reprogramming in the uterine myometrium, a cDNA microarray analysis was
performed using the Affymetrix Rat 230 2.0 array. To control for hormonal influence
and age, all tissues used for analysis were matched according to stage of reproductive
senescence and age. Stage of reproductive senescence was classified by histological
examination into AN, PP or PE (as described in the Methodology section). Eker rats
historically demonstrate a 65% incidence of uterine leiomyoma by 16 months, so
myometrium or tumors were obtained from animals at this age and RNA was isolated
from each tissue sample for microarray analysis.
After generation of raw gene expression data, dChip was used to determine
clustering hierarchy in both a supervised and unsupervised method. Unsupervised
clustering revealed a distinct differential expression profile between normal
myometrium and tumors from Eker rats. Furthermore, within the tumor samples, which
represented both tumors from unexposed or DES-exposed Eker rats, hierarchical
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clustering demonstrated a distinction between tumors from DES-exposed and
unexposed animals (Figure 2.1). These data indicate that neonatal DES exposure
changes the expression profile of uterine leiomyomas from that of spontaneous tumors
that develop in Eker rats.
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Figure 2.1 Representative heat map of microarray analysis. Heat map represents
unsupervised comparison of VEH PE myometrium and DES PE tumors from 16mo.
old animals.
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Given that uterine leiomyomas are hormonally-driven tumors that demonstrate
dependence on estrogen and progesterone for sustained growth, we chose to focus
on those differentially expressed genes that contained estrogen responsive elements
(as determined by in silico analysis). These were the primary candidate genes for
developmental reprogramming by DES. Using the algorithm in the Dragon Estrogen
Responsive Element v 2.0 program (http://sdmc.lit.org.sg/ERE-V2/index (no longer
available)) (253), which utilizes canonical and non-canonical ERE patterns to identify
known or putative EREs in genes, we identified 112/171 (65%) of the differentially
expressed genes as estrogen-responsive. Specifically, the analysis revealed 86 genes
with a putative ERE, and 26 genes with a known functional ERE. The large number of
differentially expressed genes that were identified as estrogen-responsive in tumors as
compared to normal myometrium demonstrates the hormone-dependence of uterine
leiomyoma development. Examples of the genes identified in silico as containing
EREs are listed in Table 2.1.
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TABLE 2.1

Table 1
Gene

Selected Representative ERE Containing Genes Identified by Dragon 2.0
Predicted
ERE Predicted
ERE
ERE location relative to
(Forward)
(Reverse)
the 5' end of the gene

Dio2
CalbindinD9k

GRIA2

CA-GGTCA-GGG-TGATCTT
AG-GGTCT-ATG-TAGCCCA
GA-GGTCA-GTC-TGATCAA
AA-AATCA-AAT-TGACC-CC

CAR8

GT-AGTCA-CAC-CAACC-CT
CA-AGTCA-AAA-CAACC-CT

GDF10

MMP3

GT-GGTCA-TCT-CAACC-CT
AA-GATCA-CCC-TGACCTG

R=-9376
F=50; R=-66
F=1507

GG-GGGCA-TTG-TGACCCT

F=19005; R=-51017

CC-AGTCA-TTC-TGCCC-AA
TG-GGTCC-ACT-TGCCCTC
AA-GGTGG-CTT-TGTCCAG
AT-GGACA-ATA-TGACC-TT
AT-GGTCA-AGA-TGCCTGA
AG-GCTCA-CAC-TGCCCTC

F=19719; R=-2244

GT-AGTCA-CCA-CACCC-TT

R=-12519
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F=33744; R=-38190
F=45678; R=-9263
R=-10503
R=-10442
R=-7249

After identification of estrogen-responsive genes, we chose 19 of these genes that
seemed to have the most biological relevance to uterine leiomyoma for validation
against the results from the microarray analysis. qPCR analysis of these 19 genes
showed 18/19 to be valid in differential expression using identical samples (when
available) from the cDNA microarray (Table 2.2). The 18 validated estrogenresponsive genes were used for the remainder of the study as a training set of
candidate genes for further analysis of developmental reprogramming by DES in
neonatal and adult myometrium.
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TABLE 2.2
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2.3.2 Developmental Reprogramming of Estrogen-Responsive Genes by
Neonatal Exposure to DES
Developmental reprogramming of candidate genes were analyzed for 1) their
response to DES exposure immediately after treatment (e.g. 6 hours after the last
injection on PND 12); and 2) the persistence of gene expression changes in the adult
myometrium from DES-exposed or control rats. We characterized genes as
developmentally reprogrammed if gene expression was responsive to estrogen
neonatally, and subsequently if expression was significantly different in DES exposed
myometrium in comparison to VEH (control) animals in stage and age-matched adult
myometrium. As demonstrated previously by our laboratory, neonatal exposure to
DES induces a robust reprogramming effect, which results in lack of normal estrus in
these animals (197). Hence, in order to compare gene expression accurately in VEH
and DES animals, estrogen and progesterone levels were measured and grouped into
either high estrogen/progesterone (High E/P) or low estrogen/progesterone (Low E/P),
which would be concordant with the proliferative (proestrus/estrus) phase and the
secretory (metestrus/diestrus) phase, respectively. These groups were then stage and
age-matched (5 months of age) to VEH animals for analysis of developmental
reprogramming of gene expression.
Upon analysis of candidate genes for developmental reprogramming we found
that DES initially induced precocious expression of genes that are normally either
induced or repressed after puberty by endogenous estrogen. These genes fell into two
categories: a) genes that were induced in their expression immediately after neonatal
DES exposure and whose adult expression became hyper-responsive to estrogen;
and b) genes that were repressed immediately after neonatal DES exposure and
whose expression was significantly induced in the proliferative phase as compared to
VEH. Those genes that fell into first category included one of two genes that we had
previously identified as developmentally reprogrammed by neonatal DES exposure,
Calbindin D9k (254), which served as an internal control for this study. The other gene
with a similar reprogramming profile was Dio2, which was significantly induced in
expression by DES exposure neontally and remained induced by endogenous
estrogen in the proliferative phase (Figure 2.2).
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Figure 2.2 Real-time RT-PCR for DES-reprogrammed genes induced by hormone
in uteri (PND 12) (left panel), and myometrium (5 months) (right panel). A-B)
Gene expression for Calbindin D9k and Diodinase 2 (Dio2) at PND 12 (VEH n = 9,
DES n = 9), 5 months (VEH = 5, DES = 5). ** = p≤0.001, * = p≤0.05.
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Genes whose developmental reprogramming profile fell into the second
category of initial repression followed by hyper-responsiveness in the adult
myometrium, included Car8, Gdf10, Gria2 and Mmp3 (Figure 2.3).

This striking

difference between the initial repression of gene expression, which mimicked the adult
response, was reversed by DES exposure. Specifically, in the adult exposed to DES
neonatally the response to endogenous hormones was opposite of those not exposed
to DES, which caused an increase in expression in the proliferative phase rather than
repression. These data reveal an important mechanism of DES reprogramming.
Regardless of whether the estrogen-responsive gene was normally repressed or
induced by endogenous estrogen, the effects of neonatal DES exposure was to induce
a hyper-responsiveness in the adult myometrium as compared to VEH animals.
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Figure 2.3 Real-time RT-PCR for DES-reprogrammed genes repressed by
hormone in uteri (PND 12) (left panel), and myometrium (5 months) (right panel).
A-D) Gene expression for carbonic anhydrase 8 (Car 8), growth differentiation factor
(Gdf10), glutamate receptor 2 (Gria2) and matrix metalloprotease 3 (Mmp3) at PND 12
(VEH n = 9, DES n = 9), and 5 months (VEH = 5, DES = 5). ** = p≤0.001, * = p≤0.05.
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In order to determine if these developmentally reprogrammed genes were
persistent in their overexpression in uterine leiomyoma from Eker rats, we compared
the expression of reproductively senescent myometrium to tumors in age (16 months)
and stage-matched (PE) animals

(n=8) via qPCR. Importantly, 5/6 of the genes

(Gdf10, Car8, Gria2, Dio2, and Mmp3) identified as developmentally reprogrammed by
neonatal DES exposure in the adult myometrium were found to be overexpressed in
tumors (n=4) as compared to senescent myometrium (n=4) (Figure 2.4). These data
reveal a potential mechanism by which DES induces an increased susceptibility to and
an increased incidence of uterine leiomyoma. DES induces a hyper-responsive state
in estrogen-responsive genes in the adult myometrium that are commonly upregulated
in

uterine

leiomyoma.

Unlike

VEH-treated

animals,

DES

developmentally

reprogrammed gene expression in the myometrium that correlated with uterine
leiomyoma formation, thereby altering the normal hormonal milieu in such a way as to
create an enhanced environment for uterine leiomyoma development.
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Figure 4. Real-time RT-PCR for reprogrammed genes differentially expressed in
PE tumors vs PE myometrium from reproductively senescent Eker rats. A-F)
Gene expression for Calbindin D9k, deodinase 2 (Dio2), carbonic anhydrase 8 (Car 8),
matrix metalloprotease 3 (Mmp3), growth differentiation factor (Gdf10), and glutamate
receptor 2 (Gria2) (PE myometrium n=2, PE tumors n=8) ** = p≤0.001, * = p≤0.05.
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2.4 DISCUSSION
Xenoestrogens, including DES, have been shown to induce reproductive tract
malformations via developmental reprogramming, leading to neoplastic transformation.
In utero DES exposure, as demonstrated in epidemiological studies (29, 47), is
associated with the highly prevalent reproductive tract disease uterine leiomyoma,
indicating that early life exposure to xenoestrogens is a risk factor for development of
this disease. In our previous studies we have also shown that early life DES exposure,
in the presence of a tumor suppressor gene defect, increases uterine leiomyoma
incidence to 100% (197) when exposure occurs during the critical development period
for rodent uterus formation (PND 3-12) (254). While multiple studies have identified
gene defects in uterine leiomyoma, little is known about the mechanisms of
developmental reprogramming in the reproductive tract that gives rise to increased
incidence of uterine leiomyoma. To address this gap in knowledge, we undertook a
gene expression profiling study to identify genes in the myometrium that are targets of
reprogramming by DES. Comparing uterine leiomyomas and myometrium, we
selected 18/171 estrogen-responsive genes as candidates for developmental
reprogramming by DES. Expression of 6 of these genes (Gdf10, Car8, Calbindin D9k,
Gria2, Dio2 and Mmp3) (255) were found to be reprogrammed by neonatal exposure
to DES in the myometrium, 5 of which, Gdf10, Car8, Gria2, Dio2 and Mmp3, retained
an elevated level of expression in tumors. This increased expression was identified in
tumors from both DES-exposed as well as unexposed animals, indicating that DES
induces developmental reprogramming of estrogen-responsive genes that associated
with genes that are normally differentially expressed in uterine leiomyoma.
In concordance with studies that show the dependence of uterine leiomyoma
growth on estrogen, our gene expression analysis also demonstrated that the majority
(65%) of genes found to be differentially expressed in tumors were either known or
predicted estrogen-responsive genes. In several transcriptional profiling studies (222,
256, 257), DES has demonstrated the ability to induce or repress the expression of
estrogen-responsive genes in vitro (MCF7 cells) and in vivo (neonatal rat uteri). In
addition, Hong et al. also identified Calbindin D9k to be induced by DES exposure in
immature rat uteri, which supports our findings (258). A hallmark of DES exposure that
we found in our study was its ability to induce the persistent expression of genes both
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increased and repressed normally by endogenous estrogens. These findings indicate
that DES induces a hyper-responsiveness, given that developmentally reprogrammed
genes were expressed even during phases of estrous characterized by low estrogen
levels (i.e. secretory phases; metestrus/diestrus). Importantly, in CD-1 mice
susceptible to uterine adenocarcinoma, Newbold et al. (169) found that neonatal
exposure to DES induced the persistent elevation of estrogen-responsive genes
associated with tumor development. This study together with ours indicates that in
estrogen-driven tumors, the effect of neonatal DES exposure is to reprogram gene
expression in the uterus/myometrium of genes that are important in tumor
development. These data suggest that DES leaves a “hormonal fingerprint” that alters
the normal hormonal milieu via differential gene expression, leading to increased
uterine tumor development.
The mechanisms by which developmental reprogramming of estrogenresponsive genes occurs has yet to be fully elucidated. Several studies, however,
have provided evidence to suggest that epigenetic modification may be playing a role
in gene expression alterations leading to physiological changes in estrogen response.
In particular, the perturbation of DNA methylation in estrogen-responsive genes has
been demonstrated as a mechanism of neonatal DES exposure. Li and colleagues
(171),

demonstrated

that

the

estrogen-responsive

gene

c-fos

becomes

hypomethylated at Exon 4 and subsequently remains overexpressed in the adult
uterus after neonatal DES exposure. Interestingly, the hypomethylation was most
apparent by PND 17, which corresponds with the decrease in the estrogen-binding
protein AFP and the increase in estrogen in the uterus. This indicates that the
epigenetic programming response to estrogen changes if DES exposure occurs during
development. Similarly, in a previous study by the same group, they showed that the
estrogen-responsive gene lactoferrin was also persistently up-regulated, which
corresponded to site-specific DNA hypomethylation after neonatal DES exposure in
the uterus (170). Furthermore, they illustrated the critical importance of adult
endogenous estrogen production on establishing DES-induced changes in DNA
methylation, given that only in the mature uteri was lactoferrin shown to be aberrantly
demethylated. Importantly, this aberrant methylation was also sustained in uterine
tumors from mice exposed neonatally to DES. Recently, Tang et al. (174) provided
evidence that the estrogen-responsive chromatin remodeling gene Nsbp1 undergoes
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promoter hypermethyaltion immediately after DES exposure. However, upon exposure
to adult hormones this pattern reversed, leading to hypomethylation of Nsbp1 and
over-expression that persisted in adulthood and corresponded to the formation of
uterine tumors. These data indicate that DES triggers an epigenetic event in estrogenresponsive genes that becomes unmasked in certain genes by adult hormone
exposure, which permanently changes the expression of the gene and potentially the
susceptibility to uterine tumor formation.
In conclusion, the results of this study show that DES exposure during a critical
period of formation for the uterus in rodents developmentally reprograms expression of
estrogen-responsive genes associated with uterine leiomyoma formation. As will be
demonstrated in Chapter III, the xenoestrogen genistein also modulates expression of
estrogen-responsive genes and correlates with tumorigenesis, which supports the
results of this study (Table II.3). The importance of these finding are relevant to
humans because multiple genes identified in this study are also increased in
expression in human uterine leiomyomas. The identification of genes reprogrammed
by DES prior to tumorigenesis that are also up-regulated in human leiomyoma indicate
that these genes may harbor features that make them susceptible to alteration during
development

by

premature

estrogen

exposure.

Additionally,

elucidating

the

mechanism of DES-induced developmental reprogramming of gene expression in the
reproductive tract will facilitate the process of defining the relationship between
environmental endocrine disruptors, such as xenoestrogens, and increased risk of
uterine leiomyoma.
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CHAPTER 3: XENOESTROGEN-SPECIFIC MODULATION OF NONGENOMIC SIGNALING THROUGH HISTONE METHYLTRANSFERASE,
EZH2, CORRELATES WITH DEVELOPMENTAL REPROGRAMMING
OF GENE EXPRESSION AND TUMORIGENESIS
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3.1 STUDY PURPOSE
The term “developmental reprogramming”, as described in chapter 1, is used to
describe the effects of early life exposures to adverse stimuli that can alter the
response to normal physiological signals and give rise to disease in adulthood.
Numerous studies, including those from our laboratory, demonstrate that perinatal
exposure to xenoestrogens, many found ubiquitously in the environment, can
developmentally reprogram the female reproductive tract, causing alterations in
morphology, hormonal milieu, and gene expression, which can give rise to diseases
such as infertility and cancer, as described in chapter 1 and illustrated in chapter 2 (41,
51, 252, 259-261). Developmental reprogramming of the reproductive tract by
exposure in utero to the xenoestrogen diethylstilbestrol (DES) was an early example of
this phenomena.
Although DES is no longer in clinical use, other environmental xenoestrogens
have the potential to affect the developing reproductive tract and induce
developmental reprogramming. For example, bisphenol A (BPA) can induce
morphological abnormalities of the reproductive tract in rodents exposed neonatally to
this xenoestrogen (69, 71, 72, 74, 77, 262, 263). BPA can cause precocious puberty,
persistent vaginal cornification, lack of corpora lutea, cystic ovaries, cystic endometrial
hyperplasia, and polyovular follicles in adult animals exposed perinatally to this
compound (76, 77, 264, 265). Importantly, neonatal exposure at environmentally
relevant micromolar doses has been shown to promote neoplastic transformation of
the male reproductive tract, including formation of prostatic intraepithelial neoplasia
(266). Genistein (GEN) can also induce developmental reprogramming of the female
reproductive tract in animals. As described in chapter 1, multiple studies report that
neonatal exposure to environmentally relevant doses of GEN (e.g., 2.4-6.6 µM in
plasma) (48) aberrantly affects reproductive function and morphology as evidenced by
induction of ovarian and uterine morphological abnormalities, persistent estrus,
accelerated vaginal opening, infertility, early reproductive senescence, multioocyte
follicles, and uterine adenocarcinomas (51, 54, 56). Importantly, in a recent
epidemiological study of over 19,000 women, a correlation was found between early
life soy formula consumption and increased risk of uterine leiomyomas (267), further
supporting the relevance of this study to the human disease.
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While uterine leiomyoma are the most frequent gynecologic tumor of women,
little is known about how environmental exposures may contribute to the high
incidence of this disease. Previous studies from our group have demonstrated that, in
genetically predisposed Eker rats, susceptibility to the development of uterine
leiomyoma is modulated by developmental exposure to DES via developmental
reprogramming (197, 268). In these animals, DES also reprogrammed the morphology
of the reproductive tract, giving rise to persistent vaginal cornification and ovaries that
lacked corpora lutea. And as demonstrated in chapter 2, microarray analysis identified
several estrogen-responsive genes developmentally reprogrammed by neonatal DES
exposure, which became hyper-responsive to hormone in the uteri of adult animals
prior to the onset of tumors (269).
The

mechanism(s)

by

which

xenoestrogens,

such

as

DES,

induce

developmental reprogramming of gene expression, however, is not well understood.
The canonical pathway of genomic activation by estrogen receptor (ER) is well defined
and can be induced by both steroidal (17β-estradiol) and non-steroidal chemicals
(xenoestrogens). In contrast, the non-canonical pathway of rapid ER signaling is less
well understood, though several studies demonstrate that rapid, non-genomic ER
signaling via mitogenic pathways, including Akt and MAPK, is important for blood
vessels vasodilatation, neuron survival, bone turnover and reproductive function.
Importantly, xenoestrogens can also trigger non-genomic ER signaling in vitro through
activation of PI3K/Akt, MAPK and PKA/PCK, albeit with tissue- and dose-specific
effects on pathway activation (93, 95). The importance of appropriate ER-mediated
signaling during development of the reproductive has been demonstrated in ERα
knock-out mice (ERKO), which are resistant to the DES-induced alterations in gene
expression and neoplasias of the uterus (270). Hence, inappropriate non-genomic ER
activation during development by xenoestrogens could lead to permanent alterations
in the uterine response to hormones.
Interestingly, non-genomic signaling can induce epigenetic modifications
including cytosine and histone methylation. Several studies have demonstrated a role
for

epigenetic

modulation

by

xenoestrogens,

specifically

DNA

methylation

perturbation. Alterations in DNA methylation have been observed after neonatal
exposure to multiple xenoestrogens including DES, GEN and BPA for several
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estrogen-responsive genes (i.e. c-fos, lactoferrin and Nsbp1) (170, 171, 174). The
question of how epigenetic reprogramming of gene expression by xenoestrogens
occurs, though, remains. In addition to DNA methylation, histone modifications can
create binding sites for several enzymes, DNA and histone methyltransferases (HMT),
that recognized site-specific chromatin marks. Specifically, histone methylation
catalyzed by HMTs can result in the repression (i.e. H3K27) or activation (i.e. H3K4) of
gene expression, in general. In our laboratory, we identified a mechanism by which
DES can modulate non-genomic signaling through activation of the PI3K/Akt pathway
leading to changes in phosphorylation of a histone methyltransferase, enhancer of
zeste homologue 2 (EZH2). We demonstrated, in vitro and in vivo, that increased
phosphorylation of EZH2 after DES exposure results in decreased levels of the target
of EZH2 activity, tri-methyled lysine 27 on histone 3 (H3K27me3). Reduction of
H3K27me3 levels, a repressive mark for gene expression, by siRNA knock-down of
EZH2 correlated with the increased expression of developmentally reprogrammed
genes previously identified by our laboratory, PR and Igfbp5 (271). Because this
mechanism of non-genomic ER signaling results in epigenetic modifications after DES
exposure, the purpose of this study was to investigate whether this mechanism was
shared by other xenoestrogens, GEN and BPA. Furthermore, like DES, we
hypothesized that developmental reprogramming of gene expression by GEN and
BPA would also modulate tumorigenesis in our animal model of uterine leiomyoma.

3.2 METHODOLOGY
3.2.2 Animals and treatments
Eker rats bred from a closed colony at The University of Texas M. D. Anderson
Cancer Center in Smithville, TX, were cared for in accordance with the guidelines of
the M. D. Anderson Cancer Center Animal Care and Use Committee in an ALAC
accredited facility. Female Eker rats were maintained on standard rat chow (Harlan
Teklad 22/5 rodent Diet), which is associated with a historical 65% tumor incidence in
this animal model, and this was factored into baseline data. The rats were given water
ad libitum and maintained on a 14:10 light-dark cycle. The reprogramming effects of
xenoestrogens were examined after treating neonatal Eker rats on postnatal days 10
through 12 with BPA 50 mg/kg (Acros Organics, Morris Plains, NJ) or GEN 50 mg/kg
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(Sigma Chemical Co., St. Louis, MO) dissolved (BPA) or suspended (GEN) in sesame
oil, using a total of 50 µl of this solution in vehicle for each subcutaneous injection. A
separate group of animals were given vehicle (VEH) only as controls. Upon weaning,
all animals were genotyped for the presence of the Eker mutation (Tsc-2+/+ vs. Tsc2Ek/+) and housed in no more than three per cage. For developmental reprogramming
analysis, 61 animals were killed at 3 months by CO2 asphyxiation, at which time
reproductive tract morphology and gene expression were examined. Analysis of acute
response to xenoestrogen was evaluated in 12 animals killed 6 hours after the last of 3
daily injections of xenoestrogen (postnatal day 12) by cervical dislocation. Female rats
were killed at 16 months by CO2 asphyxiation (VEH n=17, GEN n=14, BPA n=30) and
ovaries, uteri and vagina were collected. Any gross tumors were also collected
separately and snap frozen at -80°.
3.2.2 Tissue collection and histological studies
Uteri from PND12, 5 month and 16 month were fixed in 10% neutral buffered
formalin for 24-48 hours and then transferred into 70% ethanol before being
embedded in paraffin and stained with hematoxylin-eosin (H&E) or incubated with
antibody directed against Calbindin D9k (1:2000; Swant, Bellinoza, Switzerland) for
1hour as described previously (254). In addition to uteri, vagina and ovaries from 5
and 16 month old animals were also fixed, embedded and stained with H&E for estrus
categorization. Tumors were measured and sectioned for pathological examination,
and a portion of each snap-frozen in liquid nitrogen. Additionally, the uninvolved uterus
was sectioned and analyzed for microscopic tumors, which together with quantitation
of macroscopic lesions was used to calculate tumor incidence and multiplicity. Threemonth-old animals were killed and their uteri were scraped with a sterile scalpel in cold
PBS to remove endometrium from myometrium, were snap-frozen in liquid nitrogen
and stored at -80°C. To obtain adequate amounts of tissue for RNA extraction from
animals killed 6 hours after treatment on PND 12, two to three uteri were pooled
together.
3.2.3 Histological categorization of estrous
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Reproductive staging was performed in accordance with the procedure
described in chapter 2. Briefly, reproductive stage was determined by histological
examination of the ovaries, vaginas, and uteri of 16- and 3-month-old rats. The 16month-old rats were staged according to degree of reproductive senescence (pseudo
pregnant, persistent estrus, or anestrus). 3-month-old rats were categorized as being
in proestrus, estrus, metestrus, or diestrus stages of the estrus cycle.
3.3.4 Real-time PCR (qPCR)
As described in chapter 2, frozen tumors, myometrium or uteri from 16-monthold, 3-month-old and 12-day-old animals, respectively, were crushed under liquid
nitrogen with mortar and pestle and RNA isolated and DNA removed by using the
RiboPureTM Kit (Ambion Biosystems, Austin, TX) according to the manufacturer’s
protocol. Following RNA extraction, cDNA was made by reverse-transcribing 1 µg of
RNA through the Invitrogen SuperscriptTM First-Strand Synthesis III System for reverse
transcriptase (RT)-PCR (Invitrogen, Carlsbad, CA). Aliquots of cDNA were made for
each sample and stored at -20°C until analyzed. cDNA from neonatal uteri, 3-month
myometrium, or age- and stage-matched myometrium and tumors were subjected to
quantitative real-time polymerase chain reaction analysis (qPCR). qPCR was
performed by using the 7900T Fast Real-Time detection system from Applied
Biosystems (ABI, Foster City, CA). Fast Real-Time Taq-Man assays from ABI were
used exclusively to analyze expression of the Gdf10 (Rn00666937_m1), Calbindin
D9k (Rn00560940_m1), Rasd2 (Rn00592054_m1), Sfrp2 (Rn01458836_m1), Krt19
(Rn01496867_m1), Nr2f2 (Rn00756178_m1), Gria2 (Rn00568514_m1), Igfbp5
(Rn00563116_m1),

Spp1

(Rn00563571_m1),

Car8

(Rn01473820_m1),

Mmp3

(Rn00591740_m1), Tacst1 (Rn00684677_m1), Rps6k (Rn00667685_m1), Kcnk2
(Rn00572452_m1), Cspg2 (Rn01493763_m1), Aqp3 (Rn00581754_m1), Ramp1
(Rn00671666_m1) and Dio2 (Rn00581867_m1) genes. All Q-PCR reactions were
performed by mixing Universal Fast Real-Time Master Mix from ABI together with the
gene assay mix first and then adding 2 µl of cDNA from each sample to make up a 25µl volume. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or ribosomal 18s
(18s) were used as endogenous controls, including probe and forward and reverse
primers in a 25-µl reaction volume. Specifically, 18s was utilized for comparison to
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estrogen-responsive genes in the adults due to significant association of GAPDH
expression with BPA exposure. The following set of conditions were used for each fast
Q-PCR reaction: 95°C for 10 minutes, followed by 40 cycles of 1 second at 95°C and
20 seconds at 60°C.
The qPCR reactions were all performed in triplicate and were quantified by the ΔΔCT method, which uses the average CT of the GAPDH or 18s subtracted from the
target gene CT to obtain the average ΔCT. A calibrator was chosen from each set of
samples from which to subtract individual GEN, and BPA sample ΔCT values to obtain
-ΔΔCT. The fold change for each sample was calculated in comparison to the calibrator
by taking 2-ΔΔCT. The calibrator for both 16-month-old and 12-day-old rats was VEHtreated myometrium or uteri. For the 3-month-old rats, an estrus-staged matched VEH
myometrium was used.

3.2.5 Preparation of tissue lysates and immunoblotting
Frozen tissue from neonatal animals (PND 12) treated with VEH, GEN or BPA
and harvested at 1, 6 or 12 hrs after the injection was used for the preparation of
protein lysates for immunoblotting. Uteri from 3 neonatal animals were pooled together
in RSB buffer (10 mM Tris HCl pH7-7.4, 10 mM NaCl, 3 mM MgCl2, 1 mM PMSF, 1
mM Na3VO4, 1 mM NaF, and Complete Protease Inhibitor Cocktail (Roche Applied
Science, Indianapolis, IN)) with 0.5 % NP-40. Tissue was homogenized using a
dounce homogenizer and incubated on ice for 10 min. Tissue lysates were then
centrifuged for 15 min at 15,000 rpm at 4°C and supernatant collected. Protein
concentration of tissue lysate was determined using the Pierce BCA assay (Thermo
Fischer Scientific, Rockford, IL). 10-20 µg of tissue lysate was separated via SDSPAGE on 10% gels (BioRad Laboratories, Hercules, CA) and transferred overnight at
4°C to polyvinylidene diflouride (PVDF) membranes that were activate with methanol.
Membranes were blocked in 1X tris-buffered saline plus 0.5% Tween 20 (TBST) and
5% non-fat milk for 1 hour. Membranes were washed briefly with 1 X TBST and then
incubated with primary antibody for 2hrs or overnight at 4° and washed with TBST
followed by incubation for 1-2hrs with HRP-conjugated secondary antibody.
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Visualization of protein abundance was performed using Pierce ECL substrate or ECL
plus (Thermo Fischer Scientific, Rockford, IL) on autoradiograph film (Biomax MR,
Kodak, New York, NY). Immunoblotting was performed with antibodies against
phosphorylated Akt (S473) and (T308), Akt, phosphorylated S6 (S235/236), S6, and
histone H3 obtained from Cell signaling Technology (Montgomery, TX). Antibodies
against H3K27me3 and EZH2 were obtained from Active Motif (Carlsbad, CA). The
antibody recognizing phosphorylated EZH2 (S21) was obtained from Bethyl
Incorporated (Montgomery, TX).
3.2.6 Immunohistochemistry
Tissue embedded in paraffin were cut into 5 µm sections and placed on slides
for deparaffinization. Slides were heated at 60°C for 1hr and then in further deparaffinized in Citrusolv for 5 minutes 3 times. This was followed by rinsing in 100%
EtOH for 2 minutes twice. Sections were progressively rehydrated in 90%, 80% and
70% EtOH for 2 minutes each and rinsed with water for 1minute. Slides were then
boiled in Antigen unmasking solution for 5 minutes and allowed to cool for 30 minutes,
which were then rinsed with PBS for 5 minutes twice. Blocking of endogenous
peroxidase activity was performed in 2% H2O2 for 30 minutes and rinsed in PBS. After
washing in PBS, non-specific binding with blocked with Avidin D and Biotin for 15
minutes and washed with PBS. Sections were then incubated overnight at 4° in
primary antibody, calbindin D9K (1:2000, Swant), in 5% goat serum plus 0.3% Triton-X,
and then rinsed in 0.03% TBST for 10 minutes twice and washed with PBS for 10
minutes. Sections were then incubated with horseradish peroxidase-conjugated
secondary antibody for 1hr and visualized by staining with Tablet DAB (Sigma
Chemical Company).

3.2.7 Immunoprecipitation
Tissue lysates from the above preparation were pre-cleared using protein A
sepharose beads (GE healthcare, Piscataway, NJ) and rabbit IgG (Millipore, Billerica,
MA). Pre-cleared lysates were incubated with antibody against phosphorylated EZH2
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and protein A sepharose beads and then washed with Cell Signaling Technology
(CST) lysis buffer (20 mM Tris-HCl pH 7.5, 1 mM EGTA, 1 mM Na2EDTA, 150 mM
NaCl, 1 mM beta-glycerophosphate, 2.5 mM sodium pyrophosphate, 1% Triton-X, 1
mM PMSF, 1 mM NaF and Roche Complete Protease Inhibitor Cocktail). 100-500 µg
of protein lysate from immunoprecipitation was separated and immunoblotted as
describe previously.

3.2.8 Acid Precipitation of Histones from Tissue Lysate
Cell pellets obtained from preparation of tissue lysates describe above, were
resuspended in a 1:1 ratio of 5 mM MgCl2 and 0.8 M HCl and sonicated for 20 sec
(30% power) followed by a 1hr incubation on ice. Histone proteins were collected by
centrifugation for 10 min at 14,000 rpm (4° C), supernantant transferred to a new tube
and precipitated with trichloroacetic acid (50%) and ddH2O. Histone precipitants were
collected after centrifiguation for 20 min at 14,000 rpm (4° C). Histone pellets were
washed with cold acetone and allowed to dry before reconstituting in a solution of 1.5
M Tris-HCl pH 8.8 and ddH2O. Histones were quantitated after separation on Tristricine gels (10-20%) followed by staining with coomassie. After estimating protein
abudance histones were loaded equally and SDS-PAGE was performed using 10-20%
Tris-tricine gels, followed by transferring to PVDF. Immunoblotting was performed as
describe above with total H3 used to determine relative histone methylation levels or
with antibody against H3K27me3.

3.2.9 Statistics
For statistical analysis of qPCR data, a linear model analysis was applied to
ΔCT values to determine the effects of gene and treatment, which were determined to
be significant at p value of <0.05. Analysis of tumor incidence was estimated using
chi-square for the determination of significance between treatment groups. Tumor
multiplicity was analyzed using the Poisson regression for comparing multiple tumors
between VEH, GEN and BPA groups. A value of p < 0.05 was considered statistically
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significant. For detecting quantitative differences in immunblotting experiments, a
Students t-test was applied to densitometry values (n=3) to determine significance.

3.3 RESULTS
3.3.1 Xenoestrogen-specific activation of non-genomic signaling in the neonatal
uterus
In our previous report, (271) we established that neonatal DES exposure
initiates rapid ER-dependent activation of the PI3K/Akt pathway, which also induced
phosphorylation of S6, the downstream readout of mTOR activation. In this study we
investigated the ability of GEN and BPA to induce rapid activation of Akt and S6 after
neonatal exposure to DES (1 mg/kg), GEN (50 mg/kg), three different doses of BPA
(50 mg/kg, 50 µg/kg or 50 ng/kg) or VEH over a time course of 1, 6 and 12 hrs after
subcutaneous injection. On PND 12, a period defined as susceptible to developmental
reprogramming by DES (254), uteri exposed to GEN or DES (control) demonstrated
activation of Akt and S6 at 6hrs as illustrated in Figure 3.1A by the significant increase
in phosphorylation at S473 and T308 on Akt and S235/236 on S6. In contrast, neither
BPA, at any dose, or VEH induced significant activation of this pathway at any of the
time points tested (Figure 3.1B). Using DES as a control, these data support our
previous in vitro and in vivo findings showing activation of non-genomic ER signaling
via Akt, but also demonstrate in vivo that xenoestrogens do not share the same
mechanism of activation in the developing uterus.
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Figure

3.1

Xenoestrogen-specific

modulation

of

non-genomic

PI3K/AKT

signaling. A) Western blot analysis of AKT phosphorylation (T308 and S473) and S6
phosphorylation in pooled (3) uteri of PND 12 Eker rats after exposure for 1-12 hrs to
VEH, GEN (50 mg/kg) or BPA (50mg/kg) via s.c. injection. B) Lysates were collected
from pooled (2-3) Eker rat uteri on PND 12 exposed to 50 mg/kg, 50 µg/kg or 50 ng/kg
of BPA or VEH for 6hrs. Western blot analysis and densitometry of uteri revealed no
significant activation of the PI3K/AKT pathway as compared to VEH. Densitometric
quantification of western blot analysis demonstrates significant differences in activation
of AKT as represented by the ratio phospho-AKT T308 and S473 to total AKT in
xenoestrogen-exposed animals vs. VEH. Mean ± SEM is donated by error bars on
each graph. The Student’s t-test was used to determine statistical significance, which
was set at a value of *p<0.05.
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3.3.2 Xenoestrogen-specific modulation of EZH2 in the neonatal uterus
As EZH2 is critical to embryonic development, it is important to investigate the
impact inappropriate exposure to xenoestrogens has on its activity and expression. In
a similar manner to DES, GEN exposure also results in increased phosphorylation of
EZH2 at time frame that corresponds to the activation of Akt (Figure 3.2). However,
this phosphorylation event was not observed in BPA or VEH exposed uteri (Figure
3.2). Importantly, the target of EZH2 activity H3K27me3 was reduced in GEN exposed
animals, as shown in Figure 3.2 by decreased levels of H3K27me3 in chromatin. At
6hrs after exposure to BPA this trend was not observed, which is consistent with lack
of activation of Akt and phosphorylation of EZH2 (Figure 3.2). Together this evidence
supports that rapid activation of Akt via ER in the developing uterus has xenoestrogenspecific effects on EZH2 activity, which modulates global H3K27me3 levels in
chromatin.
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Figure 3.2 Xenoestrogen-specific modulation of EZH2 and H3K27me3. Neonatal
PND 12 pooled (2-3) uteri from Eker rats were homogenized 6hrs after exposure to
VEH, GEN (50 mg/kg) or BPA (50 mg/kg) and immunoprecipitated with anti-phosphoEZH2 atnibody. Western blot analysis of EZH2 from immunoprecipitants demonstrate
a significant enrichment of phospho-EZH2 in uteri from GEN-exposed rats as
compared to BPA and VEH. PND 12 pooled (2-3) from Eker rat uteri exposed to VEH,
GEN or BPA (6 hrs) were used for acid precipitation of histones. Western blot analysis
of histone proteins show a decrease in levels of H3K27me3 at 6hrs after exposure as
compared to BPA or VEH. The ratio of phospho-EZH2 to total EZH2 and the ratio of
H3K27me3 to total H3 levels were determined to be significantly different from VEH
using the Student’s t-test, which was set a value of *p<0.05.
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3.3.3 Neonatal exposure to GEN and BPA induces precocious expression of
estrogen-responsive genes

It is known that epigenetic changes occur rapidly during development, and with
respect to DNA methylation, it has been shown that exposure to DES and GEN can
transiently alter DNA methylation patterns in the uterus that are permanently reversed
when endogenous hormones are produced. These changes in DNA methylation also
correlate with persistent alterations in gene expression in the adult. We previously
identified a set of 18 estrogen-responsive genes, from a microarray-based analysis
that were candidates for developmental reprogramming in the uterine myometrium
(269). To determine a baseline of gene expression in the developing uterus after
neonatal exposure to GEN and BPA, we isolated mRNA from neonatal uteri (VEH n=9,
GEN n=6, BPA n=6) and performed qPCR to quantitate expression of this panel of 18
genes. Twelve of the 18 target genes were responsive to one or both xenoestrogens,
being either induced or repressed by GEN and/or BPA compared to VEH controls.
GEN modulated the expression of all 12 genes (Calbindin D9k, Dio2, Krt19, Gdf10,
Car8, Gria2, Mmp3, Igfbp5, Spp1, Sfrp2, Rasd2, Nr2f2) (Table 3.1). In comparison,
BPA modulated the expression of eight of the 12 genes (Calbindin D9k, Dio2, Gdf10,
Car8, Gria2, Spp1, Sfrp2, Rasd2) (Table 3.1). While qualitatively similar in terms of
induction or repression of expression, the response of these estrogen-responsive
genes to both GEN and BPA was quantitatively different with GEN resulting in the
induction of 12/12 genes and, in general, a greater increase in expression as
compared to BPA. These data indicate that while GEN and BPA are qualitatively
similar, they have xenoestroen-specific effects in their ability to modulate estrogenresponsive gene expression in the developing rat uterus.
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TABLE 3.1

TABLE 3.2
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Transactivation of gene expression was confirmed at the protein level by
examining calbindin D9k expression in response to xenoestrogens. Neonatal uteri
from animals exposed to GEN or BPA exhibited induction of the classic uterine
estrogen-responsive gene Calbindin D9k by immunohistochemistry (IHC) as shown in
Figure 3.3, confirming that these doses of GEN and BPA are estrogenic in the
neonatal rat uterus, which has been previously shown to induce Calbindin D9k
expression in neonatal rats relative to VEH controls (254).
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Figure 3.3 Histological and immunohistochemical studies of uteri of 12day-old Eker rat females. Photomicrographs of uteri stained with either hematoxylin
and eosin or calbindin D9K in VEH-, DES-, GEN-, or BPA-exposed females killed 6
hours after the last exposure on PND 12 (all photomicrographs were taken at 20X).
The length of the scale bar is 100 µm.
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3.3.4 Neonatal xenoestrogen exposure developmentally reprograms gene
expression

in

adult

myometrium

in

the

absence

of

morphological

reprogramming

DES has been shown to reprogram female rodent reproductive tract
morphology by inducing persistent vaginal cornification (persistent estrus), endometrial
hyperplasia, and polycystic ovaries lacking corpora lutea in animals exposed
neonatally to this xenoestrogen (254). IHC evaluation of the uteri, ovaries, and vaginas
from adult female rats exposed neonatally to BPA (n=17), GEN (n=14), or VEH (n=34)
demonstrated that the effect of these xenoestrogens on reproductive tract morphology
differed substantially from DES (Figure 3.4). Adult females exposed neonatally to BPA
or GEN had a more normal reproductive tract morphology as illustrated by the
presence of corpora lutea in the ovary, normal endometrium luminal epithelium cell
height, and normal estrus cycles (Figure 3.4 g-l).

79

Figure 3.4 Morphological reprogramming of the adult Eker rat uterus. Effects of
neonatal exposure to DES, GEN, or BPA on adult uterine morphology. Shown are
photomicrographs of hematoxylin and eosin–stained histological sections of
uteri,ovaries, and vaginas from adult (3-5 months old) rats exposed to VEH (a, b and
c), DES(d, e and f), GEN (g, h and i), or BPA (j, k and l) (20X). The length of scale bar
is 200 µm.
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After establishing the immediate effects of xenoestrogen exposure on gene
expression, we next asked whether the xenoestrogen-specific non-genomic signaling
effects of neonatal GEN and BPA exposure had induced persistent developmental
reprogramming of gene expression in the adult myometrium. For this analysis, we
defined a developmentally reprogrammed gene as one that displays altered hormone
responsiveness in adult rat myometrium as a result of developmental xenoestrogen
exposure. To control for differences in hormone levels associated with different stages
of the estrus cycle, 3-month-old VEH-, GEN- or BPA-exposed female rats were
grouped into proliferative phase, corresponding to animals in proestrus or estrus, or
secretory phase, corresponding to animals in metestrus and diestrus. For the qPCR
determination of levels of gene expression, average fold change in expression
compared to VEH controls was normalized to the reference gene 18s.
Interestingly, developmental reprogramming by GEN and BPA occurred in
genes reprogrammed by DES, as well as in gene sets specific for each xenoestrogen.
As shown in Table 3.1, of the 18 uterine estrogen-responsive genes previously
identified

(269),

three

were

developmentally

reprogrammed

by

all

three

xenoestrogens: CalbindinD9k, Gdf10 and Gria2. However, while both DES and GEN
reprogrammed these genes in such a way as to significantly increase expression by 24-fold during the proliferative phase of the estrus cycle (when hormone levels are
highest), BPA had the opposite effect on these genes, with reprogramming by this
xenoestrogen resulting in a 3-fold decrease in expression during the proliferative
phase of the estrus cycle.
In addition to genes that were targeted by all three xenoestrogens, GEN and
BPA also had xenoestrogen-specific reprogramming effects. As shown in Table 3.2,
neonatal GEN exposure reprogrammed expression of Dio2, Krt19, Igfbp5 and Spp1,
only one of which, Dio2, was also reprogrammed by DES (269). In contrast, BPA
exposure resulted in developmental reprogramming of Sfrp2 and Rasd2 neither of
which were reprogrammed by either DES or GEN.
While all 11 genes reprogrammed by DES, GEN and/or BPA were responsive
to these xenoestrogens in the neonate, not all were developmentally reprogrammed in
the adult myomerium. 4/7 genes became hyper-responsive to estrogen by GEN
exposure, while 4/5 genes became further repressed by BPA exposure. Thus, a
genomic response to xenoestrogen was insufficient to predict developmental
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reprogramming or its xenoestrogen-specific effects. This indicates that the nongenomic effects observed with GEN exposure, and previously with DES, together with
changes in EZH2 activity and levels of H3K27me3 were likely initiating mechanisms
responsible for the differential reprogramming effects observed in adult myometrium.
Thus, the genomic response following xenoestrogen exposure (i.e. induction or
repression of gene expression) masked the xenoestrogen-specific developmental
reprogramming effects until the promotional effects of the adult hormonal milieu
caused it to be revealed.

3.3.5 Genistein but not BPA exposure increases susceptibility to uterine tumors
The distinct non-genomic signaling and reprogramming profile of GEN and BPA
led us to determine the impact of neonatal exposure to these xenoestrogens on
susceptibility to develop uterine leiomyoma in Eker rats.

Tumor incidence and

multiplicity was determined at 16 months, the age associated with a historical tumor
incidence of 65% (272), in animals exposed on neonatal days 10-12 to GEN, BPA or
VEH. GEN exposure increased tumor incidence to 93% (GEN [n=14] vs. VEH [n=17],
p < 0.05), a significant increase above baseline tumor formation in VEH animals
(Figure 3.5a). Tumor multiplicity was also increased by GEN (1.6) exposure vs. VEH
controls (0.6) (Figure 3.5b). The increase in tumor incidence and multiplicity with
neonatal GEN exposure was comparable to DES exposed animals, which exhibited a
100% tumor incidence and multiplicity of 1.3 (254). In contrast to both DES and GEN,
BPA did not significantly increase tumor incidence or multiplicity in comparison to VEH
controls, differing significantly from the effects of GEN on tumor formation (GEN vs
BPA [n=30], p <0.01) (Figure 3.5). Tumor multiplicity followed a similar pattern in
GEN-, BPA-, and VEH-exposed animals. These data indicate that the neonatal effects
of GEN induced immediately by exposure and established by endogenous estrogen
created an environment more susceptible to the effects of loss of Tsc2 leading to
increased tumor development.
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Figure 3.5 Tumor incidence and multiplicity of Eker rats exposed neonatally to
GEN, BPA or VEH. Incidence and multiplicity of uterine leiomyomas in Eker rats after
xenoestrogen exposure. A) Tumor incidence in 16 month old Eker rats (gross and
microscopic tumors) after GEN (n=14), BPA (n=30) or VEH (n=17) exposure. B)
Tumor multiplicity in 16 month old Eker rats (gross and microscopic tumors). Statistical
significance for incidences was determined by chi square for incidence and by Poisson
regression for multiplicity analysis.
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3.4 DISSCUSSION
In our previous study, we identified a new mechanism of ER-mediated nongenomic signaling that activates the PI3K/Akt signaling pathway to modulate the
posphorylation of the HMT, EZH2 and gene expression. Using xenoestrogens as a
biological tool to identify genes that control reproductive tract differentiation and
susceptibility to hormone-dependent tumors in adults, we reveal in this study that
xenoestrogens have distinct non-genomic signaling profiles and chromatin effects that
correlate with developmental reprogramming of estrogen-responsive genes. Rapid ER
activation of Akt, which repressed the activity of EZH2 and levels of H3K27me3,
distinguished GEN from BPA immediately after exposure. This distinction persisted as
evidenced by the opposite effects GEN and BPA had on developmental
reprogramming of gene expression in the adult uterus, as well as, the modulation of
tumorigenesis.
The mechanism by which aberrant hormone exposure induces changes in
chromatin structure is poorly understood. Changes in histone methyl marks, as well as
cytosine methyaltion, are known to be heritable (273), and have been shown to
modulate one another through several mechanisms (163, 274-276). Regulation of
H3K27 methylation levels by EZH2 is required for several key functions in
development including X inactivation, bivalent chromatin maintenance and silencing of
HOX genes, which have been shown to be critical to proper murine uterine
differentiation. In a recent study of the methylome at various stages during
differentiation, the most significantly hypomethylated regions in embryonic stem cells
(hESC) were located in the HOX genes, with a progressive increase in methylation
associated with differentiation state (277). Interestingly, in Fibro cells representing
neonatal differentiation, HOXC and HOXD showed maximal DNA methylation, which
decreased in the fully differentiated cells (monocytes) indicating that these gene
clusters undergo key epigenetic modifications during later stages of differentiation.
Additionally, EZH2 can directly mediate gene silencing of estrogen-responsive genes
by inducing DNA methylation via interactions with the histone deacetylase HDAC1
followed by recruitment of DNA methyltransferases. Therefore, the reduction in levels
of H3K27me3 by xenoestrogen exposure, which may reduce levels of DNA
methylation in developmentally regulated estrogen-responsive genes, could give rise
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to aberrant differentiation of the uterus. The epigenetic heritability of these methyl
marks indicates that developmental reprogramming of the epigenome could lead to
permanent changes in genes expression that increase susceptibility to hormonedependent tumors.
The mechanism of epigenetic alteration after neonatal xenoestrogen exposure
has been shown to lead to persistent changes in gene expression that are associated
with neoplastic transformation. The precocious response to xenoestrogens seen
immediately after exposure showing during critical windows of uterine development (i.e
PND 1-5) permanently alters normal estrogen-responsive gene expression, such as
lactoferrin and c-fos, via DNA hypomethylation that persists in tumors (i.e. uterine
adenocarcinomas) (170, 222, 223). In our study, genes that became developmentally
reprogrammed responded to xenoestrogens, being precociously activated or
repressed immediately after xenoestrogen exposure in neonates (postnatal day 12) in
a pattern reflective of their normal response to hormone in the adult. For example,
both GEN and BPA induced activation of Calbindin D9k in the neonatal uterus, which
mimicked the normal hormone-responsive behavior of this gene during the proliferative
phase of the estrus cycle in the adult myometrium. In contrast to the response of target
genes to xenoestrogen in estrogen-naïve neonatal uteri, which mimicked the normal
response to endogenous hormone, the effects of reprogramming of hormone
responsiveness later in life in the adult uterus differed both quantitatively (i.e. 2-50 fold
increased expression) and in many cases qualitatively (i.e. repressed genes became
induced) relative to normal response of these genes to hormone in the adult
myometrium. The ability of neonatal xenoestrogen exposure to “reset” the normal
hormone responsiveness has also been demonstrated after brief exposure to DES or
BSA conjugated to E2, which allows only the non-genomic signaling of E2 to be
investigated. In our study, we demonstrated that a 7-day estrogen exposure (DES or
E2-BSA) and 48 h recovery followed by estrogen challenge reprograms the normal
estrogen-responsiveness to estrogen in myometrial cells. Genes identified in this study
and in previous studies as developmentally reprogrammed by xenoestrogen exposure,
PR and Igfbp5, become hyper-responsive to hormone, mimicking what occurs in adult
myometrium after neonatal exposure to xenoestrogens. Similarly, inappropriate
glucocorticoid exposure remodels chromatin around the glucocorticoid receptor (GR)regulated tyrosine aminostransferase gene (Tat) and induces DNA demethylation at
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GR-response enhancer regions, which recruits transcription factors and results in gene
activation (189). Long after removal of glucocorticoids, however, the alterations in DNA
demethylation persisted giving rise to a hyper-responsiveness to glucocorticoids when
later exposure occurred resulting in increased Tat gene expression. While the
mechanism of hormone-dependent DNA demethylation is not well understood, in a
recent study it has been demonstrated that exposure to PTH engages the nongenomic signaling pathway via PKC, which leads to phosphorylation of methyl binding
protein 4 (MBD4) (278). MBD4 recruits DNA base excision repair machinery, which
results in demethylation of the vitamin D receptor-dependent promoter of the
cytochrome p450 27B1 (CYP27B1) gene. In addition to the mechanism we have
illustrated of DES-induced activation of Akt and phosphorylation of EZH2, these data
provide additional evidence that chromatin remodeling can be permanently altered
after inappropriate hormone exposure via non-genomic signaling pathways leading to
a persistant hypomethylated state and permanent alterations in gene expression.
Overall, the xenoestrogen-specific patterns of gene expression that emerged
from this analysis reveal that the intrinsic reprogramming effects associated with
specific xenoestrogens are different. GEN developmentally reprogrammed, Gdf10,
Calbindin D9k, Gria2, Dio2, Krt19, Igfbp5, and Spp1; the first five of which were also
reprogrammed by DES (269). In contrast, while BPA reprogrammed Gdf10, Calbindin
D9k, Gria2, Rasd2, and Sfrp2, unlike DES and GEN, with the exception of Rasd2,
BPA reprogramming resulted in decreased gene expression. Therefore, in general, the
effect of BPA on gene expression was the opposite of DES and GEN. These findings
are reminiscent of those reported by Dolinoy et al. (279), where developmental
exposure to GEN and BPA had opposite effects on DNA methylation and subsequent
gene expression of the agouti gene. Together with our previous report (269) these
data indicate that xenoestrogens such as DES, BPA or GEN have both shared and
distinct effects on gene expression and developmental reprogramming of target genes.
Other differences between the effects of these xenoestrogens on the
developing uterus were also observed. Morphological reprogramming of the
reproductive tract following neonatal GEN and BPA exposure was not observed, unlike
what was seen in this model with DES (254). However, other studies have reported
reproductive abnormalities as a result of perinatal exposure to GEN and BPA (51, 53,
64, 72, 75, 280-282). Several possibilities exist for these discordant observations
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including differences in dose, route of administration, timing of administration,
background strain, and species, though all three doses of BPA did not result in nongenomic activation of Akt, in contrast to DES and GEN. Regardless, data obtained in
this rat model system clearly demonstrate that reprogramming of tumor susceptibility
and estrogen-responsive gene expression at the molecular level can occur at doses of
xenoestrogens that do not cause overt morphological changes in the female
reproductive tract. Similar to our observations, Adachi et al. demonstrated that
molecular alterations in the testis can occur in the absence of morphological
alterations (283). In this study, while neonatal DES exposure induced both
morphological and molecular alterations in the testis, GEN reprogrammed genes in the
adult testes without inducing morphological reprogramming. Therefore, the effects of
developmental reprogramming may be manifest in the absence of histological or
morphological alterations, pointing to the need to develop approaches, like that of
profiling non-genomic signaling and epigenetic alterations, to detect reprogramming
even in morphologically “normal” appearing tissues.
Futhermore, we found that the pattern of xenoestrogen-induced developmental
reprogramming in genes targeted by all three xenoestrogens examined (GEN, BPA
and DES), correlated with the ability of these xenoestrogens to increase susceptibility
to tumor formation. DES and GEN generally increased the expression of estrogenresponsive genes in adult animals relative to VEH-exposed rats, which mimicked the
significant increase in tumor formation in DES and GEN exposed animals. In contrast,
BPA resulted in general repression of estrogen responsive genes, and no increase in
tumor formation and multiplicity as compared to VEH. These differences in the effects
of xenoestrogen exposure are likely driven by intrinsic differences in the mechanism of
action of each of these xenoestrogens, for example binding to specific ER subtypes.
DES, GEN and BPA have distinct binding efficiencies for ERα and ERβ, with DES and
GEN binding with a higher affinity to ERα than BPA (DES>GEN>BPA), while BPA
binds with a much higher affinity to ERβ than ERα (15). Additionally, BPA, in contrast
to DES, can engage the G-coupled receptor pathway to activate non-genomic
signaling through PKA resulting in phosphorylation of CREB and Rb in vitro (105).
However, ablation of ER via ICI 182780 treatment did not abrogate the effects of BPA
illustrating that this is an ER-independent mechanisms of BPA. Additionally, neither E2
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nor DES could recapitulate the BPA-induced effects further illustrating the unique
effects of BPA.
In the female reproductive tract, it has been demonstrated that ERα is required
for DES-induced developmental reprogramming, as αERKO mice are resistant to
DES-induced developmental reprogramming (35, 193) and overexpression of ERα
increases the effects of DES (284). Importantly, in our previous study we
demonstrated that ERKO mice are resistant to the non-genomic effects of DES
exposure, which would support the hypothesis that early epigenetic signaling events
are ER-mediated. Similarly, xenoestrogen-specific affinity for ERα vs ERβ has been
demonstrated in male αERKO and βERKO mice exposed neonatally to DES (285).
This study demonstrated that while DES exposure induced prostate abnormalities in
the βERKO mice, that expressed ERα, αERKO mice that lack this receptor were
resistant to the effect of DES exposure. In this regard, the ability of DES and GEN to
reprogram susceptibility to tumorigenesis is consistent with ERα being the
predominate ER subtype in the female reproductive tract (286, 287).
In summary, this study demonstrates that neonatal exposure to GEN, in
contrast to BPA, activates non-genomic signaling to Akt, which phosphorylates EZH2
and reduces H3K27me3 levels in the neonatal uterus. This disparate activity of GEN
and BPA persisted in the adult myometrium as evidenced by the opposing effects on
developmental reprogramming of estrogen-responsive genes and subsequently on
tumorigenesis. The findings of the present study demonstrate a correlation between
tumor incidence and xenoestrogen-specific reprogramming of estrogen-responsive
genes following neonatal chromatin remodeling events, and highlight what are likely
important intrinsic differences between xenoestrogens. While this study highlights a
mechanism for xenoestrogen-induced epigenetic modulation of gene expression in the
uterus that correlates with developmental reprogramming of uterine leiomyoma, the
elucidation of other xenoestrogen-specific mechanisms that modulate the epigenome
during development will be critical to understanding risk xenoestrogens confer in
increasing the susceptibility to hormone-dependent tumors.
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CHAPTER 4: FUTURE DIRECTIONS AND CONCLUSION
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4.1 FUTURE DIRECTIONS
Uterine leiomyoma, like many other diseases and cancers of the reproductive
tract, is a hormone-dependent disease. As discussed in chapter 1, numerous studies
demonstrate that early life exposure to xenoestrogens leads to hormonal perturbations
in adulthood and subsequently increases the incidence of tumor development. Studies
from our laboratory (chapter 3), as well as others, have shown that neonatal exposure
to xenoestrogens can disrupt normal ER-mediated signaling and induce a
reprogramming effect in estrogen-responsive genes. The mechanism by which gene
expression is reprogrammed is still not well understood, however, an epigenetic
mechanism has been implicated in the heritable transmission of aberrant hormonal
memory created by xenoestrogen exposure during development of the reproductive
tract.
There is a paucity of research supporting the link between early life
xenoestrogen exposure and epigenetic alterations that increase disease susceptibility.
The epigenetic mechanism responsible for xenoestrogen-induced developmental
reprogramming that has been focused primarily is alterations DNA methylation given
that xenoestrogens, such as DES, have little effect on genetic mutations (288). A few
key studies have been successful in demonstrating this link, including the study from
Tang et al. (174), which showed that neonatal exposure in CD-1 mice to DES or GEN
induces steroid-hormone dependent epigenetic changes that persist throughout life
and increase the incidence of uterine adenocarcinoma. The chromatin-remodeling
gene Nsbp1 was found to have a low level of DNA methylation neonatally, which
became further hypomethyled only after DES or GEN exposure that correlated with its
overexpression in the uterus. Additionally, mice exposed neonatally to E2 or BPA
increased susceptibility to neoplastic transformation of the prostate, prostatic
intraepithelial neoplasia (PIN) (175). DNA hypomethylation of the gene PDE4D4,
which accumulated DNA methylation with age in controls, was hypomethyled by
estrogen or xenoestrogen exposure that prevented the gene silencing. Importantly,
epigenetic changes associated with developmental reprogramming of gene expression
were identified prior to the formation of PIN lesions. Likewise, we show that
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reprogramming of uterine leiomyoma-specific gene expression in adult myometrium by
neonatal exposure to xenoestrogens occurred in a xenoestrogen-specific manner prior
to the formation of uterine tumors (Chapter 3). The reprogramming effects of both DES
and GEN were the increased expression of estrogen-responsive genes, such as
Gria2, while the opposite was true of BPA. Given the similar effects of DES and GEN
on chromatin remodeling in the neonatal uterus, as opposed to BPA, leads us to next
ask whether this early chromatin remodeling event induces permanent changes in
DNA methylation that reprograms gene expression.
4.1.1 Future Directions to Determine Xenoestrogen-Induced DNA Methylation of
Developmentally Reprogrammed Genes

Collectively, the studies presented herein demonstrate that xenoestrogens
developmentally reprogram estrogen-responsive gene expression, which is preceded
by neonatal modification of a repressive epigenetic mark via xenoestrogen-specific
non-genomic signaling. Thus, we hypothesize that the mechanism resulting from this
early chromatin remodeling that promotes reprogramming of these genes is differential
DNA methylation (Aim 3), which is initiated after exposure to xenoestrogens,
established during puberty and persists into tumorigenesis. This theory would
establish xenostrogens as epigenetic “reprogrammers” of cancer risk, evidence of
which has been illustrated in the studies discussed above. Therefore, the purpose of
this future study is to determine if developmentally reprogrammed genes identified in
our previous studies have aberrant DNA methylation profiles in regulatory regions that
are controlled by xenoestrogen-induced signaling.

4.1.1.1

EXPERIMENTAL

DESIGN

ULTRADEEP

OF

BISULFITE

SEQUENCING

IN

DEVELOPMENTALLY REPROGRAMMED GENES

In order to address the above hypothesis, next generation bisulfite sequencing
of developmentally reprogrammed genes has been conducted using primers designed
to amplify bisulfite-treated DNA in myometrium and tumors. The results from this DNA
methylation profiling experiment will lead to an enhanced understanding of the regions
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in developmentally reprogrammed genes susceptible to xenoestrogen-induced DNA
methylation alterations.
Ultradeep bisulfite sequencing of 7 regulatory regions (CpG islands (CGI), ER,
PR, FoxA1, H3R17, SRC-3 and Pol II) in 10 developmentally reprogrammed genes
(Gria2, Gdf10, Calbindin D9k, Rasd2, Mmp3, Krt19, Sfrp2, Spp1, Dio2, Nr2f2) was
accomplished via massively parallel sequencing-by-synthesis (Solexa sequencing
platform). DNA samples from 20 individual animals (AM-5 month adult VEH
myometrium (n=5), DM-5 month adult DES myometrium (n=5), SM-16 month normal
senescent myometrium (n=5), VT-16 month VEH tumors (n=5)) were pooled into 4
groups after amplification of each PCR product (AM, DM, SM, VT) representing the
age, stage and treatment matched tissue listed. For 5-month myometrium samples,
the proliferative phase of estrous was utilized for DNA methylation analysis in a
manner identical to the protocol used in chapter 2 and 3 for staging estrus in VEH and
DES exposed animals (AM and DM). Similarly, animals at 16 months in the PE phase
of estrus (as described in chapter 2 and 3) were utilized for analysis of DNA
methylation. After amplicons were generated for each regulatory region for
developmentally reprogrammed genes, each amplicon was visualized by gel
electrophoresis for size determination, followed by pooling and purification (Figure
4.1). A total of 62 primers pairs were used to interrogate the DNA methylation
differences in adult and 16 month myometrium, as well as, tumors in regulatory
regions of developmentally reprogrammed genes (Figure 4.2) as described in
Appendix B “Methods for Ultradeep Bisulfite Sequencing Design and Analysis”.
Importantly, these primers can also be used in the future for ultradeep bisulfite
sequencing analysis of GEN and BPA exposed myometrium, however whole genome
bisulfite sequencing (Bis-seq) would also be useful giving an unbiased approach.

92

Figure 4.1 Experimental Design for Ultradeep Bisulfite Sequencing. Experimental
work flow for analysis of methylation in developmentally reprogrammed genes via
massively parallel sequencing (Solexa) in adult and senescent myometrium or tumors.
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Figure 4.2 Primer Design for Developmentally Reprogrammed Genes. Primers
were designed to amplify bisulfite treated DNA from myometrium or tumors. Locations
of primers are designated from the transcription start site (estimated or known) of each
gene. Figure legend denotes the regulatory regions in which the primers were
designed based off of previous ChIP-Chip data.
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4.1.1.2 QUANTITATIVE SEQUENCING ANALYSIS AND COMPARISONS
IN DEVELOPMENTALLY REPROGRAMMED GENES

OF

DNA METHYLATION

Following ultradeep bisulfite sequencing, sequences will be aligned using
BSMAP (289) bisulfite mapping software. Aligned sequences will be interrogated for
changes in DNA methyation between samples using the chi square statistical method.
In order to answer the question regarding normal age-related changes in DNA
methylation that are independent of xenoestrogen exposure or tumor development,
DNA methylation between aged normal myometrium and VEH adult myometrium (SM
vs AM) should be compared. This comparison would allow us to determine which
genes and/or regulatory regions are undergoing age-related changes in methylation.
Subsequently we could compare the age-related methylation changes to tumorspecific changes in methylation (SM vs. VT). This comparison would aid in the
understanding if genes differentially expressed in tumors acquire changes in
methylation that are susceptible to changes in hormones given that these are
hormone-dependent tumors. Identification of genes that are susceptible to hormonal
changes in DNA methylation as opposed to those genes that undergo methylation
alterations as a function of tumorigenesis or clonal expansion, would help uncover
gene and regulatory sites that are most susceptible to early xenoestrogen exposure.
Additionally, changes in methylation would also be compared to the gene expression
changes in tumors. Necessarily, we would compare VEH and DES myometrium to
determine the changes in methylation induced by neonatal exposure to DES. These
DES-related changes in methylation would then be compared to the gene expression
changes, which would demonstrate the relationship between a loss of methylation at
the promoter of a gene and the subsequent increased gene expression. More
specifically, we could also determine if changes in gene expression are correlated with
a specific regulatory site beyond the canonical promoter CpG island (i.e. ER, PR,
FoxA1, SRC-3, Pol II, H3R17) in DES myometrium and tumor samples. Identification
of specific regulatory sites that are altered in DNA methylation may provide clues to
the mechanism(s) by which xenoestrogens developmentally reprogram gene
expression and alter tumor susceptibility.
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4.1.1.3 VALIDATION OF ULTRADEEP BISULFITE SEQUENCING BY CLONING AND SEQUENCING
OF DEVELOPMENTALLY REPROGRAMMED GENES: PRELIMINARY DATA

Comparison of the DNA methyation results from bisulfite sequencing will be
accomplished via traditional cloning and sequencing of gene regions identified to have
differential methylation related to gene expression in adult animals (AM vs. DM). Once
methylation changes are validated, DNA from DES exposed PND 12 uteri (n≥5 VEH;
n≥5 DES), PND 21 (n≥5 VEH; n≥5 DES), 5 month – SM and tumors – VT should be
examined for DNA methylation changes via cloning and sequencing (n≥20 clones per
sample/site) to determine the dynamics in methylation of DES-induced developmental
reprogramming at critical stages including development, puberty, adulthood and during
tumorigenesis. This analysis would allow us to understand the critical time points of
methylation susceptibility in the myometrium to xenoestrogen exposure. As such,
these same parameters could also be applied to investigation of the changes in
methylation after Bis-seq in GEN and BPA exposed myometrium.
Preliminary data, which supports the mechanism of DES-induced methylation
alterations, has been gathered for 2 DES-induced developmentally reprogrammed
genes Gria2 and Calbindin D9k. Two regions in Gria2, a promoter CGI and an ER
binding site located 3’ to the gene (Figure 4.3), were cloned and sequenced using the
same BS-DNA samples and primers as used for ultradeep bisulfite sequencing. In a
similar manner, an ER binding site located between exons 1 and 2 was also cloned
and sequenced for validation (Figure 4.3).
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Figure 4.3 Annotation of promoter CpG islands and EREs in Gria2 and Calbindin
D9k. The CpG island in the promoter of Gria2 contains 12 CpG sites the ERE 6 CpG
sites around which bisulfite specific primers were designed. For Calbindin D9k, 2
EREs with 8 and 12 CpG sites, respectively, were used for bisulfite-specific primer
design.

97

Quantitative examination of DNA methylation in the promoter CGI of Gria2
showed a significant hypomethylation in DES vs. VEH animals among 12 CpG sites
(Figure 4.4) that corresponded to the increased gene expression seen in adult
myometrium after neonatal DES exposure as demonstrated in chapter 2. However,
analysis of the ERE (5 CpG sites) 3’ of Gria2 did not show any significant difference in
overall or site specific methylation between DES and VEH samples (Figure 4.4).
Similar to Gria2 expression, the expression of Calbindin D9k was increased in its
expression after DES exposure as compared to VEH (Chapter 2, Figure 2.3). While
overall DNA methylation analysis of the ERE (8 CpG sites) in Calbindin D9k was not
significantly different between DES and VEH myometrium, site-specific differences
were observed. Specifically, CpG site 1-3 were found to be significantly
hypermethylated, while CpG site 6 was significantly hypomethylated in DES samples
as compared to VEH (Figure 4.5). Though it remains unclear as to the impact of ERE
CpG methylation on gene expression, a plethora of data show a significant correlation
between promoter hypomethylation and increased gene expression. For this reason, it
will be important to examine the changes in DNA methylation at they relate to gene
expression changes seen in developmentally reprogrammed genes.
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Figure 4.4. DNA Methylation Analysis of Gria2 in DES Exposed Adult
Myometrium. Myometrium from 5 month old Eker rats exposued to DES or VEH on
PND 10-12 were used for bisulfite treatment of DNA. A) Amplicons from the CpG
island of Gria2 were cloned and sequenced for the presence of DNA methylation
alterations. B) DNA methylation in DES myometrium was significantly different as
compared to VEH myometrium, Students t-test p<0.05. C) No significant difference
was observed at CpGs sites at the ERE in Gria2.
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Figure 4.5. DNA Methylation Analysis of Calbindin D9k. DNA isolated from adult
Eker rats exposed to DES or VEH on PND 10-12 were treated with sodium bisulfite.
DNA containing 8 CpG sites in the ERE regions was amplified, cloned and sequenced.
CpG sites 1-3 demonstrated significant hypermethylation in DES vs. VEH
myometrium, blue stars, p<0.05 Student’s t-test. CpG site 6 demonstrated
hypomethylation, red star, p<0.05.
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The question regarding the relationship between changes in DNA methylation
and developmental reprogramming of gene expression could be addressed using
qPCR in combination with deletion constructs. The experiment would involve 1)
identifying critical regions that undergo changes in DNA methylation that correlate with
gene expression changes (induced or repressed) from Bis-seq and 2) using the
myometrial tumor cell line, ELT3, cells exposed to xenoestrogens (DES, GEN or BPA)
or VEH for 7days to reprogram gene expression as demonstrated by Bredfeldt et al.
(271) (Figure 4.6). These cells would then be treated with DMSO or 5 deoxy-azacytidine (5 aza) for 3 days (25 µM), which is incorporated into DNA and prevents DNA
methylation during replication by creating a covalent link between 5 aza-CpGs and
Dnmt1 resulting in loss of methylation and, in general, activation of silenced genes
(145). RNA would then be harvested from treated cells and qPCR would be conducted
to determine if treatment with 5 aza could reverse the reprogramming of gene
expression induced by “priming” with xenoestrogens. Preliminary data for the
developmentally reprogrammed gene Gdf10 has been conducted and results
demonstrate in vitro that Gdf10 is not induced in expression initially by a brief 24 hr
DES exposure in comparison to VEH (Figure 4.7). However, prolonged exposure to
DES, and to a lesser extent BPA, represses gene expression. Interestingly, after
priming with DES treatment, 5 aza reversed the DES-induced repression of Gdf10 and
partially relieved the BPA-induced repression. To determine if these gene expression
changes are related to changes in DNA methyation, primers designed for Bis-seq
could be used to interrogate the DNA methyation in regulatory regions of genes
reprogrammed by DES and reversed by 5 aza. These data indicate potentially that the
expression of developmentally reprogrammed genes can be “reset” after xenoestrogen
exposure by inducing changes in DNA methylation at regions critical to regulating
gene expression.
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Figure 4.6 Estrogen priming of ELT3 cells reprograms gene expression. A) ELT3
cells were treated for 7 days with VEH (PBS) or E2 conjugated to BPA. 48 hrs after
removal of treated or untreated media, or recovery, cells were treated with DES for
24hrs (50nM) and RNA was isolated for qPCR. B) ELT3 cells were treated for 7 days
with VEH or DES (100 nM), allowed to recover and then treated with DES for 6 or 24
hrs. RNA was isolated and qPCR was performed. Student t-test was performed to
determine significance, which was set at p≤0.05.
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Figure 4.7 Reprogramming of Gdf10 gene expression by priming with
xenoestrogens is reversed by 5 deoxy-aza-cytidine treatment in ELT3 cells. ELT3
cells were treated with VEH, DES or BPA for 7 days followed by VEH (DMSO) or 5
deoxy-aza-cytidine for 5 days. After treatment with VEH or DES for 24 hrs, RNA was
isolated and qPCR for Gdf10 was conducted. Fold inductions was calculated using the
reference gene 18s and calibrated to VEH – no aza – VEH.
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To determine if the regions identified in the above DNA methylation studies and
gene expression studies with 5 aza are indeed regulated in their expression by DNA
methylation at regulatory regions (previously identified above), deletion constructs
could be generated that are representative of regions in the gene under investigation.
For example, if a region within Gdf10 was found to be differentially methylated and
responsive to 5 aza treatment, as demonstrated, then deletion constructs could be
generated for these regions and subcloned upstream of a luciferase reporter construct
(as described in (290)). This luciferase deletion construct would then be grown up in
media containing M.SssI (CpG methyltransferase) or no enzyme plus SAM (mock
methylation) creating an unmethylated or methylated version of the deletion construct
to be used in transient transfections of ELT3 cells (as described in (291, 292)).
Following transfection, priming with DES or VEH would occur and cells would be
subjected to luciferase analysis to determine if prior methylation status and/or
treatment with DES (or VEH) changed expression of this critical region of Gdf10. This
experiment would, therefore, allow us to answer the question whether DNA
methylation changes induced by xenoestrogens directly regulate the expression of
developmentally reprogrammed genes.

4.1.2 Future Directions to Determine the Mechanism(s) of Non-Genomic
Signaling and Chromatin Remodeling by Xenoestrogens in Developmentally
Reprogrammed Genes

To expand on Aim 3 and investigate mechanisms governing alterations in
chromatin remodeling and DNA methylation, it would be prudent to determine the nongenomic effects of xenoestrogens in vivo in the absence of ERE-dependent genomic
signaling, given that xenoestrogens have unique effects on non-genomic signaling
(Chapter III). These studies would also be the logical next step to establish biological
relevance of in vitro non-genomic ER signaling that results in chromatin modifications
via AKT-induced phosphorylation of EZH2.
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Subsequently, to further delineate the

plasticity and dynamics of chromatin remodeling effects of xenoestrogen-induced nongenomic signaling, experiments should be conducted to monitor changes in binding of
EZH2 to chromatin and in levels of H3K27me3 in regulatory regions of
developmentally reprogrammed genes. Alternatively, other non-genomic signaling
pathways that are activated by xenoestrogens, which alter chromatin conformation,
DNA methylation and gene transcription should also be examined, such as the PKAinduced phosphorylation of methyl binding protein 4.

4.1.2.1. IN

VITRO AND IN VIVO EXAMINATION OF XENOESTROGEN-SPECIFIC NON-GENOMIC

SIGNALING AND CHROMATIN REMODELING

Collectively, the results from our studies presented herein show that 1) nongenomic

signaling

activates

AKT

and

induces

chromatin

remodeling

via

phosphorylation of EZH2 in an ER-dependent mechanism, and 2) activation of AKT
and phosphorylation of EZH2 in vivo occurs in a xenoestrogen-specific manner.
Because of the plasticity of not only the developing uterus and HPG axis, but also the
chromatin environment, the elucidation of the effects of neonatal xenoestrogen
exposure on non-genomic ER-dependent signaling would more precisely define the
effects on the epigenome. Two important studies, (293) and (294), demonstrate the
importance of non-genomic ER signaling using animal models of DNA binding domain
(DBD) deficient ERα mice (ERAA) in which the zinc finger domain of ERα has been
mutated so that mice are either deficient in ERE-dependent genomic signaling (ER
/AA

-

) or have reduced genomic signaling abilities (ER+/AA). Interestingly, ER+/AA mice

have reproductive tract morphological alterations that are reminiscent of the effects
observed in neonatal DES exposed animals, including infertility, lack of ovarian
corpora letuea and endometrial hyperplasia. Establishment of the HPG axis is also
dependent on ER-dependent non-genomic signaling as demonstrated in ER

-/AA

mice,

which have no wild-type (WT) copy ERα and one mutate (DBD) copy of ERα. This
study shows that non-genomic activation of p21-activated kinase 1 (PKA1) in the brain
is an important regulator of E2-induced negative feedback given that both WT (ER+/+)
and ER -/AA could activate PKA1 and suppress LH after E2 treatment in contrast to ER105

/-

mice. These studies illustrate that non-genomic ER-dependent signaling events

govern the proper development of the reproductive tract and HPG axis that are
independent of ERE-dependent genomic signaling. Furthermore, they suggest two
possible hypotheses of xenoestrogen induction of ER-dependent non-genomic
signaling. One, potentially the balance of genomic and non-genomic signaling is highly
susceptible to perturbation by xenoestrogen exposure during development. Two, it is
possible that the non-genomic signaling pathway is more active during reproductive
tract development as compared to genomic signaling and as such xenoestrogenspecific effects are more pronounced.
In order to address the remaining questions of the effects regarding
xenoestrogen-induced non-genomic signaling in the absence of ERE-dependent
signaling, the ER

-/AA

mouse model could be used. We have shown that membrane-

bound (E2-BSA) ER signaling in vitro activates non-genomic ER signaling and results
in chromatin modification (i.e. levels of H3K27me3). However, the potential EREindependent mechanisms have not been explored in vivo. ERα

-/AA

and ERα+/+ mice

would be exposed neonatally to DES (1mg/kg), GEN (50 mg/kg) or BPA (50 mg/kg or
50 ng/kg) on PND 1-5 (a window of uterine development shown to be susceptible to
xenoestrogen exposure in CD-1 mice) or VEH. In addition to the examination of the
developmental reprogramming of gene expression in the adult myometrium (via
microarray and/or qPCR), the non-genomic ER signaling effects could then be
examined via western blotting of AKT, S6, EZH2 and H3K27me3 along with
immunoprecipitation of pEZH2 in uteri of neonatal animals. It would also be important
to determine the morphological alterations (e.g. ovaries, uterus and vagina) induced in
these animals by xenoestrogen exposure, which would distinguish the non-genomic
ERα-dependent developmental reprogramming effects from those mediated by EREdependent genomic signaling.
To further explore the xenoestrogen-induced non-genomic signaling effects on
chromatin remodeling, experiments should be designed to address the following
hypothesis. The modulation of EZH2 activity and transient decrease of H3K27me3
levels is a mechanism by which permanent changes in DNA methylation at critical
regulatory regions is induced resulting in the developmental reprogramming of uterine
gene expression. It would be necessary determine first, in regions of developmentally
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reprogrammed genes found to have reduced levels of DNA methylation, if H3K27me3
levels

were

also

reduced.

This

could

be

accomplished

using

chromatin

immunoprecipitation (ChIP) with the antibody against H3K27me3 (as described in
(295)) in protein lysates of neonatally xenoestrogen exposed uteri. Briefly, minced uteri
would be cross-linked with 1% formaldehyde and quenched with 0.125 M glycine to fix
chromatin and protein. Cells would be lysed with acid washed glass beads and
sonicated briefly to sheer fixed chromatin into small pieces (400-800 bp) prior to
immunoprecipitation with α-H3K27me3. Cross-linked immunoprecipitated H3K27me3
chromatin would be reversed to yield DNA free of histones for purification and PCR.
PCR of purified DNA with primers designed within regions of developmentally
reprogrammed genes previously identified as having reduced DNA methylation after
xenoestrogen exposure would be performed. The data from this experiment would
show the amount of H3K27me3 present in these critical gene regions after
xenoestrogen exposure.
It would also be important to determine if these changes in H3K27me3 are
transient or permanent in critical regulatory regions of developmentally reprogrammed
genes as a result of xenoestrogen exposure. As discussed in chapter 2, the Tat gene
undergoes chromatin remodeling after glucocorticoid exposure followed by (>2-3 d)
loss of DNA methylation at a regulatory site and up-regulation of Tat expression.
However, after chromatin reverts back to its initial state of conformation, the changes
in DNA methylation remain. Initially, it would be necessary to define when estrogenresponsive genes become reprogrammed. Using Eker rats exposed on PND 10-12 to
DES (or VEH) and re-exposed to DES (or VEH) on PND 21, myometrium would be
analyzed for changes in gene expression of developmentally reprogrammed genes
(e.g. PR, Gria2). These data would delineate the critical time of gene reprogramming,
that is, if endogenous hormones “re-set” the expression of estrogen-responsive genes
or if it is established soon after genomic signaling is down-regulated following
xenoestrogen exposure. From these data, experiments could be designed using ChIP
to examine the dynamics of H3K27me3 in critical regions of developmentally
reprogrammed genes. This would necessitate investigating time points that
correspond with rapid changes in chromatin remodeling and transcription, 30 min to
24hrs, as compared with more permanent changes that may occur as a result of
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reprogramming after several days. Together, these data would link changes in nongenomic signaling with changes in H3K27me3 at critical regions in developmentally
reprogrammed genes that become hypomethylated as a result of xeneostrogen
exposure.

4.2 CONCLUSIONS AND IMPLICATIONS
Developing organisms have evolved several conserved mechanisms among
species in order to adapt to changing environments or stress. However, these
mechanisms that allow environmental adaptation to stressors can be overcome
leading to various disorders and potential teratogenicity. The ability to buffer these
environmental stressors suppresses morphological variation in favor of canalization
(296). These emergency and adaptive mechanisms consist of essentially three main
facets (297): placental toxicant defenses, metabolic adaptations and hormonal
buffering. Placental toxicant defenses, such as efflux transporters (298) and
antioxidants, prevent or buffer the passage of environmental toxins from passing the
placental barrier. Thalidomide, however, the developmental teratogen, can bypass this
buffering mechanism (299, 300). As described previously, metabolic adaptations or
maladaptations that exceed the metabolic buffering system, such as malnutrition
during pregnancy can result in offspring with a “thrify phenotype” or that are
metabolically hypersensitive giving rise to Type II diabetes and cardiovascular
disease. Hormonal perturbations during development, including xenoestrogen
exposure, can bypass hormone binding proteins, such as alpha-fetoprotein that exist
to bind and inactivate endogenous estrogens that allow for normal reproductive tract
formation. When environmental stressors surpasses these buffering systems,
developmental reprogramming can occur, which leads to morphological alterations
and development of adult diseases.
As addressed throughout this work, neonatal xenoestrogen exposure induces
developmental reprogramming of the reproductive tract and increases cancer risk, as
demonsrated by our laboratory and others. Developmental exposure to EDCs, such as
xenoestrogens, disrupts normal reproductive tract development and increases the risk
for cancer in both human and animal models. While the developmental reprogramming
effects of DES have been investigated since the 1970s, the ability of developmental
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exposure to xenoestrogens GEN and BPA have been hotly debated, with the later
coming under heavy scrutiny. However, not all xenoestrogens have the same effect
though all are classified as having “estrogenic” effects. Understanding how each
xenoestrogen induces developmental reprogramming is key to determining how
cancer risk is affected and if later generations are at risk. For example, the structures
of DES, GEN and BPA have similarities and differences, which may relate to their
affinity to ER as well as to their ability to bind to specific isoforms of ER or induce
unique dimerization complexes. The xenostrogen-specific binding and dimerization
conformation differences may also constitute the variations observed in non-genomic
signaling in the neonatal uterus. In contrast, however, all three xenoestrogens were
effective in activating the PI3K/AKT pathway in both MCF-7 cells (93). These data
suggest that developmentally-specific genes or miRNAs may be expressed that
change how signals from xenoestrogens are transmitted, further illustrating the
importance of understanding the differences in the mechanism among the
xenoestrogens during development. Unfortunately, very little is still known regarding
the mechanisms of developmental reprogramming by xenoestrogens or how they
confer an increased incidence of uterine tumors. As such, the main focus of this work
has been on identifying gene targets for developmental reprogramming by
xenoestrogens that are associated with uterine leiomyomas, as well as, the
mechanisms utilized by xenoestrogens to induce developmental reprogramming at the
molecular and morphological levels.
In Specific Aim 1 we endeavored to identify estrogen-responsive genes that
were be reprogramming as the result of xeneostrogen exposure, which may confer an
increased susceptibility to uterine leiomyoma in the genetically susceptible Eker rat.
From this gene profiling study we found that several genes associated with uterine
leiomyoma development that are developmentally reprogrammed in their response to
estrogen after neonatal DES exposure. Importantly, 5/6 of these genes that were
overexpressed in tumors were all induced in their expression prior to the onset of
tumorigenesis indicating that DES induces an aberrant hormonal environment that
promotes tumorigenesis above that which would occur spontaneously. Using these
gene candidates identified in Aim 1, we next asked in Aim 2 whether other
environmentally relevant xenoestrogens, GEN and BPA, also modulated tumor
incidence

via

developmental

reprogramming
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of

estrogen-responsive

genes.

Surprisingly, we found that GEN and BPA had opposite effects on reprogramming of
gene expression. While GEN exposure, like DES, developmentally reprogrammed
common genes, the effect was opposite of BPA. Among the genes reprogrammed by
BPA, the general effect was repression, in contrast to DES and GEN. Interestingly,
these opposing effects of GEN and BPA were correlated with their effects on
tumorigenesis, such that GEN (and DES) significantly increased tumor incidence
above the spontaneous rate, while BPA did not modulate tumorigenesis, which was
consistent with the developmental reprogramming effects. These data demonstrated
that there are xenoestrogen-specific effects on developmental reprogramming of gene
expression that correlates with the ability to modulate tumor incidence. The differences
observed in this study were intriguing and lead us to investigate the mechanisms
governing the differences we observed between these xenoestrogens.
We were able to determine a novel mechanism of how xenoestrogen exposure
could result in contrasting reprogramming effects. In chapter 3, we demonstrated that
the transmission of estrogen-induced signaling into histone modifications occurs
through interaction of xenoestrogen/E2-bound ER with the ER/PI3K/AKT pathway.
Furthermore, this pathway of xenoestrogen-induced histone modification occurred in
vivo and was ER-dependent. We also demonstrated in vitro the link between DES
exposure, or “priming”, and the reprogramming of estrogen-responsive genes that
were known to be susceptible to developmental reprogramming. Importantly, EZH2
was not phosphorylated after BPA exposure in comparison to DES and GEN. These
results indicate that, while xenoestrogens may have estrogenic properties, during
development of the reproductive tract they have very different effects on non-genomic
signaling that ultimately result in chromatin remodeling. Using our data, together with
data from another laboratory showing the importance of priming of ERα by the protein
argenine methyltransferase, PRMT1(301), we developed a new model of non-genomic
ER-dependent signaling that changes the activity of EZH2 and, thus, the levels of
H3K27me3 in xenoestrogen-specific manner. With the future directions of this project it
will possible to determine if these chromatin modification also change DNA
methylation and gene expression (Figure 4.8).
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Figure 4.8 Proposed mechanism of xenoestrogen-induced developmental
reprogramming of gene expression. Based on work from our laboratory and others
it is now known that E2 and xenoestrogens (DES/GEN) 1) bind ER, which is 2) primed
by PRMT1 and 3) leads to activation of non-genomic signaling. 4) Phosphorylation of
EZH2 by AKT reduces its activity resulting in loss of methylation on H3K27. Still
unknown, however, is whether this loss of histone methylation contributes to a loss of
DNA methylation in estrogen-responsive genes and subsequent alterations in gene
expression.

111

Understanding how reprogramming of gene expression occurs is a fundamental
question related to the mechanism of xenoestrogen-induced developmental
reprogramming and the disparate effects seen among the xenoestrogens. To address
this question we hypothesized in Aim 3 that neonatal xenoestrogen exposure induced
alterations in DNA methyaltion in developmentally reprogrammed genes. EDCs,
including xenoestrogens, have transgenerational effects in both human and animals
studies, which is indicative of an epigenetic mechanism of reprogramming.
Developmental changes in DNA methylation induced by aberrant hormone or
xenoestrogen exposure changes the response to subsequent hormone exposure. Preand postnatal DES exposure leads to an increased incidence of uterine tumors in F2
generations (9), which has also been demonstrated for the EDC vinclozolin (180).
Importantly, developmental reprogramming of spermatogenesis in later generations
was found to be correlated with changes in DNA methylation (182). DES has also
been demonstrated to result in permanent alterations in DNA methylation and gene
expression (i.e. c-fos and Nsbp1). For this reason, it is also possible that
xenoestrogens which induce changes in DNA methylation can also transmit the
increased risk to subsequent generations. In addition, the heritable nature of DNA
methylation, as well as, histone modifications, though less well understood, makes it
an obvious candidate for the transmission of information gathered from hormonal
signals during development into permanent physiological responses in adults.
Furthermore, if this aberrant exposure to xenoestrogens occurs during gametogenesis,
then alterations would be passed down to subsequent generations. Therefore, it is
important to determine the molecular mechanisms of the xenoestrogens that lead to
DNA and histone modifications. The experiments to examine this mechanism, which
are outlined above, have yielded preliminary results that show a significant
hypomethylation in the promoter of the developmentally reprogrammed gene, Gria2, in
the myometrium of DES exposed animals. These alterations, which are likely induced
by transient histone modifications in chromatin may leave permanent changes in DNA
methylation in key regions of gene regulation like Gria2.
Given the plasticity of the chromatin environment, stressors in the form of
aberrant hormone exposure may “re-set” the normal gene expression response to
endogenous hormone via changes in histones modifications that alter DNA
methylation and gene expression. This new gene expression pattern could create an
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environment that is hyper-responsive to hormones and, therefore, more susceptible to
hormone-dependent tumors. However, we demonstrate that this reprogramming event
is xenoestrogen-specific such that DES and GEN are capable of engaging the nongenomic chromatin-remodeling pathway via PI3K/AKT in the developing uterus, while
BPA does not. However, it would prudent to further investigate the pathways of BPAinduced developmental reprogramming given that gene expression was altered in the
adult myometrium. Overall, we have defined a mechanism for xenoestrogen-induced
developmental reprogramming via histone modification and are working towards
reconciling this pathway with changes in DNA methylation that may give rise to
permanent changes in gene expression.
The implications of these findings are multi-faceted. First, the unique effects
each xenoestrogen has on signaling, chromatin modification, gene expression and
tumor development create a new understanding of the epigenetic mechanisms that are
engaged by xenoestrogens. Interestingly, two in vitro studies from the Huang
laboratory demonstrate that exposing mammospheres to E2 or DES changed the DNA
methylation and histone modification patterns, which correlated with epigenetic pattern
and gene expression in tissue from breast cancer patients (211, 302). Specifically,
exposure of mammospheres to DES induced aberrant DNA methylation of miRNAs,
but also altered histone marks H3K27 and H3K9. These studies link epigenetic
changes induced after exposure of progenitor cells to E2 or DES with carcinogenesis.
Additionally, recent evidence of the predictive value of epigenetic signatures of
hormone-dependent tumors, specifically ovarian cancer, was obtained from a
comparison between normal endometrial tissue and that from patients with ovarian
cancer (303). It was found that in target genes of the polycomb group, HOXA9,
HOXA10 and HOXA11, increased methylation in normal endometrium was associated
with a significant increased risk (12.3 – 14.8 fold) of ovarian cancer. Furthermore,
HOXA10 was also found to be hypermethylated in the uterus after in utero exposure to
DES, which correlated with its persistent aberrant expression (172). Since we know
that hormone-dependent cancers display a unique epigenetic profile (303) and that
xenoestrogens induce unique epigenetic signatures in the developing reproductive
tract, being able to compare these two profiles could help to predict the risk of
developing horomone-dependent tumors, as well as, elucidating an enhanced
understanding of the mechanism of etiology. In addition, using the data from this work,
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showing the xenoestrogen-specific activation of the PI3K/AKT pathway and repression
of the activity of EZH2, may be a useful tool in evaluating the potentially harmful
effects of exposure to other xenoestrogens and the risk of developing hormonedependent tumors, such as uterine leiomyoma.
Second, defining the etiology of uterine leiomyoma and increased risk of uterine
leiomyoma from xeneostrogen exposure is also relevant to its prevention, early
identification and/or treatment. In Chapter 2 and 3 we identified genes associated with
uterine leiomyomas that are developmentally reprogrammed by neonatal exposure to
xeneostrogens. Critically, exposure to DES and GEN was also correlated with
increased incidence of uterine leiomyoma, unlike BPA. In light of the recent evidence
of increased risk of this disease that is associated with consumption of soy formula,
these results imply that, like DES, exposure to high concentrations of geneisteincontaining products, such as soy formula, during development should be re-evaluated
as a suitable alternative for breast-feeding as mechanism of prevention. In addition, a
recent transcriptional profiling study was performed using myometerium and tumors
from our Eker rat model, which was compared to normal myometrium and uterine
leiomyomas from patients (248). This study found several genes that were
differentially expressed in our analysis as differentially expressed in both Eker rat and
human uterine leiomyomas, including Gria2, which became hyper-responsive after
DES and GEN exposure but repressed further by exposure to BPA. While the
importance of Gria2 in uterine leiomyomagenesis is poorly understood, it stands out as
biomarker of this disease as shown in Table 1.3. In this study, however, they also
identified a significant up-regulation in genes of the mTOR pathway in both rat and
human tumors. Using the mTOR inhibitor, rapamycin (WAY-129327), they found that
treatment (2 weeks or 4 months) in adult animals significantly reduced tumor
incidence, volume and multiplicity. Treatment with this rapamycin analogue also
ablated the expression of pS6 kinase and pS6 in ELT3 cells and pS6 in tumors from
Eker rats. Given that DES and GEN activated this pathway aberrantly in the neonatal
uterus, which induces chromatin modifications in H3K27me3, it is possible that
activation of pS6 and reduction in H3K27me3 could be used as biomarkers of
xenoestrogens that increase the risk of hormone-dependent tumors as a result of
developmental reprogramming, such as uterine leiomyoma. Because of the high
percentage of woman who succumb to this disease and the lack of clinically
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convenient screening tools, prevention by reducing consumption of or exposure to
harmful xenoestrogens during development may be a useful adjuvant in addition to
clinical treatment with compounds like WAY-129327. The important and novel
mechanisms of xenoestrogens demonstrated in this work have illuminated key
pathways that lead to developmental reprogramming, which demonstrates the crucial
need to further explore the role aberrant estrogen exposure during development plays
in disease susceptibility.
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APPENDIX A: IDENTIFICATION OF UTERINE LEIOMYOMA GENES DEVELOPMENTALLY
REPROGRAMMED BY NEONATAL EXPOSURE TO DIETHYLSTILBESTROL IN REPRODUCTIVE
SCIENCES, 2008
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Environmental exposures during development can alter susceptibility later in life to adult diseases including
uterine leiomyoma, a phenomenon termed developmental reprogramming. The goal of this study was to
identify genes developmentally reprogrammed by diethylstilbestrol (DES) and aberrantly expressed in
leiomyomas. Transcriptionalprofiling identified 171 genes differentially expressed in leiomyomas relative
to normal myometriitm, of which 6/18genes with putative estrogen responsive elements and confirmed
to be estrogen-responsive in neonatal uteri were repwgratnmed by neonatal DES exposure. Calbindin
D9k and Dio2, normally induced by estrogen, exhibited elevated expression in DES-exposed animals
during both phases of the estnis cycle. GdflO, Car8, Gria2, and Mmp3, genes normally repressed by
estrogen, exhibited elevated expression in DES-exposed animals during the proliferative phase, when
estrogen is highest. These data demonstrate that neonatal DES exposure causes reprogramming of
estrogen-responsive genes expressed in uterine leiomyomas, leading to over-expression of these genes in
the myometrinm of exposed animals prior to the onset of tumorigenesis.

KEY WORDS:

Uterine leiomyoma, developmental reprogramming, diethylstilbestrol,
gene expression.

BACKGROUND
The plasticity of program-directing patterns of gene
expression in the developing fetus allows for adaptation
of developing tissues to environmental stimuli to optimize
survival of the fetus in the future environment. However,
when the stimuli are adverse, this plasticity can also lead to
"phenotypic modulation" or a "lack of canalization," putting in place an unfavorable physiological program that can
contribute to manv adult-onset diseases. The existence
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of this phenomenon, termed developmental reprogramming, is supported by a significant amount of evidence
demonstrating that in utero and perinatal exposure to a
suboptimal environment such as malnutrition, hypoxia,
chemicals, or ionizing radiation, at critical times during
development predisposes the fetus to chronic adult diseases." ' Numerous studies have also demonstrated that
perinatal exposure to xenoestrogens, found ubiquitously
in the environment, can developmentally reprogram the
reproductive tract, causing alterations in morphology, hormonal milieu, and gene expression, and giving rise to adult
diseases such as infertility and cancer.3~'
The association between developmental reprogramming and perinatal xenoestrogen exposure was first
discovered in 1971 as a result of human fetuses being
exposed to diethylstilbestrol (DES) in utero. Diethylstilbestrol, a pharmaceutical estrogen given to women with
high-risk pregnancies from the 1940s to the 1970s to
prevent miscarriage, was responsible for the induction
of vaginal clear cell adenocarcinoma, an otherwise rare
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form of cancer, in the daughters of treated women.
These "DES daughters" also had reproductive tract malformations including vaginal adenosis, hypoplasia of the
vagina and cervix, T-shaped uterus, and tubular irregularities,13 accompanied by infertility.14 In addition, women
exposed to DES hi utero had an increased risk for breast
cancer, preeclampsia, and in some cohort studies, uterine
leiomyoma, 9,15-17 further supporting the association
between in utero DES exposure and adult disease.
Previous studies from our laboratory and others have
demonstrated an association between early life xenoestrogen exposures, developmental reprogramming at the cellular and molecular level, and increased risk for adult
disease, including uterine leiomyoma. Uterine leiomyoma are hormone-responsive tumors that arise from
the smooth-muscle myometrial layer of the uterus, and
are the most common tumor in women. Understanding
the potential for environmental exposures to contribute
to the development of this disease is important not only
to better understand disease etiology, but also to identify
risk factors that may contribute to the extraordinarily high
incidence of these tumors. However, little is known
about genes in the myometrium that participate in the
development of leiomyoma or which genes in this tissue
may be targets for xenoestrogen-induced developmental
reprogramming.
Using female Eker rats, which develop spontaneous
hormone-responsive uterine leiomyomas due to a
germ-line defect in the tuberous sclerosis complex 2
(Tsc-2) tumor suppressor gene, we found that neonatal
xenoestrogen (DES) exposure during a critical period of
uterine development (ie, postnatal days 3-12) increased
the incidence of leiomyoma from ~65%, to between
95% and 100%.19'20 Furthermore, in rats exposed to DES
neonatally, Calbindin D9k and progesterone receptor
(Pgr) expression became hyper-responsive to estrogen in
adult females, indicating that neonatal DES exposure had
reprogrammed gene expression in the myometrium of
adult animals.
Here we report a microarray-based analysis of agematched normal myometrium and uterine leiomyomas
from Eker rats where we identified 171 genes differentially expressed in tumor versus normal tissue. Because
leiomyomas are estrogen-dependent tumors, we focused
on differentially expressed genes that contained a putative
estrogen response element (ERE), and examined a subset
of these as candidates for developmental reprogramming.
Out of 19 of these candidate genes, 18 were validated as
being estrogen responsive and differentially expressed in
tumors by real-time polymerase chain reaction (PCR).

In all, 6/18 of these genes (GdfW, Car8, Calbindin
D9k, Dio2, Gria2, and Mmp3) were subsequently identified as being reprogrammed in the myometrium by neonatal exposure to the xenoestrogen DES. Furthermore,
5/6 (GdfW, Car8, Dio2, Gria2, and Mmp3) of these
estrogen-responsive genes were overexpressed in both
spontaneous and DES-associated leiomyomas.

MATERIALS AND METHODS
Animals and Treatments
Eker rats from a closed colony at MD Anderson Cancer
Center were cared for in accordance with the study protocol approved by MD Anderson Animal Care and Use
Committee. Eker rats were given water and standard rat
chow (Harlan Teklad 22/5 Rodent Diet) ad libitum and
maintained on a 14:10 light—dark cycle, conditions historically associated with a 65% leiomyoma incidence in
this animal model. The reprogramming effect of xenoestrogen exposure was examined after treating neonatal
Eker rats on post-natal (PND) 10-12 with 1000 Hg/kg/
d of DES (Sigma Chemical Co., St. Louis, Mo) in sesame
oil, using a total of 50 u.L of sesame oil vehicle per injection. A separate group of animals were given 50 \\L of
sesame oil injections as vehicle (VEH) controls. The dose
of DES chosen for this study was derived from earlier
studies in CD-I mice, which demonstrated similar reproductive tract abnormalities to those seen in women
exposed to DES." For microarray analysis, 16-monthold Eker rats were sacrificed for tumor and myometrium
collection. For developmental reprogramming analysis,
5-month-old animals were sacrificed for myometrium
collection to determine reproductive tract morphology
and to isolate ribonucleic acid (RNA) for gene expression
analysis. Analysis of estrogen response in neonatal uteri
was evaluated by sacrificing PND 12 animals 6 hours after
the last of 3 DES or VEH injections.

Tissue Collection and Histology
Tissues (tumors and whole neonatal uteri or adult mvometrium) were snap frozen in liquid N2 or fixed in 10%
neutral buffered formalin (NBF) for 24 to 48 hours and
then transferred into 70% ethanol before paraffin embedding, sectioning, and staining for immunohistochemistry.
For gene expression analysis, uteri from adult animals
were scraped with a sterile scalpel in cold phosphate buffered saline (PBS) to obtain myometrium free of
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endometrium, and along with tumor tissue, snap frozen
in liquid NT and stored at —80°C. To obtain adequate
amounts of tissue for RNA extraction from neonatal animals, 3 uteri were pooled together per sample. Cardiac
blood was also taken from 5- and 16-month-old animals
and allowed to clot overnight at 4°C then serum was
separated by centrifugation at 4°C and stored at —20°C
until analyzed for hormone (E2 and P4) levels.

CEL files, were analyzed using Chen's dChip (http://
biosunl .harvard.edu/complab/dchip/) model-based expression analysis to obtain significant genes with fold changes
of > 1.5 or <—1.5, and a false discovery rate <0.4% of 50
permutations. After obtaining model-based expression
values, hierarchical clustering high-level analysis was performed using dChip. For statistical analysis of real-time
PCR data, a linear model analysis was applied to estimate
the interaction effects of gene and treatment.

Histological Staging of Estrus
Staging was performed in accordance with the procedure
described by Cook et al. Briefly, the stage of estrus or
reproductive senescence was determined by histological
examination of ovary, vagina, and uterine tissues of 5- and
16-month-old rats. For 16-month-old rats, they were
classified by stage of reproductive senescence (pseudo
pregnant [PP], persistent estrus [PE], or anestrus [AN]).
For 5-month-old rats, stage of estrus was categorized into
proliferative (proestrus [Pro] and estrus [Ej) or secretory
(metestrus [Met] and diestrus [DiJ) phases. For DEStreated rats that do not cycle normally due to disrupted
ovarian function, estrogen and progesterone levels were
determined via radioirnmunoassay (RIA) obtained using
the Ultra-sensitive Estradiol and Active Progesterone kits
from Diagnostic Systems Laboratories (Webster, Tex)
according to the protocol described by Cook et al. y After
RIA analysis, DES-treated rats were grouped into either
high estrogen and progesterone levels (High E/P) and
compared with proliferative phase animals, or low estrogen and progesterone (Low E/P) for comparison with
secretory phase animals.

Microarray Validation and Real-time PCR

For analysis of the gene expression changes from the
Gene Chip Rat Genome 230 2.0 array, raw signal

Validation of microarray data was conducted by real-time
PCR of complementary deoxyribonucleic acid (cDNA)
from identical samples (if available) or comparable agematched and stage-matched myometrium and tumors.
Frozen tissue (tumors or myometrium) from 16-monthold animals were crushed under liquid N2 with mortar
and pestle and RNA isolated after DNA removal according to protocol using Ambion's RiboPure Kit (Austin,
Tex). Following RNA extraction, cDNA was made by
reverse-transcribing 1 (J.g of RNA using the Invitrogen
Superscript First-Strand Synthesis System for RT-PCR
(Invitrogen, Carlsbad, Calif). Aliquots of cDNA were
made for each sample and stored at —20° C until analyzed.
Real-time PCR was performed using the 7900T Fast
Real-Time detection system from Applied Biosystems
(ABI, Foster City, Calif). Fast Real-Time Taq-Man assays
from ABI were used to analyze gene expression of GdfW,
Cspg2, Car8, Calbindin D9k, Vcaml, Kcnfl, Rasd2, Sfrp2,
Tacstdl, Krt19, Rps6kbl, Nr2f2, Gria2, IgfbpS, Sppl,
Dio2, Aqp3, Ramp3, and Mmp3. All real-time PCR
reactions were performed by mixing Universal Fast
Real-Time Master Mix from ABI together with the gene
assay mix first and then adding 2 \\L of cDNA from each
sample to make up a 25 ^L volume. For an endogenous
control, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used, which included probe and forward
and reverse primer in a 25 \\L reaction volume. The following set of conditions were used for each real-time
reaction: 95° C for 10 minutes followed by 40 cycles of
1 second at 95°C and 20 seconds at 60°C. The realtime PCR reactions were all performed in triplicate and
were quantified using the
Ct method, which uses the
average Ct of the GAPDH subtracted from the target
gene Ct to obtain the average Ct. A calibrator from each
set of samples was chosen from which to subtract individual VEH and DES samples A,Ct values to obtain the
AA
Ct. The fold change for each sample was calculated

intensities for each probe, set as they are contained in the

in comparison to the calibrator by taking 2 AA,Ct. The

Microarray Analysis
Ribonucleic acid from tumors and normal myometrium
of 16-month-old Eker rats was isolated as described previously20 and 10 ng of cRNA fragmented and hybridized
to an Affymetrix Chip Rat 230 2.0 array according to
manufacturer's protocol (Affymetrix, Santa Clara, Calif).
Analysis of the array was conducted using the GCOS
(Affymetrix GeneChip Operating Software) program
with confidence interval set at 95% and differences in fold
change in gene expression were significant at P < .05.

Microarray and Statistical Analysis
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calibrator for both 16-month and PND 12 rats was VEHtreated myometrium or uteri. For samples from 5-monthold rats, estrus-staged VEH-treated myometrium was
used as the calibrator.
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Bioinformatics Data Analysis
To identify candidate ER target genes from the microarray
analysis, we employed the use of the computational program DRAGON ERE finder (version 2.0). The program,
which uses a detection algorithm formulated from the
palindromic half sites of the ERE, was used to scan for
putative EREs in 171 sequences identified from the microarray analysis. Estrogen response element detection was set
at 83% sensitivity for analysis, (http://sdmc.lit.org.sg/
ERE-V2/index).

RESULTS
Identification of Candidate Genes for
Developmental Reprogramming by DES
To identify leiomyoma-associated genes that were candidates
for developmental reprogramming in the myometrium,
initially we conducted microarray analysis of agematched and stage-matched myometrium and uterine
leiomyomas from Eker rats. Tissues (tumor or normal
myometrium) were obtained from rats at 16 months of
age (the age at which 65% of Eker rats develop uterine
leiomyomas) and classified as 1 of the 3 stages of reproductive senescence PP, PE, or AN (as described in the
Materials and Methods). Age-matched PE myometrium
(n = 6) and PE tumors (n = 7) from rats were analyzed
using the Afjymetrix Rat 230 2.0 array.
Microarray analysis of age-matched and stage-matched
myometrium and leiomyomas identified a total of 171
differentially expressed genes. Unsupervised hierarchical
clustering clearly distinguished normal myometrium from
tumors (Figure 1). Two of the tumors were from neonatally
DES-exposed rats, which formed a distinct node within the
cluster that contained the other 5 spontaneous tumors
from untreated animals, indicating that their expression
profile had characteristics both shared and distinct from
tumors that arose in animals that had not been exposed
to DES (Figure 1).
We have previously demonstrated that expression of
Pgr and Calbindin D9k, 2 estrogen-regulated genes

Figure 1. Representative heat map of microarray analysis.
Heat map represents unsupervised comparison of VEH PE
myometrium and DES PE tumors from 16-month-old animals;
VEH = vehicle; DES = diethylstilbestrol; PE = persistent estrus;
N = normal mvometrium; T = tumor.
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Table 1.

Identification of Predicted or Functional Estrogen Response Elements (EREs)

Gene
Dio2
Calbindin D9k
Gria2
Car8
GdfW

Minp3

769

CA-GGTCA-GGG-TGATC-TT
AG-GGTCT-ATG-TAGCC-CA
GA-GGTCA-GTC-TGATC-AA
AA-AATCA-AAT-TGACC-CC
GT-AGTCA-CAC-CAACC-CT
CA-AGTCA-AAA-CAACC-CT

ERE Location Relative to the
5' End of the Gene

Predicted ERE (Reverse)

Predicted ERE (Forward)

GT-GGTCA-TCT-CAACC-CT
AA-GATCA-CCC-TGACC-TG

R = -9376

GG-GGGCA-TTG^TGACC-CT
CC-AGTCA-TTC-TGCCC-AA
TG-GGTCC-ACT-TGCGC-TC
AA-GGTGG-CTT-TGTCC-AG
AT-GGACA-ATA-TGACC-TT
AT-GGTCA-AGA-TGCCT-GA
AG-GCTCA-CAC-TGCCC-TC
GT-AGTCA-CCA-CACCC-TT

F = 19005; R =
F = 19719; R =
F = 33744; R =
F = 45678; R =
R = -105uj
R = -10441
R = -7249
R = -12519

F = 50: R = -66
F = 1507

-51017
-2244
-38190
-9263

The Dragon ERE program ver.2.0 was used to identify- predicted EREs using 0.83 sensitivity. Predicted ERE sequences, forward and reverse, are
listed for each gene.

expressed in the myometrium, become developmentally
reprogrammed in the adult myometrium as a result of
neonatal DES exposure.' To identify estrogenresponsive genes associated with the development of leiomyomas that could be candidates for developmental
reprogramming, we conducted an in silica analysis of these
171 differentially expressed genes using the DRAGON
ERJE finder program to determine if they contained a
functional or putative ERE. Table 1 illustrates the result
of this analysis for 6 representative genes. We identified
26 genes that had known functional EREs and 86 that
had putative EREs. Thus, of the 171 differentially
expressed genes, 112 (65%) were potentially regulated
by estrogen, consistent with the hypothesis that hormones, especially estrogen, contribute to the development of uterine leiomyoma. From these, we selected a
subset of 19 genes, based on biological plausibility
(Table 2) and used real-time PCR analysis to validate our
microarray data. Real time RT-PCR analysis confirmed
differential expression in tumor versus normal myometrium of 18 out of these 19 genes (Table 2), and
these 18 genes were then evaluated as candidates for
developmental reprogramming in the myometrium of
DES-exposed rats.

Identification of Genes Developmentally
Reprogrammed by Neonatal DES Exposure
For this analysis, we defined a developmentally reprogrammed gene as one that was estrogen responsive
and displayed an altered expression pattern in adult myometrium of rats exposed neonatally to DES. Myometrium
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Table 2.

Microarrav Gene Validation11

Gene

FC-Array

FC-Real-Time PCR

GdfW

6.73
3.33
4.34
9.63
2.31
2.51
4.77
37.02
5.23
5.32
6.57
-12.87
-12.63
-6.36
-3.96
-3.32
-3.24
-4.08
-5.53

19.97
1.99
2.04
28.05
-1.25
1.74
11.47
17.53
3.43
38.20
7.06
-177.30
-440.20
-2.07
-2.11
-8.65
-1.46
-16.39
-11.31

C*pg2
CarS
Calbindin D9k
Vcam 1
Kcnfl
Rn<d2
Gna2
Dio2
.\linp3
Sfip2
Tacstdi
Knl9
RpsOebl

AV2/2

ItfbpS
Sppl
Aqp3

Ramp3

Abbreviations: FC, fold change.
* Validation of 19 candidate genes using real-time quantitative RT-PCR.
Data are a representative of two independent measurements with
samples nan in triplicate. Fold change (FC) is based on the change in
fold induction (calibrator sample set at 1) of the diethylstilbestrol
(DES) group as compared to the vehicle (VEH) groups with samples
normalized to GAPDH expression.

from 5-month-old adult rats neonatally exposed to DES
were divided into high estrogen and progesterone (High
E/P) and low estrogen and progesterone (Low E/P)
groups and compared to myometrium from VEH
grouped into proliferative (estrus and proestrus) and
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Table 3. Gene Expression (Vehicle [VEH] versus
Diethylstilbestrol [DES]) in Neonatal Uteri3
Neonatal DES Response

Gene

Normal
Estrogen
Response

Fold
Change

Calbindin D9k
Dio2
GdflO
CarS
Gria2
Mmp3

Induced
Induced
Repressed
Repressed
Repressed
Repressed

39.12
7.31
-4.78
-7.14
-83.33
-3.89

Standard
Deviation
1.53
0.19

0.06
0.05
0.03
0.04

a

Gene expression in neonatal uteri treated with VEH or DES. Fold
change relative to VEH control. Vehicle values set to 1 with decreases
indicated by negative values with all samples normalized to GAPDH
expression. Data are mean + SD of two independent measurements
with samples run in triplicate.

secretory (metestrus and diestrus) phases, respectively, for
the analysis of developmental programming.
Initially, the estrogen responsiveness of candidate
genes was confirmed in neonatal uteri, where gene
expression was demonstrated to be either repressed or
induced in response to DES (Table 3). As shown in
Figure 2, some genes were induced (illustrated by
Calbindin D9k, and Dio2) by hormone and others were
repressed (illustrated by GdflO, CarS, Gria2, and Mmp3;
Figure 3) in neonatal uteri. Furthermore, this pattern of
estrogen responsiveness (induced vs. repressed) was confirmed by analyzing the expression of these genes during
the normal estrus cycle in adult myometrium, where the
expression pattern during the estrus cycle was concordant
(ie induced or repressed) with their response to DES in
neonatal uteri (Figures 2 and 3). Inducible genes were
upregulated during the proliferative (high estrogen) versus secretory (low estrogen) phase of the normal estrus
cycle whereas repressed genes were downregulated in
proliferative versus secretory phases. Once the estrogen
responsiveness of the 18 candidate genes was confirmed,
we next determined if expression of these genes had been
reprogrammed in the adult myometrium of rats exposed
neonatallv to DES. As shown in Table 4, 6/18 of these
estrogen-responsive genes were development-ally reprogrammed by neonatal exposure to DES.
Calbindin D9k, which we had previously characterized
as a gene developmentally reprogrammed by DES,"J was
also identified in this analysis as being reprogrammed in the
adult myometrium of neonatally DES-exposed animals

(Figure 2), serving as an internal positive control for the
microarray-based approach. Similar to Calbindin D9k, Dio2,
another myometrial estrogen-inducible gene, also became
overexpressed in the adult myometrium. as evidenced by
elevated expression in myometrium of 5-month-old rats
during both proliferative and secretory phases (Figure 2 and
Table 4). Although the expression o£Dio2 in high E/P DES
animals was higher but not significantly so relative to proliferative phase myometrium (when the gene is normally
induced), it was significantly higher in low E/P DES animals
relative to normal secretory phase myometrium. This pattern was also seen for Calbindin D9k, where differential gene
expression was even more pronounced in low E/P DES
animals relative to normal secretoly phase myometrium.
Thus Dio2 displayed a characteristic DES-induced hyperresponsiveness to even low levels of estrogen, as previously
reported for Calbindin D9k.~
Strikingly, in animals exposed neonatally to DES, the
expression of several genes normally repressed by estrogen (GdflO, CarS, Gria2, and MtnpS) was significantly
increased (rather than repressed) under conditions of high
estrogen (proliferative phase) relative to normal myometrium (Figure 3 and Table 4). Thus, the overall effect of
developmental reprogramming by DES was to induce
an increase in expression of estrogen-responsive genes,
even those normally repressed by this hormone.
Because the net effect of developmental reprogramming was to elevate expression and/or induce the persistent expression of estrogen-responsive genes in the
myometrium, we next asked if elevated expression of these
genes was a generalized finding in tumors. Real-time PCR
of normal myometrium and tumors from age-matched (16
month) and stage (PE)-matched animals revealed that 5/6
(GdflO, CarS, Gria2, Dio2, and Mmp3) of the developmentally reprogrammed genes were overexpressed in
tumors (n = 8) as compared to normal PE myometrium
(Figure 4 and Table 5). Importantly, these genes were
overexpressed in spontaneous tumors from both DESexposed (n = 4) and nonDES-exposed (n = 4) rats. Thus,
the reprogramming of gene expression in the myometrium
induced by neonatal DES resulted in elevated expression of
these genes in a pattern characteristic of leiomyomas.
Taken together, these data are consistent with the hypothesis that increased expression of estrogen-responsive genes
contributes to the development of uterine leiomyoma and
that increased susceptibility for tumor development in
DES-exposed animals is due to elevated expression of
estrogen-responsive genes, mimicking the promotional
effect of this hormone on leiomyoma development.
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Figure 2. Real-time RT-PCR for DES-reprogrammed genes induced by hormone in uteri (PND 12; left panel), and myometrium (5 months;
right panel). A-B, Gene expression for Calbindin D9k and Diodinase 2 (Dio2) at PND 12 (VEH, n = 9; DES, n = 9) and 5 months (VEH = 5,
DES = 5). ** = P < .001, * = P < .05. DES = diethylstilbestrol; RT-PCR = Reverse transcriptase—polymerase chain reaction; VEH = vehicle.

DISCUSSION
Diethylstilbestrol has been demonstrated in several systems to induce developmental reprogramming of the
female reproductive tract at the molecular, cellular, and
tissue levels, which leads to development of reproductive
cinoma and uterine leiomyoma). However, the precise
nature of the reprogramming events leading to tumorigenesis is not fully understood. We have previously identified a critical window of susceptibility to developmental
reprogramming of the uterus (PNDs 3-12) after neonatal
DES exposure," which can increase tumor incidence to
100%. To define the mechanism by which DES reprograms the uterus to increase susceptibility to tumorigenesis, we initiated this study to identify genes in tumors
that could be targets for developmental reprogramming
in the myometrium. Using gene expression profiling
of uterine leiomyomas and myometrium, 18 candidate

(GdflO, Car8, Calbindin D9k, Gria2, Dio2, and Mmp3)
were shown to be reprogrammed in the adult myometrium by neonatal DES exposure. Elevated expression
of 5 of these genes, GdflO, Car8, Gria2, Dio2, and Mmp3
in 8/8 tumors, including tumors that arose without DES
treatment, demonstrated that DES developmentally
reprogrammed estrogen-responsive genes associated with
tumor development.
Similar to a previous study looking at the molecular
effects of neonatal DES exposure on the endometrium,21
our transcriptional profiling of myometrium and tumors
revealed that more than half (112/171) of genes differentially expressed in tumors were either putative or known
estrogen-responsive genes, lending support to the importance of estrogen in promoting the growth of uterine
leiomyomas. Altered expression of estrogen-responsive
genes has also been demonstrated in hamster and mouse
whole uteri neonatally exposed to DES, which ultimately
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Figure 3. Real-time RT-PCR for DES-reprogrammed genes repressed by hormone in uteri (PND 12; left panel), and myometrium
(5 months; right panel). A-D, Gene expression for carbonic anhydrase 8 (Car8), growth differentiation factor (GdflO), o/iitatuate receptor 2 (Cria2),
and matrix metalloprotease 3 (Mmp3) at PND 12 (VEH, n = 9; DES, n = 9), and 5 months (VEH = 5, DES = 5). ** = P < .001. * = P < .05.
DES = diethylstilbestrol; RT-PCR = Reverse transcriptase—polymerase chain reaction; VEH = vehicle.

myometrium and the genes identified in our analysis
were not specifically investigated in those studies."""'"
Furthermore, in our study, the reprogramming of

estrogen-responsive genes occurred in the myometrium
of neonatally DES-exposed animals before the onset of
tumors. This suggests that DES increases tumor incidence
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Table 4. Gene Expression in Myometrium of
Diethyistilbestrol-exposed Rats
Adult Estrogen Response

Gene

Normal
Estrogen
Response

Fold Change
(relative to
VEH)

Calbindin D9k
Dio2
GdfW
Car8
Cria2
Minp3

Induced
Induced
Repressed
Repressed
Repressed
Repressed

3.40

0.16

2.00
2.91
4.83
4.20
6.10

0.12
0.25
0.17
0.15
0.18

Standard
Deviation

* Gene expression in myometrium of 5-month-old diethylstilbestrolexposed rats. Fold change relative to vehicle (VEH) control. Vehicle
values set to 1 with all samples normalized to GAPDH expression. Data are mean + SD of two independent measurements
with samples run in triplicate.

by increasing the expression of estrogen-responsive
genes, possibly mimicking the promotional effect of
estrogen during spontaneous tumor development. Along
with previous studies, our data identify altered expression
of estrogen-responsive genes as a hallmark of xenoestrogen exposure that precedes, and likely contributes to.
development of reproductive tract disease, including
uterine leiomyoma.
In the rat uterus, DES both induced and repressed
gene expression, similar to what has been seen for estrogens in other estrogen-responsive tissues." '"^ We
observed that neonatal DES exposure increased the
expression of genes that were normally induced by estrogen and led to persistent expression under conditions
when estrogen levels are normally insufficient to drive
gene expression (ie, low estrogen levels or secretory
phase), consistent with these genes having become
hyper-responsive to endogenous estrogen. Importantly,
we also found that several genes normally repressed by
estrogen exhibited elevated (rather than decreased)
expression under conditions when estrogen levels were
high. Thus, reprogramming by DES caused both quantitative and qualitative changes in the way reprogrammed
genes responded to estrogen.
Several mechanisms for altered estrogen responsiveness as a result of developmental reprogramming have
been investigated in other tissues, den Hollander and colleagues" proposed that one mechanism for estrogen
hyper-responsiveness occurs via epigenetic reprogramming of the estrogen receptor co-activator, Cizl, which
amplifies estrogen responsiveness in breast cancer cells
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by increased recruitment of the ER complex to chromatin
of target genes. A direct epigenetic mechanism to maintain hormonal "memory" at sites of specific genes
through DNA methylation has also been described by
Thomassin and colleagues via alterations in DNA
methylation of the tyrosine aminotransferase (Tat) gene
after fetal exposure to glucocorticoids. Similarly, differential DNA methylation of the lactoferrin gene promoter
and phosphodiesterase type 4 variant 4 (PDE4D4) gene
has also been observed in response to neonatal xenestroi
• i '8 '9
gen exposure in the
uterus and prostate, respectively."
In the prostate, these changes occur very early, with
hypomethylation ofPDE4D4 observed before the formation of prostatic neoplastic lesions (PIN) in neonatally
xenoestrogen-exposed mice. Both studies demonstrate
that neonatal exposure to xenoestrogen can induce hypomethylation of specific genes, which is maintained in the
neoplastic lesions that arise in these tissues (uterine tumors
and PIN). This suggests that gene hypomethylation
induced by xenoestrogens can serve as a biomarker of
exposure before neoplasias are observed. We also
observed developmental reprogramming in the "normal"
myometrium at 5-6 months, prior to tumorigenesis in
exposed females. Although the exact mechanism(s)
responsible for developmental reprogramming of gene
expression in the myometrium have not been identified,
these studies lend support to the hypothesis that a xenoestrogen "fingerprint," such as a specific DNA methylation
event, or altered expression of a group of developmentally
reprogrammed estrogen-responsive genes, could be used
as biomarkers to help identify individuals exposed neonatally to xenoestrogens who may be susceptible to adult
disease, including uterine leiomyoma.

Ontology of Developmentally
Reprogrammed Genes
Given the potential for developmental reprogramming of
gene expression to contribute to tumorigenesis, a gene
ontology was compiled for the genes identified in this
study that were developmentally reprogrammed by neonatal DES exposure, in the context of the potential involvement of these genes in the human disease.

Cell Signaling: Car8 and Gria2
Car8, which is developmentally regulated, and Gria2,
which is gestationally regulated, were both developmentally reprogrjammed and overexpi'essed in tumors. The
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Figure 4, Real-time RT-PCR for reprogrammed genes differentially expressed in PE tumors versus PE myometrium from 16-month Eker
rats. A-F, Gene expression for Calbindin D9k, deodinase 2 (Dio2), carbonic anhydrase 8 (CarS), matrix inetalloproiease 3 (Mmp3), growth differentiation
factor (GdflO), and glutamate receptor 2 (Gria2j; PE myometrium, n = 2; PE tumors, n = 8) ** = P < .001, * = P < .05. RT-PCR = Reverse
transcriptase—polymerase chain reaction; PE = persistent estrus.

function of CarS, part
anhydrase-related protein
unknown; however, it has
fetal brain development" '

of the acatalytic carbonic
family (CARP), remains
been shown to play a role in
as well as in the promotion

of colon cancer via increased cell proliferation and
invasion. ~ Additionally, Gria2, a receptor that functions
as an alpha-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid (AMPA)—sensitive neurotransmitter, has
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Thyroid Hormone Metabolism: Dio2

Table 5. Gene Expression in Tumors Versus Normal
Myometriuma
Tumor Response

Gene
Calbindhi D9k
Dio2
GdflO
Car8
Gria2
Mmp3

Fold Change

Standard Deviation

-6.25
3.43

0.07
0.12

19.97

0.6

5.98
11.00
38.32

0.21
0.34
3.59

a

Gene Expression in normal persistent estrus (PE) myometrium and
P£ tumors (Vehicle (VEH) and diethylstilbestrol (DES)). Fold change
relative to normal PE myometrium. Normal PE myometrium values
set to 1 with decreases indicated by negative values and all samples
normalized to GAPDH expression. Data are mean + SD of two
independent measurements with samples run in triplicate.

garnered significant interest in the uterine leiomyoma
field due to its appearance in multiple human microarray
studies of uterine leiomyoma. Subsequently, Tsibris and
colleagues" hypothesized that Gria2 could participate
synergistically with estradiol, retinoic acid, and its receptor RXR to support tumor growth. The reprogramming
of this gene in animals at increased risk for leiomyoma and
its overexpression in human leiomyomas suggest that
Gria2 is a strong candidate gene for participation in the
development of this disease.

A gene involved in thyroid hormone metabolism, Dio2,
also exhibited elevated expression in the myometrium
of rats exposed neonatally to DES, with elevated expression also observed in tumors. Dio2, which converts T3 to
T4 after activation by ERK 1/2, is necessary to regulate
thyroid hormone levels during development, particularly
in the brain, and during pregnancy. Specifically, Dio2
has been identified as an estrogen-responsive gene due to
elevated expression during proestrus as compared to diestrus." Our data also indicate that Dio2 responds to estrogen in the rat myometrium, and importantly, that Dio2
appears to become hyper-responsive to estrogen as a
result of developmental reprogramming, with elevated
expression observed under both high and low estrogen
conditions. Interestingly, several other reports have
implicated Dio2 in papillary thyroid cancer," follicular
carcinomas,40 and mesotheliomas, suggesting that Dio2
could be associated with tumors of organs other than the
thyroid, although, a mechanism by which Dio2 could
participate in uterine leiomyoma is unknown. However,
given that mitogens such as insulin, EGF, and IGF-1
(which are overexpressed in leiomyomas) also induce
Dio2 mRNA, ~ it is unclear at this time if expression
of Dio2 in tumors is due to altered expression of these
growth factors or reflective of the hyper-responsiveness
to estrogen that is characteristic of these tumors.

Growth Factors: GdflO
Extra Cellular Matrix Proteins: Mmp3
A gestationally and neonatally regulated gene"' that is
necessary for tissue development and wound healing,35M»jp3 was developmentally reprogrammed to
become induced rather than repressed under high estrogen conditions. This reprogramming was observed before
the onset of tumors, and like Car8 and Cria2, Mmp3 was
also elevated in tumors. It is well accepted that one of the
main driving forces in the growth of uterine leiomyomas
is increased expression of extracellular matrix proteins
(ECM). It is not surprising, therefore, that Mmp3, which
is involved in ECM remodeling, was also overexpressed
in uterine leiomyomas. However, the fact that this
gene was reprogrammed prior to the development of
tumors suggests that increased expression of Mmp3 could
be participating in tumorigenesis, rather than a consequence/epiphenomena associated with the increased
matrix production characteristic of these tumors.
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GdflO is expressed in the normal adult uterus43 and has
been shown to regulate growth during development,
mainly head development. 44 GdflO (Bmp3b) is also a
member of the transforming growth factor (TGF)P super
family, which is involved in regulating cell differentiation,
proliferation, and apoptosis.43 In addition, GdflO is
characterized as target of the canonical Wnt pathway,43
specifically in the development of neural tissue. GdflO
is normally repressed by estrogen; however, in rats
exposed neonatally to DES, it was overexpressed in the
adult myometrium when estrogen was high, and was
expressed at higher levels in tumors relative to agematched and stage-matched myometrium. Interestingly,
several studies observed that the GdflO gene is hypermethylated in both human bladder tumors and cells
collected form the urine of bladder cancer patients. The
CpG island in the GdflO gene is also hypermethylated in
non-small cell lung carcinomas (NSCLC), indicating that
GdflO can be cpigciiccitally regulated in some cancers."17
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Given that TGFp signaling promotes mesenchymal cell
growth, it is interesting to speculate that increased
signaling via this pathway as a result of elevated Gdfl 0
expression may be contributing to leiomyoma growth.
Since TGFP signaling is known to contribute to leiomyoma growth, further study of the role of GdfW in
development of these tumors is warranted.
Calcium Ion Binding Proteins:
Calbindin D9k
In addition to Mmp3, another calcium ion binding
protein Calbindin D9k is developmental^ reprogrammed
by xenoestrogen exposure. Calbindin D9k has multiple
biological roles including fetal calcium uptake and uterine
contractions,49 calcification of bone and teeth, and intestinal calcium uptake and transport.30 Importantly, it is
overexpressed in the immature uterus after exposure to
endocrine disrupters,3 3' as well as in the adult uterus during pregnancy and proestrus.3
This suggests that Calbindin D9k is an ideal biomarker for estrogen exposure
in the myometrium, and as shown in our studies, an
excellent reporter of developmental reprogramming by
xenoestrogens in this tissue.
In summary, these data demonstrate that neonatal
exposure to DES, and perhaps other xenoestrogens as well,
can modulate the expression of the estrogen-responsive
genes associated with uterine leiomyomagenesis. Several
of these genes have also been identified as overexpressed
in human leiomyomas, further suggesting that they may
be key targets for early life exposures to xenoestrogens.
The identification of genes that participate in uterine leiomyoma development continues to be a critical need; both
to better understand the etiology of these tumors and for
the development of new therapeutic approaches for this
disease. In particular, with the identification of genes
susceptible to developmental reprogramming in the
myometrium, in the future it will be possible to identify
causal mechanism(s) of developmental reprogramming
in this tissue, and enhance our understanding of fundamental processes that link environmental exposures to
development of this disease.
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Methodology for Ultradeep Bisulfite Sequencing
Animals and Treatments
As described previously in chapter 3, Eker rats bred from our colony were
utilized for this study in accordance with the guidelines of the M. D. Anderson
Cancer Center Animal Care and Use Committee. Female Eker rats were fed
standard rat chow (Harlan Teklad 22/5 rodent Diet) and water ad libitum and
maintained on a 14:10 light-dark cycle. The differential DNA methylation effects
of DES were analyzed after exposing neonatal Eker rats on postnatal days 10
through 12 with DES (1mg/kg) (Sigma Chemical Co., St. Louis, MO) dissolved in
sesame oil or to VEH (sesame oil) control using a total of 50 µl of DES or VEH
for each subcutaneous injection, as describe in chapter 3. Animals (DES n=24,
VEH n=25) were aged out to 5 months and were sacrificed at this age via CO2
asphyxiation. Uteri were harvested and scraped with a sterile scalpel in cold PBS
to remove endometrium from myometrium, immediately frozen in liquid nitrogen
and stored at -80°C for later DNA methylation analysis. Another group of
animals, age 16 months, were utilized in order to obtain unexposed normal
senescent myometrium or tumors from animals exposed to VEH, as describe in
chapter II and III. In addition, blood was collected from 5-month-old animals in
order to obtain serum for RIA analysis and staging, as described in chapter II.
Histology, Radioimmunoassay and Staging of Estrus
For reproductive tract morphology analysis and estrus staging of VEH or
reproductively senescent uteri, a portion of the uterine horn was fixed in 10%
neutral buffered formalin and transferred to 70% ethanol after 24 hrs. Fixed uteri
from female rats sacrificed at 5 or 16 months, were embedded in paraffin and
stained with hematoxylin-eosin (H&E) as described previously in chapter II and
III. H&E stained uteri from DES and VEH exposed animals were examined for
stage of estrus (see chapter II and III methodology). Estradiol levels were
determined via RIA, obtained using the Ultra-sensitive Estradiol kits from
Diagnostic Systems Laboratories (Webster, TX) according to the protocol
described in by the manufacturer and in chapter II. Following hormone analysis,
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DES-exposed rats were grouped into either High or Low E2 in order to
obtain proliferative (High E) animals to compare to proliferative phase VEH
animals.
Extraction and Bisulfite Treatment of DNA
For extraction of genomic DNA, a portion of frozen myometrium or tumor
from adult (5 month old VEH (n=5) or DES (n=5) exposed) or aged (16 month old
normal unexposed myometrium (n=5) or VEH exposed tumors (n=5)) animals
that were age and stage (proliferative) matched was obtained using a steril
scalpel and placed in an 1.5 mL Eppendorf tube. Tissue was digested in TNES
buffer pH 7.5 (50 mM Tris (pH 7.5), 0.4 M NaCl, 100 mM EDTA, 0.5% SDS) and
proteinase K at 55°C by shaking for 1hr. Saturated (~6M) NaCl was added and
the mixture was vortexed followed by centrifugation at 14,000 rpm for 30
minutes. Supernatant was transferred to a new tube and cold absolute EtOH was
added to precipitate DNA followed by centrifugation at 14,000 rpm for 25 minutes
at 4°C. Supernatant was discarded and the pellet was washed with cold 70%
EtOH followed by centrifugation at 14,000 rpm for 20 minutes at 4°C.
Supernatant was discarded and the pellet was dried and then resuspended in
sterile ddH2O and stored at 4°C.
For bisulfite conversion of DNA, which converts all unmethylated cytosine
to uracil, 350 ng of sample DNA was used and treated with sodium bisulfate and
desulphonated using the EZ DNA methylation or methylation Gold™Kit (Zymo
Research, Orange, CA) according to the manufactures protocol. Elution of
bisulfite converted DNA was eluted into 10-15 µL of sterilized 1 X TE buffer (10
mM Tris pH 8.0, 1 mM EDTA pH 8.0) and frozen back at -20°C.
Primers Design and RT-PCR Amplification of Bisulfite Converted DNA
Ten developmentally reprogrammed genes (Gria2, Gdf10, Calbindin D9K,
Mmp3, Spp1, Sfrp2, Nr2f2, Rasd2 and Krt19) previously identified in chapters II
and III were chosen to analyze DNA methylation differences in adult and aged
myometrium, as well as, tumors. Seven regulatory regions were annotated in
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each gene (CpG islands, ER, PR, FoxA1, SRC-3, H3R17 and Pol II binding
sites), which were obtained from the Myles Brown Laboratory at Dana-Farber
Cancer Center. These genome wide binding sites were identified in MCF-7 cells
treated with or without estradiol and probed with the antibody against each of the
transcription factors listed above (except CpG islands). A ChIP-Chip tiling array
was performed in the Brown laboratory and results from the analysis of this data
was lifted to the rat genome for this study. The USCS genome browser was used
to identify the CpG islands in and around developmentally reprogrammed genes
in addition to the binding sites of the 7 regions of interest mentioned above.
Annotation of each of these genes and their regulatory sites is located in
Appendix C-1. For primer design of bisulfite treated DNA, primers were designed
25-30 nucleotides in length in regions of DNA not containing any CpGs for
amplification of regions of interest between 220 to 700 bp in length. Except for
Gria2, Gdf10 and Calbindin D9k, all primers were designed using the publicly
available program MethPrimer (1). A list of all gene primers, genomic location,
size and amplicons is located in Appendix C-2. For the three genes listed above,
which were used in cloning and sequencing analysis, nested primers were
designed to reduce non-specific amplification of bisulfite treated DNA.
For amplification of bisulfite treated DNA, primers were first tested using
gradient RT-PCR (47°C-57°C) on the TurboCycler Gradient 96 Machine
(Stratagene, Cedar Creek, Texas). The PCR reaction was performed in two
separate reactions (PCR-1 and PCR-2) in a 96 well-plate in a 25 µL reaction
using 1µL of bisulfite treated DNA (BS-DNA) together with master mix (5X)
containing 10% MCA2 buffer (670 mM Tris pH 9, 160 mM ammonium sulfate, 1%
Triton X-100, 100 mM 2-mercaptoethanol, 20 mM MgCl2), 1% bovine serum
albumin, 0.5 % (0.125 mM) dNTPs (25 mM stock), 1% forward and reverse
primer each (10 µM stock), 1% Taq polymerase (5U/µL stock) (Applied
Biosystems, Foster City, CA), 10% Cresol red (1mM cresol red, 10 mM Tris pH
8.8, 60% glycerol in water) plus 75% nuclease free water. To the first round of
PCR-1 master mix was added an inhibitory oligonucleotide to prevent nonspecific action of Taq polymerase at temperatures below 50°C at a concentration
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of 0.012 µM. DNA was amplified under the following conditions: 1, 4-minute
denaturation cycle at 95°C; 5 cycles of 30 sec (95°C), 1minute annealing
temperature, 2 minute extension (72°C); 25 cycles, 30 sec (95°C), 1 minute
annealing, 1 minute extension (72°C); 1 cycle, 4 minutes (72°C). Following PCR2 under the same conditions, 15 µL of PCR product was resolved on an agarose
gel via gel electrophoresis and stained with ethidium bromide to visualize under
UV light to determine amplicon size. Once all primers were tested and validated,
all samples (adult myometrium (n=5), DES myometrium (n=5), senescent
myometrium (n=5) and VEH tumors (n=5)) were amplified together in two round
of PCR at the appropriate temperature determined during testing, as describe
above, in a 96-well plate. PCR products were then subjected to filtration using
the Montage PCR Centrifugal Filter Devices (Millipore, Billerica, MA) to purify and
remove salts, unicorporated dNTPs and primers. Purified PCR products were
eluted into 1 X TE buffer, quantitated and used immediately for cloning and
sequencing or frozen at -20°C until pooling could be performed for all products
for ultradeep bisulfite sequencing.
Bisulfite Cloning and Sequencing
Amplified and purified products from BS-DNA samples (5 individual
samples pooled into one of 4 corresponding sample tubes; adult myo (AM), DES
myo (DM), senescent myo (SM) or VEH tumor (VT)) were cloned in TOPO-TA
cloning system (Invitrogen). Selection media (Kan+) was used to grow up positive
colonies overnight (12-16 hrs) at 37°C. 2µL of colony broth was used in a PCR
reaction to screen for plasmids positive for insert according the reaction
described above. Plasmids positive for insert were then isolated using the
GenElute™Plasmid Miniprep kit (Sigma, St. Louis, MO). Isolated plasmid DNA
was then sequenced. Between 12-44 clones from DES or VEH samples were
sequenced for later analysis.
Bisulfite Solexa Sequencing
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For solexa sequencing, purifed PCR products were pooled in to one of
four corresponding tubes (AM, DM, SM or VT) in equal molar amounts (30
ng/µL). Prior to sequencing, pooled PCR products were sonicated in glycerol to
generate <200 bp products. cDNA libraries were created from products and
sequencing tags were applied. Tagged sequences were then bisulfite sequenced
on the Illumina Solexa Genome Analyzer II platform using single-end reads.
Alignment and Mapping of Amplicons
Computational analysis of the bisulfite Solexa sequencing (Bisulfite-Seq),
was accomplished using BSMAP whole genome bisulfite sequence mapping
program (2). Prior to mapping, both strands of the genome and solexa reads
were bisulfite transformed in silico, changing cytosines (C) thymines (T), in order
to map reads to the genome. Each converted sequence was mapped to one of
70 genome positions according to tags and primers. Detailed mapping alignment
technique and algorithms are described by Xi et al. (2). Analysis of cloning and
sequencing was performed using the in silico transformed DNA regions
analogous to the amplicon to identify differences in methylation of C between the
two sequences for DES or VEH samples.
Statistical Analysis
For analysis of differential DNA methylation of sequences from cloned
PCR products, a mean was obtained for all methylated vs. unmethylated CpGs
and % methylation was obtained based on the number of clones analyzed for
each sample. A Student’s t-test was applied to these data to determine if a
significant difference existed in % DNA methylation between samples, a value of
p<0.05 was determined to be significant. The same analysis was applied also to
individual CpG sites to determine significance.
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